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ABSTRACT 
Despite substantial advances in pharmacological and interventional strategies for the 
treatment of ischaemic heart disease and acute myocardial infarction (MI) many patients 
go on to develop dilated heart failure with high morbidity and mortality rates. Increasing 
evidence suggests that stem cells can augment re-vascularisation of the infarcted 
myocardium leading to improved cardiac function. However, the precise mechanisms 
involved are not completely understood and further work is required to realise optimised 
cell based therapy.  
 
The aim of this project was to investigate the role of endoglin, a pro-angiogenic TGFβ 
co-receptor, in bone marrow (BM)-derived endothelial progenitor cells (EPCs) and in 
cardiac-resident cardiosphere-derived cells (CDCs) using mouse models. I hypothesised 
that endoglin acts as a key marker and functional regulator of the pro-angiogenic repair 
properties of these stem cells and that manipulating TGFβ signalling by controlling 
endoglin levels could provide a better understanding of the properties of these cells, 
with the longer term goal of developing more effective revascularisation therapies. 
 
My data show that inhibiting TGFβ/Alk5 signalling in vitro increases EPC yield from 
both endoglin heterozygous and wild-type BM cells. In addition, although endothelial 
specific knock-down of endoglin in vivo led to increased endoglin expression in cells 
from the BM, these cells did not incorporate into endoglin depleted heart or lung 
vasculature. 
 
I also showed that endoglin deficiency results in a significant reduction in EPC yield 
from BM cells and inducible endoglin depletion in CDCs (using a conditional endoglin 
knock-out mouse model) impairs cellular proliferation and migration in vitro alongside 
up-regulated TGFβ/Alk5 signalling. Furthermore, injection of wild-type CDCs into the 
ischaemic border zone of the heart, following coronary artery occlusion in a mouse MI 
model, led to an increased angiogenic response at 4 weeks. This response was 
significantly reduced when endoglin depleted cells were transplanted. However both 
wild-type and endoglin depleted CDCs were able to rescue heart function, as measured 
using cardiac MRI.  
 
  iii 
In conclusion, the results of this thesis provide evidence of the important roles that 
endoglin and TGFβ signalling play in promoting angiogenesis in tissue repair. Further 
advances in this field could aid in the development of more effective cell therapies for 
MI patients. 
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1.1. Angiogenesis and Vasculogenesis 
The vascular system is essential for growth, repair and survival and develops via two 
distinct processes: vasculogenesis and angiogenesis1-2. During embryonic development 
blood vessels are formed de novo by the patterned assembly and differentiation of 
angioblasts into endothelial cells (ECs) in a process termed vasculogenesis (figure 1.1). 
This results in the formation of a primary plexus of capillaries, which progressively 
expands during the angiogenic phase of vascular development either by sprouting 
angiogenesis, through end-to-end fusion of vessel sprouts or intussusceptive vascular 
growth1-3 (figure 1.1).  In sprouting angiogenesis ECs proliferate behind the tip cell of a 
growing branch in response to specific stimuli, such as vascular endothelial growth 
factor (VEGF), and lumens can form by vacuole fusion4. Alternatively intussusceptive 
angiogenesis describes the splitting and growing of vessels by the formation of 
translumen pillars, however the molecular mechanisms involved in this process are 
poorly understood1, 3. During vessel maturation, nascent endothelial vessels are 
stabilised via the recruitment of supporting mural cells and extracellular matrix (ECM) 
is deposited1, 3, 5. Mural cells include pericytes, which provide structural support and 
protect endothelial cells from apoptosis, and vascular smooth muscle cells that bestow 
vessels with vasomotor properties5. Angiogenesis remodels the primitive capillary 
plexus into a highly organized network of arteries, capillaries and veins as blood starts 
to circulate and both genetic mechanisms and local environmental cues dictate arterial 
or venous specification3.  
 
Angiogenesis is not restricted to development. In adult life angiogenesis is important for 
tissue repair (as well as in many pathologies, discussed in more detail below) and is a 
dynamic process consisting of both activation and resolution phases1, 6.  During the 
activation phase, vascular permeability increases, extracellular matrix components are 
degraded and ECs proliferate and migrate to form new capillary sprouts. ECs cease to 
proliferate in the angiogenic resolution phase, the basement membrane reconstitutes and 
vessels become associated with stabilising mural cells as they mature and finally 
become quiescent. The transition between these two phases is referred to as the 
angiogenic switch and is tightly regulated by an intricate balance of growth inducers 
and inhibitors.  
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Figure 1.1. Development of the vascular system via vasculogenesis and 
angiogenesis. During embryonic development the process of vasculogenesis (the in situ 
differentiation and patterned assembly of mesoderm-derived angioblasts into a primary 
capillary plexus) first occurs in the extra-embryonic yolk sac as blood islands containing 
haemangioblasts differentiate from extra-embryonic mesodermal cells. Angiogenesis 
(the formation of new vessels from the pre-existing vessel plexus through sprouting or 
intussusceptive growth) expands and remodels this primary capillary network to 
generate mature vessels associated with stabilising mural cells. The primary blood 
plexus in the yolk sac connects with a primary blood plexus in the embryo proper and 
the circulatory system is established once the embryonic heart begins to beat. Primary 
embryonic vasculature is remodelled at later developmental stages and postnatally 
through both vasculogenesis and angiogenesis to meet the metabolic demands of the 
organism. Figure from7. 
   4 
Although de novo blood vessel formation (vasculogenesis) was once thought to be 
largely restricted to embryonic development recently it has been discovered that 
vasculogenesis can also take place in adult life via the incorporation of endothelial 
progenitor cells into neovessels, this will be discussed in greater detail in section 1.5.  
 
1.2.  Angiogenesis in Heart Repair 
Physiological angiogenesis in the adult is largely restricted to the cycling ovary and 
uterus as most blood vessels remain relatively quiescent2. However angiogenesis is 
stimulated in response to injury and actively contributes to wound healing and repair by 
restoring blood flow to injured tissues2, 8. Additionally, in certain disease states the body 
may lose control of the tightly coordinated processes regulating angiogenesis resulting 
in either excessive or insufficient vessel growth. Excessive angiogenesis occurs in many 
diseases, such as macular degeneration and malignancy, and results from diseased cells 
producing abnormally high levels of angiogenic growth inducers, which overcome the 
suppressant effect of inhibitors2. In these conditions neovessels feed diseased tissues 
and in the event of malignant disease new vessels can allow tumour cells to metastasise. 
Anti-angiogenic therapies, aimed at preventing neovascularisation are currently being 
investigated and trialled to combat this dysregulation of angiogenesis. However, in 
other disease states such as ischaemic heart disease, heart failure and stroke, insufficient 
angiogenesis can occur whereby blood vessel growth is inadequate to meet the 
metabolic demands of the tissue and circulation is not properly restored, increasing the 
risk of tissue death2.   
 
Myocardial infarction (MI) occurs most commonly due to coronary artery occlusion 
following the rupture of an atherosclerotic plaque and causes irreversible damage to 
cardiac tissue secondary to prolonged ischaemia9. In contrast to adult zebrafish10 and the 
neonatal mouse heart11, the adult human heart has minimal regenerative capacity. 
Therefore following infarction a reparative process is triggered that ultimately results in 
the formation of a fibrotic scar which can be associated with adverse structural and 
functional cardiac changes. This complex endogenous repair process is described in 
detail in extensive reviews9, 12-13 but will be briefly outlined here. Infarct healing 
involves three overlapping stages termed the inflammation, proliferation and maturation 
phases9 (figure 1.2). Following prolonged ischaemia dying cells trigger the activation of 
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chemokine and cytokine cascades during the inflammatory phase of repair. This leads to 
a mass influx of leukocytes, which clear the ischaemic area of dead cells and matrix 
debris. In addition, recruited macrophages release an array of cytokines and growth 
factors that result in the formation of highly vascularised granulation tissue. Hereafter 
pro-inflammatory mediator expression becomes suppressed and fibroblast and EC 
numbers expand during the proliferation phase. At this stage activated myofibroblasts 
produce extracellular matrix proteins and an extensive microvascular network is formed. 
In the final stage granulation tissue associated cells apoptose and myofibroblasts deposit 
a network of collagen resulting in the formation of a mature, thin collagen-based scar9. 
Infarct healing is closely associated with ventricular remodelling, a process that can 
occur following MI involving major changes in ventricular architecture and geometry12-
13
 (figure 1.2). Remodelling involves both infarcted and remote myocardium and occurs 
following MI due to an acute loss of viable tissue which results in an abrupt increase in 
loading conditions. During the early phase of remodelling the infarct zone expands 
whereas later stages involve the left ventricle globally and are associated with chamber 
dilatation and distortion of ventricle shape. This process can continue for weeks to 
months or until the forces of increased wall stress are counterbalanced by the tensile 
strength of the mature collagen scar. Failure to adequately normalise these forces can 
result in progressive ventricular dilatation, recruitment of border zone myocardium into 
the scar as well as deterioration in cardiac function12-13. Therefore ventricular 
remodelling is linked to the progression of heart failure and is associated with poor 
prognosis following MI.  
 
Angiogenesis forms an important part of the healing process following MI9, 14. Hypoxic 
conditions and an array of secreted growth factors stimulate angiogenesis in the 
infarcted heart9, 15. Neovessels begin to appear soon after ischaemic assault and within 1 
week the infarct zone and surrounding myocardium become rich in capillaries14, 16. 
These vessels allow increased blood flow, which greatly accelerates and promotes the 
healing response thus increasing the salvage of affected heart tissue. This new 
microvessel network is thought to develop to allow the formation of provisional 
granulation tissue and inflammatory cell infiltration8, 14. However, at a later stage of 
infarct healing whilst some newly formed capillaries mature into pericyte-coated vessels 
many others regress and degenerate through apoptosis as the collagen scar matures and 
remodelling resolves9. Following MI, in addition to angiogenesis, vascular perfusion of 
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the ischaemic area can also be enhanced by recruiting the pre-existing arterial 
circulation to bypass the site of major artery occlusion via arteriogenesis1, 17. This 
circumvention is achieved by the rapid growth of pre-existing collateral arteries and the 
maturation of capillaries into mature arterioles, which may then serve as an alternative 
route for blood flow. These collateral vessels are not used to enhance perfusion under 
normal conditions but can dramatically expand lumen diameter and increase blood flow 
to ischaemic regions at risk. Collateral vessel formation in MI patients has been 
associated with an improvement in myocardial viability as well as reduced infarct size 
leading to an overall reduction in mortality18. 
 
The enhancement of blood flow via adaptive angiogenesis and/or recruitment of pre-
existing coronary collateral vessels is frequently insufficient following severe ischaemic 
damage, leading to inadequate tissue perfusion which may result in ongoing loss of 
viable tissue, infarct extension, and increased adverse ventricular remodelling. 
Therefore a major focus of cardiovascular research is therapeutic angiogenesis, which 
aims to promote the growth and proliferation of blood vessels to enhance blood flow to 
jeopardised ischaemic regions. 
 
   7 
 
Figure 1.2. Infarct healing and ventricular remodelling; the angiogenic response. 
(A) The healing response following MI involves three distinct but overlapping phases; 
inflammatory, proliferative and maturation (discussed further in text) and is dependent 
on the sequential infiltration of the damaged myocardium with inflammatory, fibroblast 
and vascular cells. These processes are tightly associated with progressive remodelling 
which describes the structural and functional ventricular changes observed post MI, 
including LV wall thinning and dilatation and eventually damaged tissue is replaced 
with a collagen-based scar. (B) Following infarction an extensive microvascular 
network forms during the healing response to promote the formation of provisional 
granulation tissue and inflammatory cell infiltration as well as increasing blood flow to 
increase the salvage of injured myocardium. However, many neovessels regress at later 
stages as the collagen scar matures.  As a result inadequate tissue perfusion can result in 
increased adverse ventricular remodelling. (C) Therapeutic angiogenesis aims to 
promote the growth and proliferation of vessels to enhance blood flow to jeopardised 
ischaemic regions. This can significantly attenuate the adverse effects of remodelling 
and rescue heart function. N.B. the time course presented here (applies to (A) and (B)) 
is representative of a mouse model of MI and reperfusion, larger animals and humans 
exhibit delayed healing in comparison (can extend from weeks to months). Figure 
adapted from9. 
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1.3. Therapeutic Angiogenesis in Heart Repair 
Early restoration of blood flow to the infarcted myocardium via catheter based coronary 
reperfusion (angioplasty) combined with pharmacological therapy is the preferred 
clinical course following acute MI. However, in recent years there has been tremendous 
enthusiasm for the utilisation of therapeutic angiogenesis as a strategy to augment 
conventional therapies as well as for treating patients who may be unsuitable for routine 
clinical therapy due to contra-indications (such as co-morbidities). The goal of 
therapeutic angiogenesis in ischaemic heart disease is to promote neovascularisation and 
restore cardiac function (figure 1.2). The augmentation of physiological vascularisation 
can be achieved via different means including; gene, protein and cell therapies. 
 
Early strategies focused on the delivery of pro-angiogenic growth factors (such as 
VEGF and FGF) via protein or gene based approaches designed to stimulate 
vasculogenesis, angiogenesis and arteriogenesis (reviewed in19).  However these studies 
resulted in limited success presumably due to the short half life of proteins; the 
strategies employed were found to promote rapid formation of neovessels following MI 
in pre-clinical models, but these vessels were leaky and regressed easily as they failed to 
mature and anastomose with the coronary circulation20. In addition, phase I and II 
clinical trials using angiogenic growth factors to improve revascularisation of hearts in 
coronary artery disease patients have generally delivered disappointing results21. Cell-
based pro-angiogenic therapies may provide a more effective route to improve perfusion 
due to their ability to persist for prolonged periods following transfer, to differentiate 
into vascular cell types and also to secrete multiple pro-angiogenic factors that may 
work in synergy to create a more permissible environment for vessel formation.  
 
1.4.   Pro-Angiogenic Cell-Mediated Therapy for Myocardial 
Repair 
In recent years the field of cell-based regenerative medicine has exploded and multiple 
cell-types have been used to treat cardiovascular disease in pre-clinical studies and early 
phase clinical trials. This new therapeutic strategy aims to improve heart function by 
delivering stem/progenitor cells with the capacity to stimulate myocardial regeneration 
and/or neovascularisation either directly or indirectly via cellular differentiation or 
paracrine mechanisms. In this thesis I will focus on pro-angiogenic mediated repair 
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although many of the proposed therapeutic cell types have also been implicated in direct 
myocardial regeneration. Cell therapy candidates include bone marrow (BM)-derived 
cells (including endothelial progenitor cells (EPCs), haematopoietic stem cells (HSCs) 
and mesenchymal stem cells (MSCs)), tissue derived cells (including resident cardiac 
progenitor cells) as well as embryonic stem cells (ESCs), inducible pluripotent stem 
cells (iPSCs) and skeletal myoblasts.   
 
In this study I have investigated the use of BM-derived EPCs and cardiosphere derived 
cells (a heterogeneous population that includes cardiac resident stem cells) which are 
discussed in greater detail in sections 1.5 and 1.7, respectively. Advances using other 
cell types have been reviewed in several recent publications22-23. 
 
1.5. Endothelial Progenitor Cells 
1.5.1. Isolation and Characterisation of Endothelial Progenitor 
Cells  
In 1997 Asahara et al24 first described the “isolation of putative progenitor endothelial 
cells”. The authors identified a circulating CD34+ mononuclear cell (MNC) population 
with the capacity to differentiate into ECs in vitro and incorporate into ischaemic tissues 
at sites of angiogenesis in vivo.  Since this time evidence has accumulated that strongly 
supports the existence of BM-derived circulating vascular progenitor cells. 
 
Although these cells are collectively referred to as endothelial progenitor cells (EPCs), 
it is highly likely that this term represents a heterogeneous population of cells at various 
stages of differentiation. Indeed, one of the most controversial issues surrounding EPC 
biology remains the definition of EPC phenotype and their characterisation25-26. Despite 
rigorous investigation over recent years the isolation of a definitive endothelial 
progenitor has been hampered by conflicting reports which are most likely attributed to 
the varying methods utilised by different studies including different cell sources, cell 
isolation methods, in vitro and/or in vivo assays, as well as data analysis and 
interpretation. 
 
Flow cytometric immunophenotyping has been integral to the identification of putative 
EPCs residing in the BM-MNC, umbilical cord blood (UCB)-MNC or peripheral blood 
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(PB)-MNC fractions. Using this method EPCs have traditionally been characterised on 
the basis of a combination of mature endothelial and early HSC associated marker 
expression24, 27-29. The most common markers include CD34, a classic HSC marker that 
is also expressed at low levels on ECs30-31, vascular endothelial growth factor receptor 2 
(VEGFR2 also known as Flk-1 in mice or KDR in humans) a tyrosine kinase receptor 
vital to both endothelial and haematopoietic lineages32-33 and CD133 (or AC133) an 
early haematopoietic marker of unknown function34-35.  It has been proposed that co-
expression of VEGFR2 and CD133 on CD34 positive cells phenotypically identifies a 
unique population of endothelial progenitors27 and the differentiation of EPC to mature 
EC is suggested to be characterised by the loss of CD133, down-regulation of CD34 and 
the up-regulation of VEGFR2 expression36 as well as expression of other endothelial 
markers including CD31 and von Willibrand factor (reviewed in37). However, although 
CD34+VEGFR2+CD133+ cells are widely accepted as representing circulating EPCs in 
humans many studies have failed to test the ability of these cells to generate ECs in vitro 
or in vivo25. Furthermore, Case et al38 report that CD34+VEGFR2+CD133+ cells isolated 
from UCB and PB represent a population of CD45+ haematopoietic progenitor cells that 
do not differentiate into ECs. Interestingly, it has also been shown that CD34+CD45- 
BM and UCB-MNC cultures generate cells indistinguishable from ECs39 and while 
these cells were positive for VEGFR2 they did not express CD133, suggesting that 
CD34+VEGFR2+CD133-CD45- cells may be a more accurate phenotype of true 
endothelial progenitors. It is clear that further investigation including both in vitro and 
in vivo validation is necessary to definitively immunophenotype EPCs. 
 
Many investigators have cultured unfractionated MNCs to isolate and enrich EPCs. 
MNCs are cultured on coated plastic plates in endothelial specific growth media to (i) 
promote endothelial differentiation24, 27, 29, 35, 39-40, (ii) expand EPC populations ex vivo41-
43
 and (iii) to assay endothelial progenitors for colony forming ability44-47 or function 
(including angiogenesis48-51, migration50-52, adhesion49-51 and proliferation49-51 assays). 
Although many variations of the culture protocol have been devised three general 
methods are commonly described (summarised in figure 1.3). In the first method45, 53 
unfractionated MNCs are plated onto fibronectin-coated dishes for 24-48hours 
preceding a re-plating step in which non-adherent cells are removed and re-plated while 
the adherent cells (thought to include macrophages and mature ECs) are discarded. 
Discrete colonies appear after 5-9 days comprising of round central cells with spindle 
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shaped cells at the periphery. These colonies are widely referred to as CFU-Hill or 
CFU-EC and are thought to be derived from EPCs. This colony forming assay was used 
to identify an inverse correlation between EPC number and cardiovascular risk status45 
suggesting that EPCs can be used as biomarkers of cardiovascular disease. CFU-Hill 
concentration was found to be lower in patients at risk for vascular disease and higher 
during acute cardiovascular stress. However it has become apparent that CFU-Hill 
colonies contain an assortment of blood cells including monocytes, lymphocytes, and 
progenitor cells skewed towards the myeloid lineage53-54. Furthermore CFU-Hill were 
unable to form perfused vessels in an in vivo ischaemic experimental model54.  
 
In the second method42, 55-58 (Figure 1.3) MNCs are cultured on fibronectin for 4 days 
before non-adherent cells are removed and discarded leaving a target adherent 
population that is cultured for up to 7 days. The resultant cells are spindle shaped in 
appearance with limited self renewal capacity, persisting in culture for only 2 weeks.  
These cells are often referred to as early EPCs, however controversy has arisen as 
evidence suggests that they may represent monocyte/macrophage cells rather than true 
endothelial progenitors (discussed in greater detail below). Interestingly, changes in 
circulating levels of early EPCs in patients with cardiovascular disease and associated 
risk are comparable to the trend observed for CFU-Hill levels.  Vasa et al57 observed an 
inverse correlation between the risk factors for coronary artery disease (CAD) and 
circulating early EPC number and Lambiase et al58 corroborated this relationship by 
reporting a 70-75% reduction in circulating early EPC levels in patients with clinically 
diagnosed CAD.  
 
In a third approach39, 46, 59-61 (method 3, Figure 1.3) MNCs are cultured on fibronectin or 
collagen-I coated dishes and non-adherent cells are discarded after several days. Highly 
proliferative colonies arise from the adherent cell population after 2-3 weeks of culture 
and display a cobblestone-like phenotype typical of ECs. These cells are 
interchangeably referred to as late EPCs, outgrowth ECs (OECs), or endothelial colony 
forming cells (ECFCs) and can be maintained and expanded in culture for up to 12 
weeks, are reportedly phenotypically indistinguishable from cultured mature ECs and 
have de novo vessel-forming ability39, 46, 54, 59.  
While late EPCs are believed to be derived from circulating adult angioblast-like cells 
and to develop exclusively from a CD14- sub-population, evidence suggests that the 
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majority of early EPCs may arise from a CD14+ monocytic fraction of MNCs or that 
they simply represent mature ECs that have become sloughed from vessel walls39, 54, 62-
63
. Indeed, although early EPCs have been shown to display several EC-like features 
that are phenotypic (EC marker expression, LDL uptake, lectin binding), morphological 
(Weibel-Palade bodies), and functional (vascular network formation) it is now generally 
accepted that these cells represent a mixed population displaying endothelial-
monocytic/haematopoietic phenotypes and may not differentiate into true ECs and are 
therefore not endothelial progenitors39, 42, 56, 62-64. Despite this mis-nomenclature, early 
EPCs have been shown to indirectly promote neovascularisation in pre-clinical models 
of acute MI and critical limb ischaemia42, 62, 64-65. Furthermore, Schmeisser et al66 noted, 
that under angiogenic stimulation CD14+ macrophages/monocytes developed an 
endothelial phenotype and formed tubular-like structures in a 3D Matrigel assay. Thus 
early EPCs have also become to be known as EC-like cells or circulating angiogenic 
cells25-26.  The overlap of endothelial and haematopoietic phenotype and function has 
complicated analysis and made the discrimination between these two lineages difficult. 
It has now been proposed that uncultured monocytes do not possess pro-angiogenic 
properties and that culturing in angiogenic conditions is required to prime them62. 
Despite the confusion related to the different sub-types of proposed EPCs and the 
debate regarding appropriate nomenclature, both early and late EPCs are thought to 
potently promote tissue repair via neovascularisation although their modes of action are 
thought to differ in vivo (discussed further in section 1.5.2). 
 
In summary there remains much controversy surrounding the identity and true 
phenotype of EPCs as well as their role in adult angiogenesis. The current definition 
includes a cell that: 1) resides within the BM and can be recruited to sites of vascular 
injury or tumour growth by environmental cues; 2) expresses both endothelial and 
haematopoietic cell surface markers; 3) can be distinguished from mature circulating 
ECs by these markers and the ability to form outgrowth colonies; 4) can integrate into 
sites of vessel repair or angiogenesis and promote tissue repair67. However due to 
multiple conflicting reports this definition remains continuously evolving. 
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Figure 1.3. Schematic summarising common EPC culturing methods. Method 1,   
MNCs are cultured for several days prior to adherence depletion. Non adherent MNCs 
then give rise to   EPC colonies (termed colony forming unit (CFU)-Hill or CFU-EC) 
within 4-9 days. Method 2, MNCs are cultured for 4 days, thereafter non-adherent cells 
are discarded whilst adherent cells form early EPCs (also known as circulating 
angiogenic cell (CAC), early outgrowth endothelial cell (EOECs) and EC-like cells). 
Method 3, Adherent MNCs are cultured for up to 12 weeks in endothelial conditions. 
Colonies appear between weeks 1 and 3 and give rise to a cobblestone-like cell 
monolayer. These cells are referred to as late EPCs, outgrowth endothelial cells (OECs) 
or EC-forming cells (ECFCs). Figure adapted from26. 
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1.5.2.  EPCs in Angiogenesis and Cardiac Repair; Pre-Clinical 
Models 
Since the first publication detailing the discovery of an adult endothelial progenitor24 
many pre-clinical studies have supported a beneficial role for EPCs in vascular and 
cardiac repair. Early evidence indicated that circulating EPCs functioned as an 
endogenous repair mechanism to maintain the integrity of the endothelial monolayer by 
contributing to the re-endothelialisation of grafts and denuded arteries68-70. Many 
investigators also demonstrated that infusion of MNCs or ex vivo expanded EPCs 
(defined in a variety of ways) augments neovascularisation in both physiological and 
pathological pre-clinical settings including peripheral ischaemia42, 62, 71-74, wound 
healing75-77, atherosclerotic plaques78-79 and tumour neovessels28, 80.  Of particular 
interest, the injection of stem/progenitor cells in animal models of acute MI significantly 
increased neovascularisation and blood flow, reduced adverse left ventricular 
remodelling and improved cardiac function65, 81-87.  Correspondingly, initial stage I and 
II clinical trials indicate that BM- and PB-derived progenitor cells are a useful tool for 
therapeutically improving the blood supply of ischaemic tissue (discussed in section 
1.5.4). 
 
Terminally differentiated mature ECs do not promote neovascularisation in vivo 42, 83, 88 
suggesting that it is a property specific to EPCs that enhances vascular repair in pre-
clinical models. However, different EPC sub-types have displayed functional 
differences with regard to their effects in vivo. Engraftment levels within experimental 
models vary widely and in some studies the incorporation rate of cells with an 
endothelial phenotype has been undetectable or relatively low25, 89 therefore the direct 
contribution of BM-derived progenitors to the endothelium has been down-played in 
recent years.  Indeed, Ziegelhoeffer et al90 report that BM-derived cells do not 
incorporate into the adult growing vasculature but do provide structural support as 
primary leukocytes, fibroblasts or pericytes that accumulate around the growing vessels. 
Other studies corroborate these findings and report that the major contribution of the 
BM to angiogenic processes may come from progenitors for peri-endothelial mural 
cells, which contribute to vascular stability and remodelling91-92 (discussed further 
below). Moreover the release of pro-angiogenic factors in a paracrine manner has been 
suggested as an alternative mechanism responsible for the augmentation of 
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neovascularisation.  In this context, cultivated EPCs are known to secrete an array of 
pro-angiogenic growth factors and cytokines, including VEGF, HGF, G-CSF and GM-
CSF56, 93-96. Thus, two phenotypes have emerged from data regarding the differentiation 
of the EPC; one which integrates into the endothelium and another that takes residence 
immediately around the vessel and provides paracrine signals to nearby ECs56, 91, 95, 97. 
In the second of these situations, early EPCs act similarly to monocytes/macrophages, 
which can increase arteriogenesis by providing cytokines and growth factors98-99, further 
fuelling the hypothesis that early EPCs represent a subset of ‘angiogenic monocytes’.  
However Urbich et al62 demonstrated that an infusion of macrophages did not 
incorporate into vessel-like structures and induced only a slight increase in 
neovascularisation after ischaemia, indicating that the capacity of EPCs to physically 
contribute to vessel-like structures may contribute to their capacity to improve 
neovascularisation. In contrast to early EPCs, late EPCs are thought to enhance 
neovasculogenesis by providing a sufficient number of ECs to allow for structural 
integration into new vessels88. Interestingly, evidence suggests that co-transplantation of 
both early and late EPCs results in enhanced neovascularisation in vivo compared to that 
achieved using single-cell-type transplantation as these cells can act in synergy during 
vascular repair100.  
 
Indeed, vessel formation involves multiple additional cell types other than ECs. 
Arguably the most important of these are the mural cells (or pericytes) which commonly 
originate from mesenchymal cells, surround the surface of the blood vessel and are 
associated with vessel stabilisation, haemodynamic processes as well as having a direct 
role in vessel formation via a complex communication with ECs (reviewed in101). The 
importance of cell–cell interactions in the development of mature vasculature is further 
demonstrated by several studies in which the transplantation of endothelial lineage cells 
alone was not sufficient to produce a stable vascular network.  The newly formed 
vessels tended to show minimal perfusion and rapidly regressed102-103. Furthermore, 
although the potential of EPCs to form functional vascular networks in vivo has 
previously been reported many times, more recent reports show that to obtain stable and 
durable vessels co-implantation with perivascular-like cells is required104-105 and MSCs 
are currently championed as the most appropriate clinical source of these cells106-107.  
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1.5.3.  Molecular Mechanisms Controlling the Mobilisation and 
Homing of EPCs 
In the BM the majority of EPCs remain quiescent within the ‘stem cell niche’108. This 
microenvironment governs the maintenance and mobilisation of stem cells, which are 
bound to stromal cells by integrins. Although the exact mechanisms of cellular 
mobilisation are not completely understood many contributing factors have been 
identified and the process is thought to be regulated by complex crosstalk between a 
myriad of cytokines/chemokines, growth factors, proteinases and cell adhesion 
molecules. Mechanistically, mobilising cytokines/chemokines or growth factors 
interfere with interactions between stem and stromal cells permitting the stem cells to 
leave the BM via transendothelial migration94. This process is mediated by the 
activation of proteinases such as elastase, cathespin G and matrix metalloproteinases 
(MMPs), which cleave cellular adhesive bonds94 between stem and stromal cells. 
MMP9 has been shown to cleave the membrane-bound Kit ligand (mKitL) and induce 
the release of soluble KitL (sKitL or stem cell factor (SCF)), which is known to promote 
the proliferation and motility of stem cells within the BM109. 
 
Physiologically, vascular trauma and ischaemia are believed to be the predominant 
events inducing EPC mobilisation94, 110-111 and have been associated with the 
upregulation of SDF1 (CXCL12)112-113 and VEGF76, which enter the circulation and 
induce mobilisation and homing of EPCs from the BM via a MMP9-dependent 
mechanism. The SDF1/CXCR4 axis has an important role in stem cell retention within 
the BM niche as well as mobilisation and migration to sites of injury (reviewed in114). 
The crosstalk between EPCs expressing CXCR4 (the predominant receptor for SDF1) 
and BM stromal cells expressing SDF1 is thought to be involved in stem cell retention, 
whereas the release of SDF1 by damaged or ischaemic tissues induces EPC mobilisation 
and homing. Therefore it appears that both cleavage of SDF1 within the BM, to disrupt 
the adhesive bonds between EPCs and stromal cells, and increased circulating levels of 
SDF1 are required for EPC mobilisation. Such that SDF1 over-expression by adenoviral 
vector delivery augmented circulating EPC levels in murine models115, whereas 
fucoidan (a drug which displaces SDF1 bound to BM endothelium and extracellular 
matrix (ECM)) resulted in mass egress of CD34+ EPCs from the BM116. VEGF acts in a 
similar chemotactic manner to SDF1; it is also produced by damaged/ischaemic tissues 
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and is thought to direct EPCs to sites of injury. In experimental models increasing 
VEGF levels enhances circulating levels of EPCs76, 117, while in patients with peripheral 
vascular disease EPC expansion and motility were promoted following VEGF gene 
transfer73, 118.  Interestingly it appears that VEGF and SDF1 are interdependent with 
VEGF up-regulating the SDF1/CXCR4 axis and SDF1 is more potent when infused 
with VEGF-A implying that these cytokines act synergistically119. Additional factors 
shown to enhance levels of circulating EPCs in both human and animal studies include 
erythropoietin120, GM-CSF71, angiopoietin-1115, 117, IL8121-122 and physical exercise123. 
 
Pharmacologically, HMG-CoA reductase inhibitors (statins) have been shown to elevate 
the levels and functional activity of EPCs in vitro and in vivo124-125. This was confirmed 
by the demonstration that statins augmented the incorporation of BM mobilised EPCs 
into foci of corneal neovascularisation124. Similarly, the anti-diabetic and anti-
inflammatory peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists promote 
differentiation and mobilisation of BM-derived angiogenic progenitor cells and improve 
re-endothelialisation after vascular injury52. Angiotensin converting enzyme inhibitors 
and angiotenisin II receptor antagonists have also been shown to be beneficial in the 
mobilisation of EPCs126-127. 
 
Several studies indicate that the activation of the PI3K/Akt pathway plays a role in the 
statin-induced augmentation of EPC levels125, 128.  Additionally SDF1, VEGF, EPO and 
exercise are also known to augment the PI3K/Akt pathway129-132.  Akt1 inhibits cellular 
apoptosis and stimulates endothelial nitric oxide (NO) synthesis by endothelial nitric 
oxide synthase (eNOS), which has been shown to be essential in maintaining adequate 
progenitor cell mobilisation in response to distinct stimuli including VEGF, statins and 
exercise130-131, 133. Therefore the activation of Akt appears to promote phosphorylation 
of eNOS, increasing endothelial NO production and hence EPC growth and migration94. 
Thus it seems apparent that although the mechanisms governing EPC mobilisation are 
complex, several of the contributory factors may share signalling pathways.   
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1.5.4. Therapeutic use of EPCs: Clinical Trials using Adult 
Autologous Cell Therapy to Treat Ischaemic Heart Disease  
Following encouraging pre-clinical studies suggesting that stem cell treatment can 
dramatically improve cardiac function following ischaemic injury (see section 1.5.2), 
autologous BM cell transplantation has rapidly been introduced into the clinical setting. 
Initial phase 1 trials showed that this technique was safe, feasible and overall 
demonstrated a beneficial effect on ventricular function134-136. Subsequently, a number 
of small randomised and controlled trials have been performed. In most studies 
unselected BM- or PB-MNCs have been injected either into the circulation supplying 
the ischaemic region or directly into the damaged tissue, however conflicting results 
have been reported. 
 
Schächinger et al137 published the results of the 4 month REPAIR-AMI trial 
(multicenter, double-blind and fully controlled) and revealed that following BM cell 
infusion, the absolute improvement in ventricular function was greater amongst cell-
recipient MI patients than those given placebo. Subgroup analysis also suggested that 
the benefit was greatest in those patients with the largest infarcts. Furthermore, a 
reduction in death, recurrence of MI and re-hospitalisation was observed at 12 
months137-138. These findings provide evidence of the beneficial effects of BM cell 
transplantation after acute MI, however enthusiasm was somewhat restrained due to the 
modest size of the effect (approximate 5.5% increase in left ventricular ejection fraction 
(LVEF) in cell-recipient group). Furthermore, the longer term results of the BOOST 
trial showed that the relative improvement in ventricular function after infusion of BM-
MNCs observed at 6 months was no longer significant at 18 months suggesting that the 
controls eventually “caught up” with the treated group and that the predominant effect 
of the cells was an acceleration of recovery139-140. The smaller ASTAMI trial did not 
detect a significant improvement in ventricular function in the BM cell group at 6 
months as compared with the control group141. Technical differences in the 
characteristics or handling of the infused cells might explain the different outcomes 
between trials, for example the ASTAMI trial injected 7x107 ficoll separated BM-
MNCs into patients compared to 2.4x108 of the same cell type used in the REPAIR-
AMI trial. However, Janssens et al142 also failed to report an improvement in global 
ventricular function in patients who received infusions of BM-MNCs as compared with 
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the control group at 4 months, although infarct size was reduced and regional wall 
motion was improved in the BM cell treated group.  
 
The heterogeneous cell populations used during BM cell infusion may help explain why 
apparently similar protocols can yield contrasting results. Identifying which of the 
cellular constituents is necessary for beneficial effects, and whether these effects are 
mediated directly by the transplanted cells or indirectly through involvement of other 
cells, would enable targeted delivery of essential components and is a likely critical step 
in the optimisation of this therapy. Furthermore, it may be that unselected BM-MNCs 
do not represent the ideal cell population to treat cardiovascular disease and that greater 
efficacy could be realised by the delivery of a more defined cell type. However to date 
CD34+143-144 and CD133+145-148 selected MNCs have not resulted in greater benefit than 
unselected cells in the few clinical trials that have adopted this approach and 
importantly one study has linked CD133+ cell infusion with an increase in adverse 
coronary events following acute MI149. It remains unknown whether marker-based 
selection of cardiac repair cells will increase their efficacy and further investigation is 
required. Also of interest, the TOPCARE-AMI trial compared the efficacy of cultured 
circulating progenitor cells and freshly isolated BM mononuclear cells. Both cell types 
led to a similar small but significant increase in LVEF (approximately 10%), improved 
regional wall motion in the infarct zone and reduced end-systolic left ventricular 
volumes at 4 months150.  In addition Assmus et al151 evaluated the effects of BM and PB 
progenitor cells in patients with chronic ventricular dysfunction in the TOPCARE-CHD 
crossover trial. The absolute change in ventricular function was significantly greater 
among patients receiving BM cells than among those receiving circulating progenitor 
cells. The groups received the other type of cell in the next phase of the trial, but the 
result was independent of the order in which the cells were given, suggesting that the 
superior effect of BM-derived cells is specific. 
 
Despite conflicting reports, recent systemic reviews and meta-analyses of randomised 
studies summarising data from over 1000 patients have revealed a significant, albeit 
moderate, improvement in LVEF, infarct size and end systolic volumes (ESV) post MI 
following cell treatment (in addition to conventional treatment)134-136. Overall, these 
analyses concluded that stem cell treatment for acute MI still holds promise and the data 
suggests that improvement over conventional therapy can be achieved. Furthermore, 
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subgroup analysis revealed that there was a significant difference in LVEF in favour of 
BM cells when they were infused within 7 days following acute MI and when the cell 
dose administered was higher than 108 cells, thus highlighting the numerous factors that 
need to be considered to optimise this therapeutic approach135 (figure 1.4). 
 
Critically, several possible concerns have arisen regarding the role and risks of cell 
based therapies. Whereas the regeneration of the endothelium by EPCs protects against 
lesion formation, BM-derived progenitor cells may also contribute to plaque 
angiogenesis thereby promoting plaque instability152. Additionally, EPCs have been 
implicated in tumour neovascularisation and thus are being considered as novel targets 
for anti-angiogenic therapies (reviewed in153). Furthermore, several ‘unknowns’ have 
been identified during the clinical translation of cell-based therapy for cardiovascular 
disease, these include; the source and subtype of cells, preparatory methodology, the 
time at which cells are administered, the route by which they are given, the number of 
cells transplanted, the volume given and outcome measurement (figure 1.4). The task 
force of the European Society of Cardiology propose that the clinical need, feasibility, 
and safety of the treatment as well as the need to resolve discrepant results mandate 
larger, adequately powered trials using optimal dosing, longer term outcome 
assessments, and more patient-centred outcomes154. The field will also be further 
advanced by simultaneously attempting to elucidate the mechanisms underlying 
physiological improvements observed with cell transplantation through basic research. 
This can help guide clinical investigation by encouraging future work and also 
introduce more pragmatic approaches to demonstrating clinical efficacy154.   
 
In summary, despite the positive preliminary clinical evidence for patient benefit from 
EPC therapy, the rapid transfer from ‘bench to bedside’ has meant patients are being 
given a therapy about which very little is known.  It is important to rectify this 
knowledge gap and to elucidate the true identity of EPCs as well as the mechanisms 
responsible for modulating EPC function, which may lead to improved therapeutic 
strategies. Also, additional larger multicenter and controlled trials are needed to 
evaluate the clinical effect of this therapy in the longer term, to deduce optimal dosing 
regimes and to address other identified uncertainties including route and timing of 
delivery154 (see figure 1.4). 
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Figure 1.4. A summary of the outstanding challenges, limitations and open 
questions that remain to be addressed for the optimisation and clinical translation 
of stem cells for therapeutic angiogenesis following MI. Figure from 155. 
 
1.6. Cardiac-derived Stem Cells for Therapeutic Repair 
Until recently the adult heart was considered a terminally differentiated organ without 
the ability to regenerate. However the discovery of antigenically distinct cardiac-
resident stem/progenitor cell populations (CSCs) has challenged this prevailing dogma. 
CSCs have been shown to retain the capacity to differentiate into and repopulate the 
three major cardiovascular cell lineages: cardiomyocytes, endothelial and smooth 
muscle cells both in vitro and in vivo156.  CSCs are presumed to function physiologically 
to offset a low rate of cardiac cell loss over time. However, the number of CSCs in the 
adult heart is thought to be relatively low and quantitative data from mouse, rat, dog, 
and human studies have estimated that there is 1 CSC per approximately 30,000 to 
40,000 myocardial cells156. Such a low presence may offer an explanation as to why 
endogenous repair mechanisms are insufficient to reverse major injury, such as after 
acute MI. Furthermore, it has been observed that within one day of MI up to 40% of 
resident CSCs are depleted157 and it may be speculated that ischaemic injury may limit 
the proliferation and self-renewal of remaining CSCs, thereby precluding restoration of 
the stem/progenitor cell pool and preventing myocardial repair. Therefore, there has 
been a great effort to try to identify and expand CSC populations ex vivo with a view to 
define and harness their therapeutic potential. CSCs have been identified in many 
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species including humans, although they were initially identified in rodents by their 
expression of stem cell-related markers, including c-Kit (CD117, the receptor for stem 
cell factor), and Sca-1 (stem cell antigen-1), as wells as displaying other phenotypic 
properties such as those attributed to progenitor side populations (ability to efflux 
Hoechst dye and expression of Abcg2) and expression of the embryonic-related cardiac 
progenitor islet-1 (reviewed in156). Several studies have isolated and expanded CSCs 
exclusively based upon the expression of stem cell related antigens (e.g. cKit+ or Sca-1) 
and have further demonstrated the ability of these sub-populations to attenuate heart 
damage in rodent models (reviewed in156) although it is undetermined whether these 
different CSC sub-types have clearly distinct phenotypes. In addition to CSC isolation 
and expansion based on antigen expression, CSCs have also been identified by their 
ability to form spheres following ex vivo 3D culture of myocardial tissue.  This method 
of CSC isolation and expansion was employed in this thesis and will now be discussed 
in more detail.  
 
1.7. Cardiospheres and Cardiosphere-derived Cells 
1.7.1.  Isolation and Characterisation of Cardiosphere-derived 
Cells 
In 2004 Messina and colleagues158 observed that cardiac surgical biopsy specimens 
yielded an outgrowth of cells when cultured as explants ex vivo. Once subjected to a 
second phase of suspension culture, these explant derived cells (EDCs) spontaneously 
formed spherical cell clusters that were shown to be progenitor rich aggregates 
containing sub-populations of cKit and Sca-1 positive cells. These spherical structures 
were termed ‘cardiospheres’ (Csphs) in analogy to the observation that neural stem cells 
can be expanded from primary tissue as self-assembling spherical aggregates dubbed 
‘neurospheres’. Following this discovery, Eduardo Marban’s laboratory proceeded to 
slightly modify the original protocol by introducing a post-cardiosphere expansion stage 
to advance this cell type towards clinical translation159. Cardiospheres were plated and 
expanded as a monolayer of cardiosphere-derived cells (CDCs) to achieve 
therapeutically relevant cell numbers in a timely manner from relatively small amounts 
of starting tissue (percutaneous right ventricular endomyocardial biopsy specimens, 
approximately 10-40mg)159. Cardiospheres generated in their study consistently 
expressed cKit, endoglin (a TGFβ family regulatory receptor discussed further in 
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section 1.9.3) and the gap junctional protein connexin 43 as well as staining positive for 
Ki67 within the core of the sphere indicating proliferating cells. Following in vitro CDC 
expansion, the majority of cells at passage 2 were endoglin positive (>95%), with 
significant sub-populations also expressing cKit (~20%), CD90 (~40%), CD34 (~5%) 
or CD31 (~10%), whilst being largely negative for CD45 and blood lineage markers. 
Thus as well as stem cells, CDCs also appear to contain sub-populations that resemble 
mesenchymal cells or fibroblasts (CD90+, endoglin+) and endothelial cells (endoglin+, 
CD31+, and CD34+). 
 
Since this first study describing and characterising the derivation of CDCs from cardiac 
tissue the Marban group have further characterised CSph and CDC properties160-162 and 
many independent laboratories have reproduced and verified the Csph and CDC 
phenotype163-167. Furthermore the Csph/CDC method of CSC isolation has been 
reported in many animal species including mouse158, 166, rat161-163, dog164, 168 and pig169-
171
 and has also been successful with biopsies from chronic heart failure patients159 as 
well as those with congenital heart defects172. 
 
However, other studies have challenged the cardiac explant and Csph culture method 
for isolating and enriching cardiac resident stem cells, claiming that resultant cell 
populations do not represent progenitor/stem cells but rather are blood-borne derived 
cells, without multi-lineage differentiation potential or clonogenic capacity173-174. 
Detailed rebuttals of these critical works refuted these claims and attributed their 
findings to significant technical and methodological deviations in cell culture 
techniques175-176. The Marban group went on to confirm that EDCs, Csphs and CDCs 
represent a complex heterogeneous population of cells with clonogenic and multilineage 
potential (cardiomyocyte, smooth muscle and endothelial). Furthermore, they 
demonstrated consistently that both EDCs and cardiospheres contain cKit positive sub-
populations, whilst uniformly staining negative for markers of haematological lineages, 
CD45 and the mast cell marker AA4. In contrast, Anderson et al174 postulate that 
cardiospheres consist predominantly of fibroblasts as well as blood-borne cells. It is 
generally accepted that a significant sub-population of CDCs do express the 
mesenchymal marker CD90, which is also found on fibroblasts. However, Carr et al163 
found that less than 10% of CDCs expressed the fibroblast-specific marker DDR2. In 
addition, both of the papers critiquing cardiospheres as a source of stem cells173-174 
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failed to identify a cKit positive population in their cell populations. This important 
difference suggests that Anderson et al174 were indeed characterising a cell population 
distinct to that described by Marban and others, rendering comparisons difficult. 
However comparing these studies does imply that even slight technical deviations in 
culture methods can have significant consequences on the marker profile of CDCs. This 
is an important consideration in preparing these cells for future heart repair studies.  
 
Another matter that is currently debated is the true origin of cardiac resident stem cells. 
It has been suggested cKit+ progenitor cells within the heart are actually derived from 
extra-cardiac tissue and as such have been described as BM cells ‘out of place’177. This 
follows a study by Massberg et al178 showing that cKit positive cells leave the BM in 
small numbers to scavenge pathogenic molecules in peripheral tissues, including the 
heart, as part of a local innate immune response. Furthermore in human heart transplant 
patients, recipient derived cardiomyocytes and ECs have been observed within the 
donor heart suggesting that circulating stem cells may migrate into the myocardium179, 
although it has also been suggested that host stem cells may simply have migrated from 
residual atrial tissue into the donor heart156. Still, a study of patients receiving allogeneic 
BM transplantation revealed that at least 2-5% of cardiomyocytes were chimeric 
indicating that circulating cardiac committed cells are able to reach the myocardium180.  
Conversely, using retrospective clonal analysis in mouse, Eberhard et al181 show the 
intracardiac origin of adult myocytes and do not support the notion of an influx of stem 
cells with cardiogenic capacity into the adult heart, at least under physiological 
conditions. Their study, however, does not discount the presence of circulating stem 
cells in the heart, just their ability to develop into cardiomyocytes and the authors do 
concede that the effect of pathological insult, such as acute MI or heart transplantation, 
may trigger a mass influx of BM-derived stem cells with multi-lineage potential.  In 
relation to the preparation of cardiosphere cultures, White et al182 have recently shown 
that endogenous CDCs have no detectable extra-cardiac contribution using short-
tandem nucleotide repeat testing, fluorescence in situ hybridization and Q-PCR in cells 
cultured from heart transplant patients. However sample sizes in this study were small 
(n=2 to 10) and none of the hearts were known to be affected by ischaemia which may 
be required for extra-cardiac derived stem cell re-population of the heart. Consequently, 
Barile et al156 have shown that in an ischaemic setting BM-derived cKit positive stem 
cells do migrate into the heart. In this study GFP-expressing donor BM cells were 
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transplanted into WT irradiated recipient mice and following haematological 
reconstitution and experimental MI, cardiospheres were cultured from recipient mouse 
cardiac tissue. The majority of these spheres contained GFP positive cells thus 
suggesting that under pathological conditions circulating cKit positive cells are able to 
populate the heart. In conclusion the true origin of stem cell sub-populations residing in 
the heart is still being debated and extensive in vivo lineage tracing will be required to 
resolve this issue. Whilst there is strong evidence suggesting that the heart may become 
enriched for BM-derived stem cells following injury, this does not exclude the 
possibility that adult stem cells of intrinsic cardiac origin do exist. Regardless of their 
specific cellular origins, it is the ability of these cells to contribute to endogenous 
cardiac repair that should remain the focus of ongoing studies. Indeed, it may be that the 
migration and residence of BM-derived stem cells in the heart following injury primes 
them to promote superior cardiac repair over that achieved by transplanting stem cells 
isolated directly from the BM.  
 
When prepared correctly CDCs are a heterogeneous mix of cells which express multiple 
markers of stem/progenitor (cKit, Sca-1, CD34 and endoglin), endothelial (CD31, vWF 
and endoglin), cardiac (troponin1, α-sarcomeric actin, connexin-43) and mesenchymal 
(CD90, endoglin, DDR2) cells (refer to table 1.1 for references). In addition, CDCs are 
clonogenic and exhibit multilineage differentiation potential (cardiomyocyte, 
endothelial and smooth muscle cells)158, 175 thus fulfilling key criteria for cardiac stem 
cells.  Furthermore, cardiospheres and CDCs derived from adult tissue have been shown 
to express cardiac transcription factors (Nkx2-5, GATA-4 and islet-1)159, 163, 172, 183, 
which are crucial markers of cardiac progenitor cell state in foetal hearts, as well as 
pluripotency markers (Oct3/4, sox-2 and nanog)160, 163.  
 
Three-dimensional (3D) culture is known to maintain embryonic stem cells in an 
undifferentiated state160. Although this technique has not been well studied in adult stem 
cells the rationale for including a 3D cardiosphere stage in the generation of a CSC 
population ex vivo is the postulation that sphere culture encloses a mixed population of 
cells which, as in the stem cell niche, could promote the viability and proliferation of 
stem cell sub-populations184. Similarly it is the hypothesis of Marban et al159 that a 
mesenchymal cell sub-population within CDC expansion culture may serve to provide 
physical or secretory support to cKit positive progenitor cells.    
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Li et al160 tested the hypothesis that growing human cardiac EDCs as 3D cardiospheres 
recapitulates a stem cell niche-like microenvironment favouring cell survival by 
comparing cardiospheres with EDCs cultured under traditional monolayer conditions. 
As previously demonstrated, EDCs self-assembled into spherical stem cell niche-like 
structures in vitro and immunostaining revealed that these cardiospheres consisted of 
centrally localised cKit positive cells surrounded by cells expressing collagen IV and 
endoglin160. Thus architecturally, cardiospheres resembled in vivo stem cell niches, 
where central stem cells are bound together by supporting cells and linked by interactive 
ECM molecules185. Li et al160 also showed that cKit+ cells were significantly increased 
in cardiosphere cultures relative to baseline EDC levels (16.9%±2.1% vs. 9.1%±0.7%, 
p<0.01), whereas when EDCs were expanded directly as a monolayer the proportion of 
cKit positive cells markedly declined (5.2%±1.0%, p<0.01 vs. baseline). Furthermore, 
Q-PCR and immunostaining revealed the increased expression of many stem cell-
related factors in cardiosphere cultures as compared with monolayer expanded EDCs. 
These factors included (i) transcription factors (Nanog and Sox2), (ii) proteins 
associated with stem cell growth and maintenance of a stem-like undifferentiated state 
(including IGF-1, HDAC2 and Tert) and (iii) ECM and adhesion molecules (such as 
collagen IV and MMPs). Additionally, in response to oxidative stress, apoptosis was 
blunted in cardiospheres in comparison to monolayer cultured cells160. Therefore this 
study concluded that compared with traditional monolayer culture, the formation of 
cardiospheres augments the “stemness” profile of cells and enhances the expression of 
many ECM and adhesion molecules. The authors suggest this may be attributed to a 
recreation of a stem cell niche-like microenvironment and HDAC2-mediated epigenetic 
modification. However, it should be noted that although it is suggested that 3D 
cardiosphere culture acts to enrich a CSC population the formation of spheres in culture 
is not a feature specific to stem cells as other terminally differentiated cells (such as 
fibroblasts) have also been found to form spherical structures under cardiosphere culture 
conditions167, 174.  
 
Despite evidence from the Marban laboratory pointing to the high stem cell content and 
efficacy of cardiospheres in heart repair160, another study from the same group 
advocated the use of EDCs for myocardial repair directly thus avoiding the time taken 
for cardiosphere formation or CDC expansion162. Here the authors characterised EDCs 
and identified markers of cardiac progenitor cells (Abcg2, cKit and SSEA-1) in cells 
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derived from rat atrial and ventricular tissue using RT-PCR. Two distinct cKit sub-
populations were identified defined by the co-expression of either Abcg2 (a side 
population marker) or SSEA-1 (a marker of embryonic origin). It is standard practice in 
many studies to repeatedly harvest EDCs from cardiac tissue explants. Interestingly this 
study showed a peak of cKit expression at the third harvest (~12%). A small population 
of SSEA-1 expressing cells peaked at harvest 1 at 1.0±0.1% and was undetectable by 
the final harvest. In contrast, the proportion of cells expressing Abcg2 increased during 
culture (harvest 5: 7±1%). EDCs also showed constant expression of the mesenchymal 
marker CD90 (~30%) as well as small sub-populations expressing endothelial markers 
that declined with progressive time in culture (harvest 1: CD31+ 3.2±1.2%, CD34+ 
3.1±2.9%; harvest 5: CD31+ 2.2±0.5%, CD34+: 2.4±0.3%). Minimal co-segregation was 
evident between stem cell markers and those of mesenchymal and endothelial lineages. 
EDCs were negative for the markers Sca-1 and Isl-1 as well as markers of 
haematological origin (including CD3, CD11b, CD45) and mast cell lineage (AA4+).  
 
The in vivo repair capacity of EDCs, cardiospheres and CDCs will be discussed below. 
 
1.7.2. Cardiosphere and CDC-Mediated Cardiac Repair; Pre-
Clinical Models 
In their original study Messina et al158 showed that cardiosphere transplantation in a 
mouse model of experimental MI successfully contributed to attenuated adverse LV 
remodelling as evidenced by increased anterior LV wall thickness and fractional 
shortening. Since this time, many studies have shown that EDCs162, 166, cardiospheres158, 
160, 186
 and CDCs159, 161, 163, 169, 172, 187 are able to improve heart function in pre-clinical 
mouse158-160, 166, 187, rat161-163, 172, 186 and pig models169, 171 of heart injury (selected 
studies are summarised in table 1.1). Taken together these studies predominantly 
demonstrate that cell transplantation results in increased LVEF and improved 
haemodynamic function. Of particular interest is the efficacy of the distinct cell 
populations identified at each of the 3 stages that make up the cardiosphere culture 
method: EDCs, cardiospheres and CDCs.  As discussed above the 3D cardiosphere 
structure is thought to recreate a stem cell niche-like environment, favouring stem cell 
survival as well as improving functional benefit in vivo. Several studies have borne this 
proposal out in direct comparisons between cardiospheres and CDCs. Using the mouse 
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MI model Li et al160 have shown that implantation of human cardiospheres into 
infarcted mouse hearts disproportionately enhances cardiac function relative to 
dissociated cardiospheres cultured as monolayers of CDCs (LVEF; 15% versus 10% 
increase over vehicle only recipient controls). Furthermore, in a mini-pig model of 
cardiomyopathy either cardiospheres or CDCs were delivered to animals via 
intramyocardial injection 4 weeks following MI. While both cell treated groups showed 
an equivalent increase in LVEF relative to placebo controls 8 weeks after treatment, 
those animals receiving cardiospheres showed superior haemodynamic function and a 
greater attenuation of adverse remodelling than CDC recipients169. Despite these 
observations the benefit of CDC monolayer culture over cardiospheres lies in the 
significantly faster proliferative rate of these cells (3-fold versus 1.2 fold increase after 7 
days)160, leading to therapeutically relevant cell numbers being produced in a timely 
manner. Additionally, cell transfer in the clinic tends to be via the less invasive 
percutaneous catheter based intracoronary route which is simple and safe, but due to the 
relatively large size of cardiospheres (50 to 200µm in diameter) intracoronary infusion 
runs the risk of embolising blood vessels therefore direct intramyocardial injection 
would be necessary169. However, Johnston et al170 report that the larger size of human 
CDCs relative to BM-MNCs (20.6±3.9µm versus 8.6±1.8µm) also poses a risk to 
microvascular occlusion given that the average capillary luminal diameter is 7-10µm. 
More importantly, the authors associated this risk with the observation of 
microinfarction  in dogs receiving MSCs (similar size to CDCs at 21.0±3.3µm) via 
intracoronary delivery (myocardial ischaemia observed in 2/6 animals)188. Therefore 
precautions were taken to limit risk in their porcine study170. They found that 100U/ml 
heparin in the cell suspension sufficed to eliminate cell-related thrombus formation. In 
animals receiving catheter-based intracoronary CDC delivery 4-weeks post MI, in the 
optimised infusion solution, troponin levels were measured after 24 hours. Interestingly 
troponin I remained within normal limits (<0.5ng/ml) following transplantation of 
<2.5x107 CDCs indicating safe infusion without thromboembolic complication. 
However greater cell doses raised troponin levels in a dose-dependent manner, likely 
due to micro-infarction.  This study defined a safe dosage range for future clinical trials 
(discussed in section 1.7.4).  
 
CDCs and EDCs were shown to be equivalent in their capacity to improve cardiac 
function following MI in a rat model162. Clinical use of EDCs directly (i.e. without 
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subsequent cardiosphere stage) is an attractive option as it would improve production 
efficiency as well as limit the possibility of culture-associated phenotypic drift or 
cancerous transformation. However, a conflicting report failed to demonstrate any 
beneficial effect of EDCs in vivo189. Additionally cKit-positive lineage-negative EDCs 
have been shown to increase LVEF by only 8% over controls when delivered into 
infarcted mouse hearts166 whereas several Csph/CDC studies show increases in LVEF 
(over controls) in the region of 15%159-161, 187. These studies are summarised in table 1.1 
and possible reasons for variable outcomes are discussed further below.   
 
Similar to studies addressing BM-derived cell transplantation in heart injury models and 
their subsequent inferences regarding primary functional mode of repair, it has been 
noted that the number of engrafted cells following Csph/CDC delivery into ischaemic 
hearts is too low to account for the observed improvements in cardiac improvement160, 
163, 187
 – see also table1.1. Therefore there has been a shift towards the ‘paracrine 
hypothesis’ to explain the beneficial effect of Csph/CDC delivery, whereby transplanted 
cells produce soluble factors that are beneficial to the injured heart. Indeed, Chimenti et 
al187 have shown that human CDC-conditioned media exerts both anti-apoptotic and 
pro-angiogenic effects in vitro and CDCs secrete VEGF and HGF when transplanted 
into infarcted mouse hearts. In fact, this study claims that paracrine mechanisms account 
for up to 80% of the observed functional benefit (approximately 15% increase in LVEF 
relative to fibroblast control group) as opposed to only 20-50% assigned to direct 
myocardial and/or vascular regeneration (as judged by the number of engrafted human-
specific cells). In support of their conclusion the authors also report that injection of 
CDCs in the peri-infarct zone increases the expression of Akt as well as decreasing the 
apoptotic rate (judged by activated caspase 3 levels in the heart) indicative of an overall 
cardio-protective role.  In light of these findings it is important to highlight that while 
significant progressive decline in cardiac function is observed in untreated infarcted 
hearts, CDC/Csph recipient mice show reduced detrimental progression and therefore 
exhibit an increased functional capacity in comparison to these control groups; cell 
transplantation does not improve function over baseline measurements (typically taken 
1-3 days following surgery). For example, Smith et al159 describe an ~15% increase in 
LVEF relative to controls 3 weeks following CDC transplantation (p<0.05) however 
there was no significant change from baseline measurements (2 day since surgery) in 
these mice. This suggests that the role of the transplanted cells is to promote higher 
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tissue resilience and attenuate adverse remodelling by limiting fibrosis and increasing 
capillary density rather than by regenerating the myocardium. This is in agreement with 
the findings of Chimenti and colleagues187. Also of interest is the demonstration by this 
study that cardiospheres express higher levels of both VEGF and HGF than CDCs in 
culture and  they additionally secrete IGF1187. These findings imply that any paracrine 
contribution of these factors is maximal at the cardiosphere stage, however this was not 
tested in vivo. Delivery of HGF and IGF-1 into a porcine MI model has been reported to 
activate endogenous cKit positive cardiac stem cells and improve cardiomyocyte 
survival as well as reducing fibrosis and cardiomyocyte hypertrophy190, indicating the 
potential functional importance of the above findings.  
 
Multiple pre-clinical studies have demonstrated the positive effect of CDC/Csph 
transplantation on in vivo cardiac function (see table 1.1). Improved parameters include 
increased LVEF and haemodynamic function, reduced infarct size, as well as increased 
fractional shortening, increased viable myocardium within the infarct zone and 
increased LV wall thickness (table 1.1). However, conflicting reports regarding the 
efficacy of these cells for heart repair have also arisen. Intracoronary delivery of 3x106 
porcine CDCs into pig hearts 8 weeks following balloon occlusion and reperfusion was 
shown to reduce infarct size and improve haemodynamic function however no 
difference in LVEF was detected170. Furthermore, in another study, Li et al189 showed 
that injection of in vitro expanded EDCs into infarcted mouse hearts did not result in 
any change in cardiac function, haemodynamics or infarct size. Additionally, wide 
variation exists between studies reporting functional benefit following cell 
transplantation.  While Chimenti et al187 report a 16% increase in LVEF (measured by 
echocardiography) at 3 weeks following the injection of 105 CDCs into infarcted mouse 
hearts, Davis and colleagues162 describe only a 6% increase (measured using cardiac 
MRI) at 3 weeks following administration of 106 CDCs into a rat model of MI. 
Conflicting reports and variation may be attributable to differences in culture techniques, 
model species, cell number, delivery route or analysis methods. Interestingly human 
cardiospheres were shown to increase LVEF and attenuate LV remodelling to a greater 
extent than spheres derived from rat tissue when both were transplanted into a rat MI 
model186.  Additionally, the degree of engraftment and survival of delivered cells may 
dictate the differences in functional outcome reported by these studies. Indeed, using in 
   31 
vivo bioluminescent imaging Li et al189 showed very poor transplanted cell survival 8 
weeks following transplantation. 
 
Expanding this point, it has been demonstrated that irrespective of which cell type or 
pre-clinical model is used for cardiac repair, the level of functional improvement 
attained is limited to the level of cell retention.  Following delivery into the heart, 
reported cell seeding efficiencies vary, whilst acute cell retention in many studies is 
reported to be less than 10%191. This represents a major obstacle to the cardiac stem cell 
therapy field.  Survival of transplanted cells is largely dependent upon the status of the 
host tissue. Therefore, paradoxically, transplantation of donor repair cells into the 
ischaemic heart may result in large losses due to an inhospitable environment. 
Furthermore, in addition to cell death, both venous drainage and the mechanical force of 
the beating heart are proposed to account for a significant loss of donor cells192. Poor 
cell retention would arguably be detrimental to the ability of infused cells to contribute 
to repair either by direct or paracrine means. Mechanisms that improve functional 
outcome in pre-clinical models of heart injury with CDC/Csph treatment include co-
administration of donor cells with basic fibroblast growth factor (bFGF)171, 
preconditioning cells in physiological (5% O2)193 or hypoxic (0.1% O2 for 6 hours)166  
conditions as well as magnetic targeting of cells  to the infarct zone161 and application of 
a fibrin glue seal over the intramyocardial injection site194. These measures were all 
found to significantly improve cell survival and retention and positively correlated with 
an improvement in cardiac function. The significance of these studies lies in the 
demonstration that additional interventions/mechanisms may be employed to improve 
the efficacy and outcome of cardiac stem cell therapy.  
 
In summary both Csphs and CDCs are able to improve cardiac function following 
transplantation into pre-clinical models of heart injury, including clinically relevant 
large animal models of myocardial infarction. Despite this generally consistent finding, 
several conflicting reports do exist which call into question the degree of efficacy of 
these repair cells and highlight the importance of recognising variations between 
studies, especially methodological differences with respect to CSC isolation. 
Furthermore the beneficial effect of cell therapy may be improved via a number of 
modifications that target donor cell survival and retention in vivo. In addition, several 
studies suggest that cardiospheres confer an improved functional benefit over 
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monolayer expanded cells. The mechanisms underlying the superiority of cardiospheres 
over CDCs have been postulated as (i) an increase in cKit expressing cells in 3D culture 
with a concurrent up-regulation of stem cell related genes, (ii) higher levels of growth 
factor secretion and (iii) an enhanced resistance to oxidative stress over monolayer 
cultured cells. In addition, increased retention and engraftment in vivo has been 
proposed to be due to the increased expression of ECM proteins by cardiospheres160. It 
is clear that further work is required to determine if the cardiosphere culture stage is 
required or indeed if it offers any advantage over expanded CDC monolayers. 
Nevertheless, significant proof of principle has been demonstrated and CSC therapy has 
now moved towards clinical translation, this will be discussed in greater detail in section 
1.7.4. 
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Cell Type 
& Source Markers Study Details 
Cell 
Engraftment Cardiac Function Angiogenic Response Ref 
EXPLANT-DERIVED CELLS (EDCs)    
Rat EDCs 
(versus CDCs) 
SSEA1, cKit, abcg2, 
CD90, CD31 
Rat: acute MI 
Peri-infarct I/M injection (~106 cells/mouse) 
6 weeks;  cardiac MRI; n=6-8 (fibroblast control) 
EDC engraftment  
(not quantified) 
↑ LVEF: (EDCs & CDCs: (+) ~6-8%  vs fibroblast) 
↓LVEDP:(EDCs & CDCs:(-)~2mmHg vs fibroblast) 
↑ Contractility 
In vitro: EDCs & CDCs formed tubules 
on Matrigel  
162 
Mouse       
ckit+lin- EDCs Not Determined 
Mouse: acute MI  
Tail vein infusion (106 cells/mouse) 
28 days post injection; Echocardiography 
EDC engraftment  
(not quantified) 
↑ LVEF: ((+) ~8% vs vehicle controls) 
↑Fractional shortening: ((+)~5% vs vehicle controls) 
↓ Infarct size: ((-) ~15% vs vehicle controls) 
↑ peri-infarct capillary density 
((+) ~36% vs controls) 
vWF+ engrafted donor cells  
166 
CARDIOSPHERES (Csphs)    
Human Cshps CD34, cKit, CD31, Sca1 
Mouse: acute MI 
Peri-infarct I/M injection (~10 spheres/mouse) 
18 days; echocardiography; n=3-6 
Csph engraftment  
(not quantified) 
↑ Infarcted anterior wall thickness 
↑Fractional shortening: ((+) ~ 2-fold vs vehicle 
controls) 
In vivo: neovessels containing aSMA+ 
and CD31+ engrafted donor cells (not 
quantified) 
158 
Human and Rat 
CSphs  
(sheet form) 
cKit, αβMHH, cardiac 
Troponin, vimentin, 
SMA, vWF  
Rat: acute MI  
3 weeks: LV pressure-volume loops 
<10% engraftment at 
day 21 
↑ LVEF: (Rat: (+) ~19%; Human (+) 28% vs 
controls) 
↓ ESV and EDV 
↑ capillary density   
((+) ~100%  vs  controls) 
vWF+ engrafted donor cells  
186 
Human Cshps 
(versus CDCs) 
cKit, endoglin, 
collagenIV 
Mouse: acute MI 
Peri-infarct I/M injection, ~105 cells/mouse 
21days; echocardiography; n=7-11 
Csph: 1.69%±0.70%  
CDC: 0.41%±0.25% 
(% area) 
 ↑ LVEF: (Csphs: (+) ~15% vs vehicle controls; 
CDCs: (+) ~10% vs vehicle controls) 
↓ LV adverse remodelling (Csphs>CDC) 
vWF+ engrafted donor cells identified, 
not quantified 
 
160 
CARDIOSPHERE-DERIVED CELLS (CDCs)   
Human CDCs  
 
cKit, Endoglin, CD90, 
CD31, cardiac Troponin, 
Connexin 43 
Mouse: acute MI 
Peri-infarct I/M injection, ~105 cells/mouse 
21days; echocardiography; n=7-11 (fibroblast control) 
CDC engraftment  
(not quantified) 
↑ LVEF: ((+) ~15% vs controls) 
↑ Viable tissue: ((+) ~1.4-1.8-fold vs controls) 
vWF+ engrafted donor cells identified, 
not quantified 
159 
Human CDCs Not Determined 
Mouse: acute MI 
Peri-infarct I/M injection (105 cells/mouse) 
21 days; echocardiography; n=>3 (fibroblast control) 
CDC engraftment  
(not quantified) 
↑ LVEF: ((+) ~16% vs controls) 
↑ Viable tissue: ((+) ~1..2 fold vs controls) 
↑ neo-angiogeneis: ((+) ~50% infarct 
border capillary density; ~20% of neo-
vessels contain human cells) 
187 
Rat CDCs cKit, CD90, CD31 
Rat: acute MI 
Peri-infarct I/M injection (106 cells/mouse) 
21 days; echocardiography; n=9-12 
24hour: 20% retention  
21days: 2% retention  
↑ LVEF: ((+) ~15% vs vehicle controls; 
(+)~20% with magnetic targetting) 
vWF+ engrafted donor cells identified, 
not quantified 
161 
Pig CDC Not Determined 
Pig: Cardiomyopathy (4 weeks post MI) 
Intracoronary infusion (300,000 cells/kg) 
8 weeks; Cardiac MRI; n=7 
Low, not quantified 
(-) LVEF 
↓ infarct size 
↑ Haemodynamic function 
Engrafted cells identified lining arteriole  170 
Pig CDCs 
(vs Csphs) Not Determined 
Pig: Cardiomyopathy (4 weeks post MI) 
Peri-infarct I/M injection (x107 cells/pig) 
8 weeks; Ventriculography, echocardiography; n=5-9 
CDC engraftment  
(not quantified) 
↑ LVEF: (CDCs & Csphs: (+) ~8% vs vehicle 
controls) 
↑ Haemodynamic function: (Csphs>CDCs) 
Not Determined 169 
Human CDCs 
(neonate–2 
years) 
cKit, CD90, Endoglin, 
Connexion43, NKX2-5, 
α-Sarcomeric actin,  
Rat: acute MI 
Peri-infarct I/M injection (106 cells/mouse) 
28 days: echocardiography;  n=4-6 (fibroblast control) 
CDC engraftment  
(not quantified) 
↑ LVEF: ((+) ~11% vs fibroblast controls) 
↑Fractional shortening: ((+)~3% vsfibroblast group) 
↑ viable tissue: ((+) ~1.4  fold vs fibroblast controls) 
In vivo: vWF+ engrafted donor cells 
identified, not quantified  
In vitro: EC differentiation (CD31)  
172 
Neonatal Rat 
CDCs 
cKit, CD90, Endoglin, 
vWF DDR2, α-
Sarcomeric actin 
Rat: acute MI/reperfusion 
Peri-infarct I/M injection (2x106 cells/rat); 48 hours 
later tail vein infusion (4x106 cells/rat) 
16 weeks; Cardiac MRI; n=3-7 
Cell retention 
observed at 16 weeks 
(not quantified) 
↑ LVEF: ((+) ~10% vs vehicle controls) 
↓ ESV and Infarct Size 
↓ Collagen Density 
↑ peri-infarct capillary density 
((+) 44% over control hearts; 
~12±3% vWF+, ~8±2% SMA+)  
In vitro: EC differentiation (vWF ) 
163 
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Table 1.1.  A summary of pre-clinical studies addressing the potential of cardiac 
tissue derived EDCs, cardiospheres and CDCs to contribute to repair and improve 
heart function following MI. 
 
1.7.3. The Role of CDCs in Neovascularisation following Heart 
Injury 
The majority of studies investigating the repair efficacy of Csphs and CDCs have 
heavily focused on the potential of these putative CSCs to contribute to myocardial 
regeneration via direct differentiation into cardiomyocytes rather than their effect on 
angiogenesis. However several publications have addressed this important mode of 
repair162-163, 166, 171-172, 186-187. Table 1.2 summarises the major findings of several of these 
studies in terms of their pro-angiogenic effect following cell transplantation into 
preclinical disease models (predominantly acute MI). Although  a number of the listed 
publications do not perform an in depth analysis of the effect of cell transplantation on 
neo-angiogenesis, they do demonstrate that these cells are able to differentiate into both 
endothelial and smooth muscle cells in vitro and in vivo. In addition both EDCs and 
CDCs have been shown to spontaneously form tubules in a 2D Matrigel angiogenesis 
assay in vitro potentially indicating that these cells retain intrinsic pro-angiogenic 
capacity162.  However this should be interpreted with caution as tubule formation on 
matrigel is not unique to ECs. More robust evidence for a pro-angiogenic role of these 
cells has come from in vivo studies, demonstrating that cKit-positive, haematopoietic 
lineage-negative EDCs, Csphs and CDCs significantly increase capillary density 
following delivery into ischaemic hearts. Tang et al166 found a 36% increase in peri-
infarct capillary density 4 weeks following intravenous injection of murine cKit+ EDCs 
as compared to control mice. Moreover hypoxic preconditioning of these cells (0.1% O2 
for 6 hours) enhanced neovessel formation by approximately 50%, likely due to the 
increased secretion of vascular growth factors (e.g. VEGF, osteopontin, basic FGF, 
erythropoietin and stem cell factor) observed following hypoxic culture166. Human 
cardiosphere transplantation into rats led to a 2 fold increase in capillary density in 
ischaemic myocardium 3 weeks post infusion186. Similarly, Chimenti et al187 noted a 
50% increase in ischaemic border zone vessel density in human CDC treated mice as 
compared to untreated controls at 3 weeks. Approximately 20% of the neo-vessels 
contained human derived cells, indicating that significant paracrine contribution 
   35 
accounts for the majority of neovascularisation187. Finally, capillary density, measured 
using immuno-staining for CD31, was increased by 44% in the peri-infarct region of 
CDC-treated rats at 16 weeks compared with untreated infarcted hearts163. Although 
CDC differentiation along the endothelial lineage was observed in vivo, the authors 
suggested that paracrine factors most likely accounted for the majority of 
neovascularisation however this was not directly quantified. 
 
Taken together these results strongly suggest that neo-angiogenesis plays an important 
role in CDC mediated heart repair. Importantly, whilst Csphs and CDCs have been 
shown to differentiate into ECs in vitro and in vivo this tends to occur at relatively low 
frequency. Indeed Mishra et al reported a <1% endothelial differentiation efficiency in 
vitro (as indicated by CD31 staining)172 and Carr et al note an increased frequency of 
cardiomyocyte rather than EC differentiation163. Given that during development 
coronary ECs are derived from the sinus venosus and/or epicardium195-196, while the 
haemangioblast (common ancestor to both haematopoietic and ECs) is resident within 
the BM it is tempting to speculate that BM-derived cells in the adult are more likely 
than CSCs to contribute directly to vascular regeneration. However, it is also likely that 
enhanced angiogenesis following CSC delivery into ischaemic myocardium is largely 
due to paracrine mechanisms rather than the ability to differentiate into ECs. This theory 
is supported by the studies of both Tang et al166 and Chimenti et al187, which both 
demonstrated CDC secretion of vascular related growth factors. 
 
1.7.4. Therapeutic Potential of CDCs following Myocardial 
Infarction 
With regard to clinical translation the Marban group have recently announced the 
preliminary results of the first phase I/II clinical study of CDCs (CADUCEUS; 
Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction)197-
198
. In this trial 17 male human subjects with a recent MI (~10 weeks previous) and left-
ventricular dysfunction (LVEF ranging from 25–45%) received 12.5–25x106 autologous 
CDCs (harvested from endomyocardial biopsies) via intracoronary infusion. An 
additional 8 patients served as controls and received conventional treatment only. The 
preliminary 6 and 12 month follow-up data included MRI-assessment of infarct scar 
mass, viable mass, LV volumes and function. Interestingly there was no change in 
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LVEF between cell recipient subjects and controls although trends did indicate 
attenuated adverse LV remodelling in the former group (reduced end diastolic and end 
systolic volumes). CDC treatment also appeared to improve regional function in treated 
segments as indicated by a reduction in peak systolic strain as well as a significant 
increase in systolic wall thickness relative to controls. Marban and colleagues have also 
revealed that CDC recipient patients had a reduced scar mass with a corresponding 
increase in viable myocardial mass as judged by reduced delayed gadolinium 
enhancement on MRI. They conclude that these results provide the first evidence of 
stem cell mediated myocardial regeneration in human subjects. However, although a 
shrinking scar with concomitant increase in viable mass would be expected in true 
regeneration further evidence is required to definitely prove that this is occurring. An 
alternative interpretation of these results may be that CDC treatment results in “reduced 
vascular permeability with evidence for enhanced muscle mass associated with 
improved muscle regional function”199. Importantly this trial did demonstrate that 
autologous CDCs could be safely infused into patients via intracoronary infusion197. Of 
note vascular function and tissue perfusion was not assessed in this study however it 
cannot be discounted that the observed benefit associated with CDC treatment may be 
partly due to an increase in neovascularisation. 
 
In addition the initial results of another phase I trial of heart derived stem cells (SCIPIO; 
Stem Cell Infusion in Patients with Ischaemic CardiOmyopathy) were recently 
published200. Rather than treating patients before they developed heart failure, as was 
the study design in the CADUCEUS trial, here the aim was to directly treat severe heart 
failure resulting from ischaemic heart disease (defined as a LVEF of less than 40%). A 
total of 0.5-1x106 cKit purified heart derived cells (atrial outgrowth) were infused into 
coronary artery bypass patients via the intracoronary route 4 months after tissue 
harvesting. A total of 16 patients were assigned to the treatment group and 7 to the 
control group (conventional therapy only). No adverse cell-infusion related problems 
were reported at 12 months.  Using echocardiography and MRI analysis cardiac 
function in treated patients was found to be markedly improved within 1 year relative to 
controls. Baseline measurements of LVEF in the treatment group averaged at 30.3%, 
however 4 months after receiving CSCs this increased to 38.5% and in 8 patients who 
were followed for 12 months LVEF increased to an average of 42.5%. Additionally in 7 
of the treated patients in whom cardiac MRI could be performed infarct size was also 
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found to be reduced by up to 30% at 12 months. Interestingly the control group showed 
no change in LVEF (30.1% at baseline and 30.2% at eight months post CABG), 
although the natural tendency is for cardiac function to slowly and progressively 
improve following coronary artery bypass grafting (CABG) therefore this lack of 
change in LVEF is surprising. Neither the CADUCUES trial nor the SCIPIO study were 
blinded therefore they were not controlled for the placebo effect. In addition the small 
sample sizes involved make it difficult to generalise findings to a larger population of 
heart disease patients. However these initial trials do suggest that CSC infusion via the 
coronary route is safe and provides encouraging results regarding efficacy, however it is 
clear that larger phase II trials are required.  
 
To summarise CDCs are safe to use in MI patients; and although they do not show 
significant cell retention following delivery they do have pro-angiogenic properties that 
may be fundamental to their ability to reduce adverse ventricular remodelling following 
acute MI. As the majority of CDCs express endoglin, I was interested to discover 
whether this was a functional marker that affected CDC properties during heart repair. 
Endoglin is a co-receptor for certain members of the transforming growth factor β 
(TGFβ) family and affects cell responses to this important family of ligands. 
 
1.8. Transforming Growth Factor-β Superfamily Signalling  
1.8.1.  TGFβ Superfamily of Ligands  
TGFβ isoforms (TGFβ1-3) are the prototypic members of the TGFβ superfamily of 
cytokines, a group of over 30 evolutionary conserved and structurally related secreted 
growth factors that additionally include bone morphogenetic proteins (BMPs), activins 
and growth differentiation factors (GDFs)201. TGFβ superfamily members are 
multifunctional and play pivotal roles in embryonic development, adult tissue 
homeostasis as well as the pathogenesis of many disease states201. BMPs are known to 
have important roles in embryonic patterning and morphogenesis whereas the TGFβ 
ligands regulate many processes including wound healing, cellular proliferation, 
adhesion, and immunity202. Extensive studies have also revealed pivotal roles for both 
TGFβ and BMP signalling in angiogenesis and vascular homeostasis (discussed in 
section 1.9). 
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Many TGFβ family proteins are generated as inactive prepropeptide dimers with each 
polypeptide consisting of a small C-terminal mature domain and a larger N-terminal 
pro-region7. Specific sites between these two domains are cleaved to generate active C-
terminal dimers.  However, even after proteolytic cleavage the active domains of many 
TGFβ ligands remain non-covalently associated with the propeptide which blocks 
binding to receptors thus rendering the ligands latent7. Extracellular dissociation of 
these latent complexes to release active ligands is achieved via a variety of mechanisms 
including proteolytic processing7.  This post-transcriptional regulation determines the 
bioavailability of TGFβ ligands for their receptors, while other family members (such as 
BMPs) are secreted in active form and are regulated by reversible interactions with 
extracellular antagonists203. The active ligands mediate their pleiotropic effects from 
cell membrane to nucleus by signalling through heteromeric complexes of type I and 
type II serine/threonine-kinase receptors and activating downstream nuclear effectors, 
the Smad proteins.  
 
1.8.2. TGFβ Receptors and the TGFβ Smad Signalling Pathway 
The structures of type I and II receptors are very similar with both consisting of small 
cysteine rich extracellular domains, single transmembrane regions and intracellular parts 
that contain serine/threonine kinase domains204. However the type I receptors also have 
a characteristic glycine/serine sequence upstream from the kinase domains, which is 
phosphorylated by the type II receptor204. At the cell surface these receptors exist as 
homodimers but in the presence of active ligand they form heteromeric signalling 
complexes that are thought to minimally consist of a heterotetramer with two type I and 
two type II receptors204. While some ligands are able to bind directly to their type II 
receptors, others bind preferentially to a type I receptor or a type I-type II complex.  
 
Upon ligand binding and formation of a signalling complex the constitutively active 
type II receptor phosphorylates and activates the type I receptor which determines 
signalling specificity205. Thereafter subsequent phosphorylation of Smad proteins takes 
place allowing propagation of signal to the nucleus206-207.  There are three distinct types 
of Smads: receptor regulated (R-Smad1, 2, 3, 5 and 8), common mediator (Co-Smad4) 
and inhibitory Smads (I-Smad6 and 7). R-Smads are phosphorylated by the type I 
receptor and interact with Co-Smad4. This complex translocates to the nucleus where it 
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participates in transcriptional regulation of target genes208-209. R-Smads and Co-Smad-4 
share two conserved domains, termed MAD homology (MH)1 and MH2, which can 
both interact with sequence-specific transcription factors204. I-Smads prevent the 
activation of R-Smads by antagonistically competing for receptor interaction210-211, 
recruiting ubiquitin ligases to activated receptors212-213 or by recruiting phosphatases to 
dephosphorylate activated type I receptors214.  
  
Seven type I (also termed activin receptor-like kinases (Alk1-7)) and five type II 
(Tgfbr2, Bmpr2, Acvr2a, Acvr2b and Amhr2) serine/threonine-kinase receptors have 
been identified. In addition two accessory receptors (or type III receptors), endoglin and 
betaglycan, are known to regulate ligand–receptor interactions and have a more indirect 
role in TGFβ signal transduction204. Versatility in receptor combinations allows for 
differential ligand binding or differential signalling in response to the same ligand. 
Additionally, a receptor combination may bind different ligands, and patterns of ligand 
and receptor expression often dictate which receptors are activated. This infers a high 
level of cross-talk between the different TGFβ signalling pathways, allows for context 
dependent responses and partially explains the complex and divergent range of cellular 
functions regulated by the TGFβ superfamily. 
 
1.9. The Role of Endoglin and TGFβ Signalling in Angiogenesis 
1.9.1. TGFβ Signalling is Pivotal to the Regulation of Angiogenesis 
and Vascular Homeostasis 
Genetic studies in mice have revealed that TGFβ signalling pathways play essential 
roles in vascular development including the maintenance of the vessel wall integrity, 
smooth muscle cell recruitment, deposition of extracellular matrix and differentiation of 
arteries and veins215. Furthermore, perturbed TGFβ signalling has been implicated in 
several human diseases7. TGFβ acts as both an inhibitor and stimulator of angiogenesis 
in vitro and in vivo depending on experimental conditions6, 215 and BMPs have also been 
shown to play an important role in angiogenesis and vascular homeostasis via an 
interplay between two groups of pro- and anti-angiogenic ligands216.  During 
embryogenesis TGFβ1 is expressed in many tissues including endothelial and 
haematopoietic progenitor cells215 and targeted disruption of this ligand in C57Bl/6 
mice results in mid-gestation lethality due primarily to defects in the yolk sac 
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vasculature217. Although initial differentiation of mesodermal precursors into ECs 
occurs, subsequent differentiation and remodelling into capillary-like tubules is 
defective resulting in fragile vessels with decreased wall integrity. Tgfbr2-deficient 
mice demonstrate a similar mutant phenotype218 and gene knockout mouse models of 
additional TGFβ receptors and downstream signalling proteins also cause vascular 
defects (see table 1.2), providing further evidence of the central role of TGFβ signalling 
in vascular development. 
 
1.9.2. TGFβ Type I Receptors Balance the Activation State of the 
Endothelium and Regulate the Angiogenic Switch  
Within the endothelium TGFβ is known to bind Alk5 as well as Alk1 type I receptors in 
conjunction with Tgfbr2 leading to both TGFβ/Alk5 dependent phosphorylation of 
Smad2/3 and TGFβ/Alk1 induced Smad1/5 activation219 (figure 1.5). Thus in ECs 
TGFβ can activate two distinct type I receptor/Smad signalling cascades. Functional 
studies have revealed that these divergent pathways have opposite roles in endothelial 
biology and it is proposed that a fine balance between TGFβ/Alk5 and TGFβ/Alk1 
signalling regulates angiogenesis6, 219. Hence, whilst TGFβ signalling via the 
Alk5/Smad2 pathway leads to a quiescent endothelial phenotype by inhibiting EC 
proliferation and migration, in contrast TGFβ dependent Alk1/Smad1/5 signalling 
activates the endothelium and stimulates cellular migration and proliferation219.  In 
support of this model, microarray analyses have revealed marked differences in target 
gene expression profiles for these two signalling pathways220. For example, the Alk5 
pathway stimulates expression of fibronectin (an ECM protein involved in endothelial  
cell adhesion) and plasminogen activator inhibitor type I (Pai1)220 (an inhibitor of 
fibrinolysis and a negative regulator of EC migration in vitro and angiogenesis in vivo). 
Target genes of the Alk1-Smad1/5 pathway include inhibitor of DNA binding 1 (Id1), 
which is involved in cell cycle progression, proliferation and inhibition of 
differentiation, as well as interleukin 1 receptor-like 1 (Il1rl1), which is suggested to 
participate in cell growth220.   
 
In addition to mediating opposite responses in ECs, Alk5 and Alk1 receptors also cross 
talk with each other. Alk5 is necessary for both Alk1 recruitment into a TGFβ receptor 
complex and efficient Alk1 activation221. Also, Alk1 has been shown to directly 
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antagonize Alk5/Smad2/3 signalling at the Smad level221. Thus, the requirement for 
Alk5 in Alk1 signalling and the opposing actions of Alk1 and Alk5 provide ECs with an 
intricate mechanism for precisely regulating TGFβ-induced biological responses during 
angiogenesis.  
    
Gene Knock-Out Phenotype Lethality Ref 
TGFβ1 Defect in embryonic mesoderm and haematopoiesis. Inadequate 
tube formation. 
E10.5 217 
 
Tgfbr2 Defect in yolk sac vasculogenesis and haematopoeisis E10.5 218 
Bmpr2 Abnormal mesoderm formation. Heterozygotes; thickened 
arteries, increased pulmonary vascular resistance. Transgenic 
BMPR2-mutant allele; vascular defects 
Embryonic lethal 
(pre-angiogenesis) 
222-224
 
Alk5 Defects in angiogenesis. Impaired EC migration, proliferation 
and fibronectin production 
E10.5 225 
 
Alk1 Defects in angiogenesis. Impaired differentiation and 
recruitment of SMCs 
E11.5 226-227 
 
Smad5 Lack or normal development of the yolk sac vasculature. 
Irregular distribution of blood cells and large blood cells 
E9.5-E11.5 228-229 
 
Smad1 Failure in establishing chorion-allantoic circulation. Lack of 
VCAM-1 expression 
E9.5 230-231 
 
Endoglin Defects in angiogenesis. Impaired differentiation and 
recruitment of SMCs. Cardiac malformations due to defects in 
mesenchymal transformation and cushion tissue formation 
E10-E11.5 232-234 
 
Betaglycan Cardiac defects E13.5 235 
Table 1.2. TGFβ signalling: Gene ablation studies in mice. Defects in components of 
the TGFβ signalling pathway lead to cardiovascular abnormalities and embryonic 
lethality.  
 
The precise roles of the Alk1 and Alk5 pathways during angiogenesis have been 
difficult to determine. Over-expression studies have demonstrated that signalling 
through Alk1 may inhibit EC proliferation and migration suggesting a role in the 
resolution phase of angiogenesis226, 236. Importantly, these observations concur with the 
phenotype of Alk1 knock-out mice, which have fragile blood vessels and display up-
regulated expression of pro-angiogenic genes226-227. The discrepancies between these 
findings and data from other studies implying a pro-angiogenic role for Alk1219, 237 may 
be explained by different cell types/experimental models being used, adaptive processes 
occurring in response to Alk1 loss or it may be that Alk1 signalling cascades are 
involved in both angiogenic activation and resolution phases.    Interestingly, BMP9 and 
BMP10 were recently identified as novel ligands of Alk1238-239. BMP9 has been shown 
to induce both Smad1/5 and Smad2 phosphorylation through Bmpr2/Alk1 and the 
activin type II receptors in ECs240. It was observed that both Bmpr2 and activin type II 
receptors were required for Smad1 activation whereas Smad2 phosphorylation was 
   42 
mediated mainly through activin type II receptors240. Interestingly, BMP9 was found to 
reduce angiogenesis using a number of different assays: BMP9 inhibited (i) EC 
proliferation and migration in vitro238-239, (ii) VEGF-induced angiogenic sprout 
formation in a mouse metatarsal assay ex vivo239, (iii) bFGF-induced angiogenesis in a 
murine sponge assay and (iv) blocked angiogenesis in the chick chorioallantoic 
membrane (CAM) assay in vivo241. Shao et al242 have proposed BMP9 to be a vascular 
quiescence factor following observations that high doses of BMP9 could attenuate the 
pro-angiogenic effects of TGFβ in ECs. Although these findings suggest that BMP9 and 
BMP10 may have predominantly anti-angiogenic effects, other studies have reported 
that BMP10 induces angiogenesis in the CAM assay243 while BMP9 was found to 
stimulate EC proliferation both in vitro and in vivo244. Additionally in combination with 
TGFβ, BMP9 has been shown to potentiate VEGF-induced EC proliferation in vitro and 
VEGF/bFGF-induced angiogenesis in vivo245.  Therefore it may be that BMP9 
signalling in ECs exhibits both pro- and anti-angiogenic effects in a context dependent 
manner. Pardali et al201 propose a working model whereby TGFβ/Alk1 signalling leads 
to the activation of angiogenesis whereas BMP9 signalling through Alk1 can stimulate 
endothelial quiescence or activation in a context dependent manner (see figure 1.6.). 
Further studies are required to elucidate the true role of Alk1 signalling in angiogenesis.  
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Figure 1.5. TGFβ Signal transduction through the Smad signalling pathway. TGFβ 
superfamily ligands bind to specific serine/threonine kinase type I and II receptors and 
induce heteromeric complex formation. The type II receptors activate type I receptors 
via phosphorylation and subsequently, the type I receptor propagates the signal to the 
nucleus by phosphorylating intracellular effector proteins; R-Smads, which form 
heteromeric complexes with Smad4 (Co-Smad). These Smad complexes translocate to 
the nucleus and interact with transcription factors to regulate gene expression. TGFβ 
activates two distinct signalling pathways with opposite effects in endothelial cells. 
Signalling through the TGFβ/Alk5 pathway and subsequent Smad2/3 phosphorylation 
leads to inhibition of cell proliferation and migration to maintain endothelial quiescence 
and hence is associated with the resolution phase of angiogenesis. In contrast, signalling 
through the TGFβ/Alk1 pathway (via phosphorylation of Smad1/5) induces both cell 
proliferation and migration and promotes the activation state of angiogenesis. The 
accessory receptors betaglycan and endoglin can modulate signalling via the type II and 
type I receptors. Betaglycan has been shown to enhance TGFβ2 binding to TGFβ 
receptors, whereas endoglin is required for efficient Alk1 signalling and has been 
implicated in the inhibition of the TGFβ/Alk5 pathway. Figure adapted from 201. 
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1.9.3. The Role of Endoglin in TGFβ Signalling and Angiogenesis 
Endoglin (also known as CD105) is a disulphide-linked homodimeric transmembrane 
glycoprotein and as previously mentioned it is a TGFβ accessory receptor246. Endoglin 
belongs to the zona pellucida (ZP) family of proteins and consists of a large 
extracellular domain that harbours a ZP region and a short cytoplasmic domain 
containing serine/threonine residues which can be targeted by serine/threonine kinases 
including type I and II TGFβ receptors246.  The N terminus region of the ZP domain 
plays a role in protein-protein interactions and is involved in ligand dependent and 
independent associations with TGFβ family receptors246. With the exception of BMP9 
endoglin cannot directly bind exogenous ligands in the absence of type I and II 
signalling receptors although it can bind to heteromeric TGFβ receptor complexes 
independently of bound ligand247-248.  It has been shown that endoglin interacts with 
TGFβ1, TGFβ3, activin-A, BMP2 and BMP7 ligands when associated with type I and 
type II TGFβ receptors247-248 but can bind BMP9 directly through its extracellular 
domain239, 249.  Endoglin is thought to modulate cellular responses by regulating the 
activation of receptor complexes in response to TGFβ family ligands and subsequent 
signalling via downstream Smads.  
 
Endoglin is predominantly expressed by proliferating ECs during angiogenesis, wound 
healing and inflammation, all of which are associated with vascular structural alterations 
and TGFβ signalling (reviewed in250). In addition to activated ECs, endoglin is 
expressed by monocytes and upregulated during monocyte-macrophage transition251.  
Endoglin is also upregulated by injured vascular smooth muscle cells in patients with 
athersosclerosis252 and is expressed by cardiac fibroblasts253. Furthermore endoglin is 
expressed by circulating MSCs254, a subset of neural crest stem cells255, in 
syncytiotrophoblasts of term placenta256, in adult BM-HSCs257 and is a functional 
marker that defines long-term repopulating HSCs258.  
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Figure 1.6. A working model for TGFβ/Alk1 and BMP9/Alk1 signalling in 
endothelial cells. (A) TGFβ binds to Tgfbr2, which subsequently recruits and 
phosphorylates Alk5 and Alk1 in a common complex. Activated Alk1 induces Smad1/5 
phosphorylation resulting in the activation of Alk1-specific target genes, which induce 
endothelial activation. (B) BMP9 can induce both Smad1/5 and Smad2 phosphorylation 
in ECs through the Bmpr2/Acvr2/Alk1/2 pathways leading to both pro- and anti-
angiogenic effects in a context dependent manner. Endoglin is required for efficient 
TGFβ/Alk1 and BMP9/Alk1 signalling. Figure adapted from 201. 
  
Mouse embryos homozygous for mutations in the endoglin gene die at E10.5 due to a 
failure to form mature blood vessels with evidence of endothelial dysfunction secondary 
to impaired smooth muscle cell differentiation and recruitment232-234. Although vessels 
can form in the yolk sac of mutant animals they are dilated, fragile and readily 
susceptible to damage and haemorrhage. The in situ differentiation of ECs does take 
place but there is a subsequent failure to remodel the primitive vasculature into a more 
mature network suggesting a role for endoglin in angiogenesis rather than in 
vasculogenesis. This phenotype is similar to that of TGFβ1, Tgfbr2, Alk1 and Alk5 
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deficient mice indicating a functional link between endoglin and TGFβ signalling 
during embryonic vascular development (see table 1.2). There is a further link between 
these gene families in that patients with mutations in endoglin or Alk1 have been 
associated with variant forms of an autosomal dominant multi-system vascular dysplasia 
termed hereditary haemorrhagic telangiectasia (HHT). HHT1 and HHT2 are associated 
with mutations in endoglin and Alk1 respectively259-261, and the similar clinical 
phenotype of HHT1 and HHT2 patients suggests that endoglin and Alk1 share a 
common signalling pathway. HHT is characterised by small dilated blood vessels 
(telangiectases) in the nasal, oral, and gastrointestinal mucosa as well as larger 
arteriovenous malformations (AVMs) in the vasculature of the lung, liver and brain. 
Telangiectases are prone to bleed, and can lead to patient anaemia, whilst the clinical 
consequences of AVMs include an increased disposition to stroke, cyanosis or high 
output cardiac failure.  
 
Mice heterozygous for mutations in endoglin have been used to model HHT1 however 
the manifestation of clinical symptoms appears to be strain dependent. While endoglin 
heterozygous mice of the 129/Ola strain display fragile blood vessels, telangiectases and 
nosebleeds233, 262, mice from other genetic backgrounds failed to show such a phenotype 
indicating the existence of modifier genes233, 263. Haploinsufficeincy is the proposed 
mechanism underlying HHT1 with reduced endoglin levels leading to dysfunctional 
TGFβ/BMP9 signal transduction. 
 
The defective vascular phenotype resulting from endoglin deficiency reveals an 
important role in angiogenesis and several studies provide evidence that endoglin 
modulates the angiogenic switch by balancing TGFβ/Alk1 and TGFβ/Alk5 signalling 
pathways. Indeed, endoglin has been shown to potentiate TGFβ/Alk1 signalling, while 
attenuating the TGFβ/Alk5 pathway in ECs as well as in other cell types (see figure 1.5). 
Lebrin et al237 identified endoglin as a requirement for efficient Alk1 signalling in 
mouse embryonic ECs (MEECs) with endoglin deficient cells displaying abrogated 
Alk1 signalling (loss of TGFβ dependent Smad1 activation and impaired cell 
proliferation) and upregulated Alk5 signalling.  Supporting these findings it was shown 
that endoglin counteracts the inhibitory effect of TGFβ/Alk5 on cellular proliferation, 
migration and tubule formation in human umbilical vein endothelial cells (HUVECs)264. 
Furthermore, ectopic expression of endoglin prevented TGFβ-induced growth inhibition 
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in monocytes and myoblasts248, 265 and ECM synthesis in myoblasts266. Thus endoglin is 
regarded as a negative regulator of the Alk5 pathway. Corroborating this theory, 
neutralizing antibody for endoglin was found to potentiate the inhibitory effect of TGFβ 
on EC migration and growth267 and ectopic expression of endoglin  inhibited Smad3 
transcriptional activity in rat myoblasts268.  However the hypothesis that endoglin 
promotes EC proliferation and migration has been contradicted by several reports. Pece-
Barbara et al269 reported that endoglin null MEECs proliferated faster than control cells 
in response to TGFβ1 treatment, while in another study although endoglin deficiency 
resulted in reduced numbers of neovessels in an in vivo subcutaneous Matrigel implant 
assay, endoglin-deficient retinas from the same inducible endoglin knock out mouse 
model exhibited increased endothelial proliferation270. In addition to promoting the 
TGFβ/Alk1 pathway, endoglin has also been shown to mediate BMP9/Alk1 signalling 
responses which are associated with both angiogenic activation and resolution (see 
figure 1.6).  Despite these conflicting reports and the suggestion that the role of 
endoglin may be context dependent the balance of evidence strongly supports the 
prevailing hypothesis that endoglin plays an important and functional role in 
angiogenesis. Additionally this role is likely to be pro-angiogenic therefore indicating 
that this receptor may also be important in cell-mediated therapeutic angiogenesis. 
 
1.10. The Role of TGFβ Family Signalling and Endoglin in Cell-
Mediated Cardiac Repair  
 Although a role for TGFβ in cardiac fibrosis and remodelling following MI is well 
recognised this is not the focus of this thesis and has been reviewed elsewhere9. 
 
At the advent of this study there was little data on how TGFβ might affect stem cell 
proliferation, mobilisation or pro-angiogenic repair potential. However, although not 
much research has been conducted specifically using CDCs, preliminary data does 
suggest that TGFβ signalling may be important in the regulation of EPC migration and 
differentiation.  Human EPCs and MNCs have been shown to express TGFβ receptors 
(Tgfbr2, Alk1, Alk5 and endoglin) and exhibit downstream Smad 
phosphorylation/activation following exposure to TGFβ ligand61, 271, strongly indicating 
that EPCs have an active TGFβ pathway. In addition preliminary published data 
supports the idea that TGFβ plays a pivotal role in controlling proliferation and 
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differentiation responses of EPCs in vitro.  Henrich et al272 propose TGFβ1 plays a 
pivotal role in EPC differentiation induced by serum of polytrauma patients. The 
authors cultured MNCs with serum derived from multiple trauma victims and observed 
a significant increase in EPC numbers, which displayed enhanced capacity to form 
vascular structures in matrigel, while neutralisation of TGFβ1 in the serum using 
specific antibodies resulted in a significant decrease in EPC differentiation272. Data from 
Zhu et al273 also indicate TGFβ1 is critical for regulating EPC differentiation.  The 
vascular wall is mainly composed of ECs and SMCs and the cross talk between these 
two cell types is critical in the vascular maturation process. The authors report TGFβ1 
expressed in SMCs increases EPC differentiation (as judged by positive staining for 
endothelial markers vWF and VE-cadherin) as well as adhesion (as judged by the 
adhesion force between EPCs and SMCs)273. They propose TGFβ1 can also induce EPC 
migration and differentiation by increasing the amount of VEGF and VEGFR1.  
Furthermore Sales et al274 have shown that TGFβ1 enhances ECM production and 
modulates the proliferation and apoptosis of EPCs in tissue engineering scaffolds.   
 
In addition the importance of endoglin in stem-cell mediated heart repair has been 
established. Endoglin is expressed by MNCs and in endothelial culture conditions 
expression levels increased from 15% of the total MNC population to 80% after only 4 
days271. Furthermore, when grown over a longer period, the resultant endothelial-like 
cells derived from MNCs with endoglin mutations (from HHT1 patients) have 
disorganized and depolymerised actin fibers and demonstrated impaired tubule 
formation in an in vitro angiogenesis assay61.  In 2006 Linda van Laake et al275 provided 
the first evidence indicating the essential role of endoglin in endogenous heart repair.    
Decreased levels of endoglin in endoglin heterozygote mice resulted in reduced 
angiogenesis one week following MI and a 50% reduction in LV function at 4 weeks 
post MI compared with WT controls. This study also showed that normal levels of 
endoglin are critical for human MNCs to promote heart repair in a mouse model of MI.  
Essentially although the number of EPCs (defined by FACS analysis for standard EPC 
markers; CD34 and VEGFR2) was the same in the peripheral MNC fractions of control 
and endoglin-deficient (HHT1) patients, the biological activity of the latter group was 
impaired. EPCs were injected into infarcted mice intravenously via the tail vein and 
cells from HHT1 patients were found to reach the infarcted region of the heart at 
reduced efficiency and were less able to promote repair than control cells.  In 
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collaboration with the authors of this seminal study Post et al276 went on to demonstrate 
that these endoglin deficient MNCs displayed a defective CXCR4/SDF1 axis suggesting 
perturbed homing of the MNCs to the site of injury. However the effect of transplanting 
endoglin deficient cells directly into the coronary circulation or myocardium was not 
assessed.  In addition, Gaebel and colleagues277 recently reported that endoglin enriched 
MSCs from human UCB showed increased survival and led to reduced fibrosis 
following transplantation into infarcted hearts when compared to transplanted total 
MSCs. These studies all serve to highlight the potential importance of endoglin in cell 
mediated heart repair. 
 
1.11.  Aims of Thesis 
Endogenous pro-angiogenic stem cells form part of the bodies defence against vascular 
assault and the threat of ischaemic injury. However as the number of cells that can be 
isolated from any one patient are limited, ex vivo expansion of repair cells will be an 
important part of future therapies. This is especially true for patients with 
cardiovascular disease and associated risk factors, such as those with hypertension or 
diabetes, who tend to have reduced numbers of both EPCs and cardiac resident stem 
cells and attempts to increase the endogenous mobilisation of EPCs using stimulatory 
growth factors have proved incompatible with the severity of their clinical condition. 
Therefore, to improve the efficacy of autologous cell-mediated therapies it would be 
beneficial to expand harvested populations and identify factors that both distinguish 
repair cells as well as control their proliferation while maintaining or even enhancing 
their pro-angiogenic properties. This will help to maximise patient benefit and 
optimisation of this process will be critical for the success of future therapies. 
 
Drawing parallels with recent findings relating to the functional significance of the 
balance of endothelial TGFβ/Alk1 and TGFβ/Alk5 signalling on angiogenesis as well as 
the regulatory role of endoglin in this process, it is likely that these pathways act as 
critical mediators of the balance between cell differentiation and proliferation responses 
in vivo.  Furthermore as endoglin is expressed in mesenchymal stem cells such as CDCs 
and a subset of the EPC populations prepared from BM it is probable that the activity of 
endoglin will be important in these cell types for their contribution to vascular repair. 
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The overall goal of this project was to investigate the regulation of EPCs and CDCs via 
TGFβ signalling, focussing on the role of endoglin. I tested the hypothesis that 
manipulating TGFβ/Alk5 signalling can direct EPC proliferation and differentiation 
responses; and that endoglin performs an important role in CDC-mediated heart repair. 
 
The specific aims of this project were to; 
1) Determine the effect of inhibiting Alk5 kinase activity and reducing endoglin 
expression on EPC yield from mouse BM in vitro 
2) Investigate the effect of endoglin depletion on CDC function and TGFβ 
signalling responses in vitro 
3) To establish a mouse model of myocardial infarction and test the effect of 
endoglin depletion on the ability of CDCs to contribute to neovascularisation 
and reduce adverse ventricular remodelling in vivo. 
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CHAPTER 2. 
 
Materials and Methods 
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2.1. Suppliers 
Chemicals and reagents were purchased from Becton Dickinson (BD), BD Pharmingen, 
VWR International, eBiscience, Sigma-Aldrich, Vector Laboratories, Fisher Scientific, 
Polysciences Inc., Severn Biotech Ltd., GE Healthcare, Pierce Biotechnology, Qiagen, 
Roche or Invitrogen. 
 
All plasticware and apparatus for tissue culture, western blotting and general laboratory 
use was purchased from BioRad Laboratories, Iwaki, Greiner, RA Lamb, or Scientific 
Laboratory Supplies. 
 
Medium and supplements for cell culture were purchased from Promocell, Gibco 
Invitrogen, Lonza and Peprotech. 
 
Oligonucleotides were purchased from the Molecular Biology Facility (Newcastle 
University, Newcastle upon Tyne, U.K.) or TAGN (Centre for Life, Newcastle upon 
Tyne, U.K.). 
 
Surgical equipment and instruments were purchased from Harvard Apparatus and Fine 
Science Tools (FST). 
 
2.2.  Mouse Strains and Genotyping 
All animal procedures were permitted under UK Home Office licence and were 
preformed in accordance with national guidelines for the care and use of laboratory 
animals. 
 
Mice were maintained in a ventilated, germ free facility in a 12 hour light-dark cycle 
and fed a standard diet with water ad libitum.  
 
2.2.1. Mouse Strains 
Endoglin heterozygote (Eng+/-) Line  
Eng+/- mice were developed in my host laboratory232. In the targeted allele a premature 
stop codon was introduced into exon 8 (via homologous recombination in ES cells) 
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resulting in the expression of a truncated, non-functional protein. Eng+/- mice were 
generated and maintained in a pure NIH background (backcrossed for 16 generations). 
 
Endoglin floxed/floxed (Engfl/fl) Line 
Engfl/fl mice were developed in my host laboratory278. LoxP sites flank exons 5 and 6 
which are subsequently deleted when exposed to transgenic Cre-recombinase.  This 
results in a frameshift mutation and the introduction of a premature stop codon in exon 
7 of the endoglin gene, giving rise to a truncated, non-functional protein. Engfl/fl mice 
were maintained in a C57Bl/6 background (backcrossed for 5 generations). 
 
Inducible Cdh5(PAC)-CreERT2 Line  
Cdh5(PAC)-CreERT2 mice were obtained from Dr Ralf Adams (CRUK, London). They 
express tamoxifen-inducible Cre recombinase (CreERT2) under the regulation of the 
vascular endothelial cadherin (VE-Cadherin or Cdh5) promoter. Cdh5(PAC)-CreERT2 
mice were backcrossed  for 5 generations with C57BL/6 to generate an approximately 
syngeneic line and were mated with Engfl/fl mice to generate Engfl/fl;Cdh5(PAC)CreERT2 
mice. 
 
Inducible Rosa-CreERT2 Line  
Inducible Rosa-CreERT2 mice were generated in Dr. A. Joyner’s Lab (New York, USA) 
and obtained from Dr. Caiying Guo (University of Connecticut, USA). This mouse 
expresses tamoxifen-inducible Cre recombinase (CreERT2) under the regulation of the 
ubiquitously expressed Rosa26 promoter and is on a C57Bl/6 background. Rosa-
CreERT2 mice were mated with Engfl/fl mice to generate a Engfl/fl; Rosa-CreERT2 line. 
 
Rosa26R Line  
Rosa26R mice279 (in a mixed genetic background) were obtained from Professor 
Deborah Henderson (Newcastle University).  These mice contain a transcriptional stop 
sequence flanked by loxP sites upstream of the LacZ gene. The expression of LacZ is 
driven by the ubiquitous Rosa26 promoter and is conditional on the removal of the 
preceding stop codon by Cre-mediated excision. Subsequent expression of the LacZ 
gene product (β-galactosidase) can be detected by X-gal staining and used to map 
expression of Cre-recombinase in murine tissue or primary cell types. Rosa26R mice 
were crossed with inducible Cdh5(PAC)-CreERT2 and inducible Rosa-CreERT2 mice. 
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CAG-farnesylated-eGFP (CAG-farnesyl-eGFP) Line  
CAG-farnesyl-eGFP mice were obtained from Prof A. Medvinski (Edinburgh 
University) and maintained in a pure C57Bl/6 background. In this line eGFP expression 
is under control of the CAG promoter (a combination of the chicken beta actin promoter 
and the CMV promoter) whilst the farnesyl group anchors the eGFP to the cell 
membrane. CAG-farnesylated-eGFP mice were intercrossed with Engfl/fl; Rosa-CreERT2 
mice over sufficient generations to generate a homozygous triple transgenic Engfl/fl; 
Rosa-CreERT2; CAG-farnesyl-eGFP line. 
 
Tamoxifen-mediated Cre-Recombinase Activation in vivo. To activate CreERT2 and 
induce the conditional knockout of endoglin via Cre-recombinase mediated excision in 
vivo, adult mice (≥8 weeks) were injected (via intraperitoneal route) with 2mg 
tamoxifen (Sigma) injections for 5 consecutive days followed by a 2 further injections 
on days 7 and 9. 
 
Please refer to figures 4.1, 4.2 and 4.4 for an explanation of the Cre-LoxP 
recombination strategy and schematics detailing the inactivation of the endoglin allele 
and the activation of the Rosa26 reporter.  
 
2.2.2. DNA Extraction 
Lysis buffer 1 (25mM NaOH and 0.2 mM EDTA) 
2.5ml of 0.5M NaOH + 0.02ml of 0.5M EDTA in 50ml of milli-Q H2O, adjust to pH12 
with NaOH. 
 
Lysis buffer 2 (40mM Tris-HCl) 
4ml of 0.5M Tris-HCl in 50ml milli-Q H2O, adjust to pH5 with HCl. 
 
Tissue. Ear clips of adult mice and tail tips of young pups were used for DNA 
extraction and subsequent genotyping of the animal. Each biopsy was incubated for 1 
hour in 100µl of lysis buffer 1 in a thermomixer set at 95°C and 350rpm.  The tubes 
were then vortexed and 100µl of lysis buffer 2 was added to neutralize the pH. Again, 
tubes were briefly vortexed and then centrifuged at 13,000rpm for 5 minutes to pellet 
any undigested tissue or impurities. The extracted DNA contained within the 
supernatant was stored at -20°C until required. 
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Cells. 106 cells were pelleted and used for preparing DNA for genotying. The protocol 
used was as described above. 
 
2.2.3. Genotyping  
All genotyping was performed using the polymerase chain reaction (PCR). 
 
Standard PCR Amplification: PCR reactions were made up to a total volume of 25µl 
in 0.2ml thin walled PCR tubes. Individual reaction mixtures consisted of 2.5µl 25mM 
MgCl2, 2.5µl 10x Reaction Buffer IV, 0.2µl Red Hot Taq DNA Polymerase (all 
purchased from ABgene, Thermo Scientific), 0.25µl of each forward and reverse primer 
(20µM), 0.5µl 10mM dNTPs (New England Biolabs), 2µl template DNA and dH2O 
made up to a final volume of 25µl. 
 
Primer details are listed below in table 2.1 
 
All genotyping PCR included both negative (sterile ddH2O) and positive controls and 
reactions were carried out using the conditions detailed in table 2.2 with an annealing 
temperature of 58oC and a programme of 35 cycles. A C1000 thermal cycler (Biorad) 
was used. 
 
Agarose Gel Electrophoresis:  
1X TAE Buffer 
40mM tris base-acetate and 1mM EDTA 
 
DNA Loading Dye 
0.25% bromophenol blue, 0.25% xylene cyanol FF and 40% sucrose in dH2O 
 
All PCR products were resolved on 2% agarose gels, which were made by dissolving 2g 
of DNA agar (Seakem LE Agarose for gel electrophoresis) in 100ml of 1xTAE buffer 
by boiling in a microwave until the agarose was fully dissolved. The gel was allowed to 
partially cool before it was cast in a horizontal gel tray with well combs and left to set 
for at least 45 minutes. Once set, the well comb was carefully removed and the gel was 
placed in an electrophoresis tank and fully immersed in 1xTAE buffer. Following PCR, 
samples were prepared by adding DNA loading dye to ensure accurate loading into the 
gel and to allow visual tracking of DNA migration during electrophoresis. A 1kb DNA 
ladder (Invitrogen) was also loaded alongside the samples to allow assessment of PCR 
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product size. The loaded gel was left to run at approximately 80volts for 60 minutes. 
The DNA bands were visualised by immersing the agarose gel in Ethidium Bromide 
solution (1µg/ml in dH2O) for 30 minutes followed by exposure to UV light and image 
capture using a GeneGnome System and GeneSnap Software (Syngene Bio Imaging). 
 
Line Primer Sequence (5’-3’) Product Size (bp) 
NIH Eng+/- meng9a-F ACCATCTTGTCCTGAGTAGCG 330Eng + 
 
meng9b-R TGAGCCTGACGGGAAACTG 
Neo F ACGTACTCGGATGGAAGCC 266Eng - Neo R CAAGCTCTTCAGCAATATCACG 
Eng2fl VECad-CreERT2 
Eng2fl Rosa-CreERT2 
Eng F4 GGTCAGCCAGTCTAGCCAAG 602 null allele Eng R7 CCACGCCTTTGTCCTTGC 
 
Eng F6 GACGCCATTCTCATCCTGC 420 wt allele 
500 floxed allele Eng R7 CCACGCCTTTGTCCTTGC 
CreS F TGCCACCAGCCAGCTATCAACT 191 CreS R AGCCACCAGCTTGCATGATCTC 
CAG-f-eGFP eGFP F TCGTCCTTGAAGAAGATGGTG 244 
 
eGFP R ACGTAAACGGCCACAAGTTC 
Rosa26R WT-R26 GCGAAGAGTTTGTCCTCAACC 600 wt allele 
 
R26 GGAGCGGGAGAAATGGATATG 
R26Gtrgeo AAAGTCGCTCTGAGTTGTTAT 310 R26 allele 
Table 2.1. Details of primers used to genotype different mouse lines. 
 
 
Table 2.2. PCR programme used to genotype mouse lines. 
 
2.3.  Cell Culture 
2.3.1. Primary Cell Culture 
2.3.1.1. Endothelial Progenitor Cells 
2.3.1.1.1. Long and Short Term Culture of Mouse BM Cells 
Endothelial Cell Growth Medium 2 - EGM-2 (Lonza) 
Endothelial basal media supplemented with 20% fetal calf serum, 100Units/ml 
penicillin, 100µg/ml streptomycin, hEGF, hydrocortisone, gentamicin, amphotericin B, 
VEGF, hFGF-B, IGF-1, ascorbic acid and heparin  
 
Commercial fibronectin and collagen I pre-coated plates (BD)  
 
Reaction Steps Reaction Conditions 
1 95oC – 1 minute 
2 95oC – 15 seconds 
3 58oC – 30 seconds 
4 74 oC – 1 minute 
5 74 oC – 7 minutes 
6 4 oC infinite 
Cycles (steps 2-4) 35 
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All procedures were carried out under sterile conditions in a tissue culture hood. 
 
Isolation and Culture of Mononuclear Cells from Murine Bone Marrow. Adult 
mice (≥ 8 weeks old) were culled via CO2 inhalation and femurs/tibias were dissected 
from the animal using sterile instruments. Murine bone marrow (BM) was extracted by 
flushing the femurs and tibias with PBS (approx 10ml into a 15ml greiner falcon tube) 
using a 25G needle and syringe.  BM was washed once by spinning cells in excess PBS 
at 1500rpm for 10mins at room temperature. The supernatant was carefully removed 
and discarded while the cell pellet was re-suspended in 3ml of PBS. The mononuclear 
cell (MNC) fraction was then isolated by density gradient centrifugation in Histopaque-
1083 (Sigma). Briefly, 3ml total BM suspension was carefully layered on top of 3ml 
Histopaque-1083, pre-equilibrated to room temperature, and further centrifuged for 
30mins at 1700rpm without brake.  MNCs were aspirated from the ‘buffy coat’ using an 
18G needle (approx. 2ml) and transferred to a 15ml falcon tube.  PBS was added to a 
total volume of 10ml and the cell suspension was centrifuged at 1500rpm for 10min at 
room temperature. The supernatant was discarded and the cell pellet re-suspended in 
3ml PBS. A sample (20µl) was used to calculate cell number using a modified neubaur 
counting chamber slide.  The cell suspension was centrifuged a final time at 1500prm 
for 10minutes and the cells re-suspended in an appropriate amount of EGM-2 media to 
give 3x106 MNCs per ml of media. 
Short Term Culture. 3x106 cells were plated in one well of a 24 well plate coated with 
fibronectin (BD). A minimum of 3 wells were plated per experiment. Cells were 
incubated at 37 oC in 5% CO2. Media was changed on the fourth day of culture and on 
the seventh day early EPCs were quantified. 
Long Term Culture. 3x106 cells were plated in one well of a 24 well plate coated with 
collagen I (BD). A minimum of 3 wells were plated per experiment. Cells were 
incubated at 37oC in 5% CO2. Media was changed on the fourth day of culture and 3 
times weekly thereafter for 4-6 weeks. 
 
2.3.1.1.2. Isolation of Mouse CD31+ BM Cells using Magnetic 
Dynabeads 
0.1% BSA/PBS 
0.05g BSA (≥ 98%, Sigma-Aldrich) disolved in 50ml sterile PBS and filter sterilised 
using a 0.22µm filter. The solution was stored at 4oC and used within 48 hours of 
preparation. 
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All procedures were carried out under sterile conditions in a dedicated tissue culture 
hood. 
 
Preparation of anti-CD31 Dynabeads. 75µl sheep anti-rat Dynabeads (approx. 4x108 
beads/ml, Invitrogen) were re-suspended in 5ml of filter sterilised 0.1% BSA/PBS in a 
15ml falcon tube and then placed on a magnetic separator (DynaMag-15, Invitrogen) for 
1min. The supernatant was removed and this washing step was repeated 3 times. Beads 
were then re-suspended in 1ml 0.1% BSA/PBS in a cryovial and incubated with 15µl of 
rat anti-mouse CD31 antibody (0.5mg/ml, BD Pharmingen) overnight at 4oC with 
constant agitation. Excess antibody was removed by washing beads with 0.1% 
BSA/PBS four times using the magnetic separator as previously described. Finally, 
beads were re-suspended in 1ml 0.1% BSA/PBS, stored at 4°C and used within 48 
hours. 
 
Magnetic Cell Sorting. Within a sterile laminar flow hood a cell suspension of short or 
long term cultured MNCs was filtered through a 70µm cell strainer (Falcon) into a 50ml 
tube containing 20ml of EGM-2 medium and centrifuged for 5 minutes at 1500rpm. The 
supernatant was carefully removed and the cell pellet was re-suspended in 1ml EGM-2 
medium. This cell suspension was incubated with anti-CD31 pre-coated Dynabeads for 
40 minutes at 4oC (to reduce phagocytic activity and other metabolic processes) with 
constant rotation. The cell/bead suspension was then transferred to a 15ml falcon tube 
and 0.1% BSA/PBS was added up to 5ml. The tube was mounted onto a magnetic 
separator and left for 1 minute. Thereafter the supernatant was removed following 
rigourous trituration (to reduce the incidence of contaminating non-endothelial 
mesenchymal cells and increase purity of yield) and discarded. This washing step was 
repeated three additional times, until the supernatant became clear. Finally, the cells 
were re-suspended in EGM-2 growth medium and plated into collagen-coated 6-well 
tissue culture plates. The following day the cells were washed three times with growth 
medium to remove any loosely adherent cells and surplus beads. Cultures were 
maintained by replacing medium every 3 days. When sub-confluent, cells were washed 
with PBS and detached with a 0.25% Trypsin, 0.03% EDTA (Life Technologies) 
solution at 37°C for 15-20 minutes. Cells were spun at 1000rpm for 5 minutes and re-
seeded at a 1:2 dilution. 
   59 
2.3.1.2. Cardiosphere-Derived Cells 
Complete Explant Medium (CEM) 
IMDM supplemented with 20% fetal calf serum, 1% L-glutamine, 100Units/ml 
penicillin, 100µg/ml streptomycin and 0.1mM  2-mercaptoethanol 
 
Cardiosphere Growth Medium (CGM) 
35% CEM/65% DMEM-Ham’s F-12 mix supplemented with 2% B27, 0.1 mmol/L 2-
mercaptoethanol, 20ng/ml EGF, 80ng/ml bFGF, 40nmol/L Cardiotrophin-1 and 
40nmol/L thrombin.  
 
Preparation of fibronectin-coated plates: (i) explant culture: add 100µl aliquot of stock 
fibronectin (1mg/ml, BD) to 12 ml PBS. Use 1ml of working solution to coat a 35mm 
petri dish. Incubate at 37oC for 30 minutes, then remove the solution and wash once 
with PBS prior to use. (ii) CDC culture: add 25µl aliquot of stock to 6 ml PBS. Use 3ml 
of working solution to coat a T75 flask. Incubate at 37oC for 30 minutes, then remove 
the solution and wash once with PBS prior to use. 
Preparation of Poly-D-Lysine-coated plates: add 100µl aliquot of stock poly-D-lysine 
(2mg/ml low molecular weight, BD) to 12 ml PBS. Use 0.5ml of working solution to 
coat each well of a 24 well plate. Incubate at 37oC for 30 minutes, then remove the 
solution and wash once with PBS prior to use. 
 
All procedures were carried out under sterile conditions in a dedicated tissue culture 
hood. 
 
Tissue Dissection. 3-6 day old mouse pups were culled via cervical dislocation and 
whole hearts were dissected using sterile instruments. Tissue was stored in ice cold 
serum-free CEM and processed for explant culture within 20minutes. 
Explant Culture. Following three washes in PBS isolated myocardial tissue was 
digested in 0.05% Trypsin/EDTA for 5minutes whilst being cut into 1-2mm3 pieces 
using sterile instruments. Enzyme activity was inhibited by the addition of CEM. The 
tissue fragments were individually seeded onto fibronectin coated (~8.4µg/ml) 35mm 
Petri dishes and cultured as explants in 2ml CEM at 37°C and 5% CO2.   Every third 
day of culture 0.5ml of CEM was added to each dish to prevent adherent explant 
fragments from drying out. After a period ranging from 10 to 14 days a confluent layer 
of outgrowth fibroblast-like cells appears, over which loosely adherent small phase 
bright cells migrate. These cells were collected by pooling; one PBS wash, one 1-2 min 
incubation with Versene (0.53 mmol/L EDTA) and one 2-3 min incubation with 0.05% 
Trypsin/EDTA (Invitrogen) at room temperature followed by gentle trituration.  
   60 
Cardiosphere Culture. The collected explant derived cells (EDCs) were seeded at 
1x105 cells per well onto poly-D-lysine-coated (~2.4µg/ml) 24 well plates with 400µl 
cardiosphere-growing medium (CGM) per well.  After four days of culture an additional 
200µl of CGM was added to each well. By culture day six loosely adherent 
cardiospheres had formed and these were counted before being harvested using gentle 
trituration.  Cardiospheres were collected in a 50ml falcon tube and allowed to settle at 
the bottom of the tube. The supernatant was discarded to remove any contaminating 
stromal-like cells. This sedimentation step was repeated before the cardiospheres were 
spun down at 1000rpm for 8 minutes. The pelleted cells were gently triturated to 
promote partial dissociation of the cardiospheres. 
 
Cardiosphere-derived Cell Culture. Cardiospheres were seeded onto fibronectin 
coated (4.2µg/ml) T75 flasks in 15ml of CEM (generally the yield from one 24 well 
plate was plated into one T75 flask) and cultured at 37oC in humidified air with 5% CO2.  
Cells were maintained by replacing medium every three days and cultures were 
passaged once they reached sub-confluency (generally performed every 3-5 days). Cells 
were dissociated by washing with 5ml of PBS before being incubated with 5ml of 
Accutase cell detachment reagent (eBioscience) for 10min at room temperature and the 
flask was knocked harshly to release cells into suspension. Cells were spun at 1000rpm 
for 8 minutes and re-seeded at a 1:2 dilution. 
 
2.3.2. Immortalised Cell Lines 
The mouse skin endothelial (sEND-1) cell line was originally derived from skin 
microvasculature of transgenic mice expressing polyoma middle T oncogene and was 
obtained from Dr. Roy Bicknell (University of Oxford). The NIH-3T3 fibroblast cell 
line was originally derived from mouse embryos and was obtained from Caroline 
Dalgliesh (Newcastle University). 
  
All procedures were carried out under sterile conditions in a dedicated tissue culture 
hood. 
 
Cell Culture. Both immortalised cell lines were grown as monolayers at 37oC in 
humidified air with 5% CO2 and were cultured in Dulbecco’s modified Eagle's medium 
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(DMEM) supplemented with 10% heat inactivated fetal calf serum.  The medium was 
replaced every 3 days. When sub-confluent, cells were washed with PBS and detached 
with a 0.05% Trypsin/EDTA solution at 37 °C for 5 minutes. Cells were centrifuged at 
1000rpm for 5 minutes and re-seeded at a 1:4 to 1:12 dilution.  
 
Cryopreservation and Cell Recovery. Sub-confluent cells were detached with 
Trypsin/EDTA as described above and pelleted in cold medium. Cells were then re-
suspended in ice-cold recovery cell culture freezing medium (Invitrogen) on ice (~1ml 
per T75 flask) and 0.5ml of cell suspension was transferred into one pre-labelled 
cryovial. Cells were slowly cooled to -80oC using a cell freezing container containing 
isopropanol and after 1–3 days the cryovials were transferred to liquid nitrogen for 
long-term storage.  To recover frozen cells, cryovials were removed from liquid 
nitrogen storage and transferred to a cell culture fume hood on dry ice. The cells were 
then rapidly rolled between hands and once they started to thaw 1ml of pre-warmed 
growth media containing 10% FCS was added to the cryovial. This cell suspension was 
transferred to a falcon tube containing a total volume of 10ml media and cells were 
centrifuged at 1000rpm for 5 minutes. Cells from each cryovial were seeded into one 
T25 flask and cultured as standard.  
 
2.4. Cell Staining 
2.4.1. Acetylated-LDL and Isolectin-B4 Dual Staining 
Short term cultured (STC)-EPCs were identified via positive staining for DiI-labelled 
acetylated-LDL (Invitrogen) uptake and FITC-labelled-GSL-I-B4 (Griffonia 
simplicifolia I B4 Isolectin 4, Vector Laboratories) binding. Day 7 BM-MNC cultures 
(in 24 well tissue culture plates) were washed once with fresh media prior to being 
incubated with 0.5ml DiI-acetylated-LDL (5µg/ml EGM-2 media) per well, for 1 hour 
at 37 oC.  The cells were then washed twice with media and incubated with 0.5ml FITC-
GSL-I-B4 (10µg/ml media) again for 1 hour at 37oC. Cells were washed twice and then 
imaged under a Zeiss Axiovert microscope with phase contrast and fluorescence 
conditions using a digital camera. 
 
2.4.2. Immunofluorescent Cell Staining 
   62 
Cells were seeded onto 8-well glass chamber slides (Lab-Tek, Nunc) and allowed to 
adhere and grow for 24 hours. Additional cell treatments were performed as indicated in 
the following results chapters for the stated times. Cells were then washed twice with 
PBS and fixed with acetone for 5 minutes at room temperature. The fixative was 
removed by washing cells 3 times with excess PBS.  To diminish background 
fluorescent signal, the cells were incubated with blocking solution (5% goat serum, 1% 
BSA) for 20 minutes at room temperature. The blocking solution was removed and 
primary antibody (diluted in blocking solution) was applied and cells were incubated at 
4oC overnight (see table 2.3 for antibody details and dilutions). The slides were then 
washed three times in excess PBS and (if a non-conjugated primary antibody was used) 
a fluorochrome-conjugated secondary antibody (see table 2.3) was applied for 1 hour at 
room temperature (1/200 dilution in blocking solution). Cells were again washed three 
times in excess PBS and finally slides were mounted with anti-fade hard set mountant 
with DAPI (Vector Laboratories) under a glass coverslip prior to examination using 
fluorescent microscopy. 
 
Primary Antibody Stock Concentration Dilution Incubation Source 
CD31 (MEC13.3 Clone) 0.5mg/ml 1/25 Overnight at 4oC BD Pharmingen 
Endoglin (MJ7/18) 0.5mg/ml 1/100 Overnight at 4oC eBioscience 
GFP-alexa 488 2mg⁄mL 1/100 1 hour at room temperature Invitrogen 
Secondary Antibody Stock Concentration Dilution  Source 
Goat anti-Rat IgG Alexa-488 or 594  2mg/ml 1/200 1 hour at room temperature Invitrogen 
Table 2.3. Antibodies and conditions used for immunofluorescent cell staining. 
 
2.4.3. X-Gal Cell Staining 
X-Gal Staining Solution 
6ml of 0.5M K3 Ferricyanide, 6ml of 0.5M K4 Ferrocyanide, 120ml of 0.5M Phosphate 
Buffer (pH7.2), 1.2ml of 1M MgCl2, 6ml of 1%NaDeoxycholate, 1.2ml of 10% NP40, 
make up to 600ml with dH2O. This staining solution should be stored in the dark at 4°C. 
 
X-Gal  
0.25g of X-gal dissolved in 10ml of dimethylformamide and stored at a stock 
concentration of 25mg/ml in the dark at -20°C. Added to pre-warmed staining solution 
at a final concentration of 1mg/ml immediately prior to use. 
 
Glutaraldehyde 
Stock glutaraldehyde is at 25% and stored at -20OC. 
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Cells were seeded onto 8-well glass chamber slides (Lab-Tek, Nunc) and allowed to 
adhere and grow for 24 hours. Tamoxifen-mediated Cre-Recombinase activation in 
vitro was achieved by treatment with 1µM-5µM 4-hydroxy Tamoxifen to cell cultures 
and incubation for 24-96 hours, as indicated in the following results chapters. Cells 
were then washed twice with PBS and fixed with 0.5% gluteraldehyde/PBS for 10 
minutes at room temperature. The fixative was removed by washing cells 3 times with 
excess PBS containing 1mM MgCl2.  X-Gal staining solution was added to the cells 
prior to incubating chamber slides at 37oC until the desired staining was achieved (2-
16hours). The cells were washed three times with PBS and lightly counterstained with 
eosin (slides stained with 1/30 eosin dilution for 1 minute and briefly washed in tap 
water). Slides were mounted with histomount (National Diagnostic) under a glass 
coverslip prior to examination under the microscope. 
 
2.5. In vitro Cell Proliferation and Migration Assays 
2.5.1. Proliferation/Cell Count Assay 
Cells were seeded at a density of 2x104 cells per well in 24 well cell culture plates 
(standard culture media), they became adherent after 6-12hours and were transferred to 
a live cell imaging facility (Nikon Biostation). Cells were maintained at 37oC/5% CO2 
and after a period of 2hours (to allow for acclimatisation and to minimise condensation) 
the Biostation was programmed to take phase contrast images at regular 2 hour intervals 
using a 10X objective. A minimum of 4 fields of view were programmed per well and 
each experiment was performed in triplicate. Images were downloaded and cells were 
counted at each timepoint using Image J software. 
 
2.5.2. MTT Assay 
The 3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
colorimetric assay is used to measure cell viability.  Yellow MTT tetrazolium salt is 
enzymatically reduced to form quantifiable purple formazan crystals in metabolically 
active cells280.  Cells were seeded at 5x103 cells per well in 96-well flat bottomed plates 
and cultured for 24hours with or without additional treatments. Thereafter 10µl of MTT 
(5mg/ml in dH2O) was added to each well and plates were incubated for a further 5 
hours at 37oC. Cell media was removed and 100µl DMSO was added to each well to 
solubilise formazan. The plate was shaken to ensure all crystals were dissolved and 
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metabolic activity was recorded using a spectophotometric plate reader (MultiScan 
Ascent, Thermo Labsystems) set to measure absorbance at 570nm.  Each experiment 
was performed in triplicate.  
 
2.5.3. Wound Healing/Scratch Assay 
The scratch assay was used to study cell migration in vitro.  Cells were seeded at a 
density of 5x104 cells per well in 12 well plates and cultured in standard growth 
medium until the monolayer became confluent (~90%). A sterile trimmed cell scraper 
(~1.5-2mm) was used to scrape the cell monolayer in a straight line to create a ‘scratch’ 
wound. Each well was rinsed twice with PBS to remove debris. Growth medium was 
replaced and plates were transferred to the live imaging facility (Nikon Biostation). 
Cells were maintained at 37oC/5% CO2 and after a period of 2hours (to allow for 
acclimatisation and to minimise condensation) the Biostaion was programmed to take 
phase contrast images of the closing ‘scratch’ at regular 2 hour intervals using a 4X 
objective until the cells on the edge of the ‘scratch’ migrated to fully close the gap.  A 
minimum of 3 fields of view were programmed per well and each experiment was 
performed in triplicate. Images were downloaded and the area between the two 
migrating fronts was calculated by drawing around them and employing the measure 
tool using Axioviosion Rel. 4.8 software (Zeiss). These measurements were used to 
calculate the percentage of area healed (gap closed) at each time-point. 
 
2.6. Flow Cytometry 
2.6.1. Murine BM-MNCs 
2.6.1.1. Immunophenotyping BM-MNCs 
Bone marrow (BM) was harvested by flushing freshly dissected femurs and tibiae with 
PBS using a 25G needle and syringe as described above. Cells were washed once by 
centrifuging at 1500rpm for 10minutes and red blood cells were lysed by incubating 
with Pharmlyse solution (BD biosciences, ammonium chloride at proprietary 
concentration; 1:10 dilution) for 10minutes at room temperature. Cells were then 
filtered through a 40µM cell strainer (BD biosciences) and quantified using a modified 
nebauer counting chamber slide.  Cells were re-suspended in PBS at 5x106 cells/ml and 
100µl of cell suspension was transferred to 12x75mm round bottom FACS tubes. 
Primary antibody or IgG isotype control was added to 5x105 cells at a dilution listed in 
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table 2.4 in a 100µl final staining volume. Cells were protected from light and incubated 
for 20minutes at 4oC before washing three times using a cell lyse/wash assistant (BD 
Biosciences). If unconjugated primary antibody was used, cells were then stained with 
secondary antibody (goat anti-rat alexa fluor 647 conjugated IgG (dilution 1:40, 
Invitrogen)) for 20minutes at 4oC and again washed three times. To allow exclusion of 
dead cells, DAPI was added at a final concentration of 1µg/ml and cells were incubated 
for a further 5-10minutes at room temperature. FACS analysis was performed 
immediately using a FACSCalibur instrument with CellQuest software or a LSRII flow 
cytometer and FACSDIVA software (all BD biosciences). 
 
Each analysis included a minimum of 30,000 events. Only viable, single cells were 
included and they were identified on the basis of a forward scatter and side scatter plot. 
Data was displayed on dot plots and histograms with gates to delineate the boundary for 
negative cells. Gates were positioned using negative IgG isotype and no primary 
antibody controls.  A minimum of three replicates were included per sample. 
 
Primary Antibody Stock Concentration Dilution Source 
CD34-FITC  0.5mg/ml 1/100 BD Pharmingen 
FLK1-PE 0.1mg/ml 1/100 BD Pharmingen 
Endoglin (MJ7/18) 0.5mg/ml  1/100 eBioscience 
CD45-FITC 0.5mg/ml 1/100 eBioscience 
Secondary Antibody Stock Concentration Dilution Source 
Goat anti-Rat Alexa-647 2mg/ml 1/40 Invitrogen 
Table 2.4. Antibodies used to immunophenotype BM cells. 
 
2.6.1.2. FDG Staining to Detect LacZ Expressing Cells 
Fluorescein di-β-D-Galactopyranoside (FDG, Marker Gene Technologies Inc.) is a β-
galactoside analogue, which is cleaved by-galactosidase yielding fluoroscein in LacZ 
expressing cells.  
 
BM cells were harvested as previously described and washed twice by centrifuging for 
5minutes at 1200rpm in excess PBS/5%FCS. Cells were then filtered through a 40µM 
cell strainer (BD biosciences) and quantified using a modified nebauer counting 
chamber slide. Cells were re-suspended in ice-cold PBS/5%FCS at a concentration of 
5x107/ml. Cytoplasmic loading of cells with FDG was achieved by adding 20µl of 2mM 
of FDG (diluted in dH2O) to 20µl of cell suspension (106 cells) for 75 seconds at 37oC. 
N.B. total volume is critical as it aids uptake by osmotic shock. Cell-uptake was stopped 
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with the addition of 500µl ice cold PBS/5% FCS and then cells were incubated on ice 
for 3 hours in the dark to allow enzymatic cleavage of the FDG substrate.  Cells were 
washed three times using a cell lyse/wash assistant (BD Biosciences) and DAPI was 
added at a final concentration of 1µg/ml to allow exclusion of dead cells. FACS analysis 
was performed using a LSRII flow cytometer (BD biosciences). Fluorescein 
isothiocyanate (FITC) and DAPI were detected on the 488/530 and 407/450 channels, 
respectively, and data were analysed using FACSDIVA software (BD biosciences). 
Each analysis included a minimum of 50,000 events per sample (performed in triplicate) 
and only viable, single cells were included. Data was displayed on dot plots and 
histograms with gates to delineate the boundary for negative cells. Gates were 
positioned using positive and negative controls: isolated BM cells from a Rosa-CreERT2 
mouse with ubiquitous lacZ expression were used as a positive control for lacZ staining, 
and NIH-wild type BM cells were used as a negative control.   
 
2.6.2. Immunophenotyping Murine Cardiosphere-derived Cells  
Sub-confluent passage 2 CDCs were harvested from culture flasks by incubating with 
accutase dissociation reagent for 10 minutes at room temperature. The cell suspension 
was transferred to a 50ml falcon tube and excess PBS was added prior to centrifuging 
cells at 1000rpm for 8minutes at room temperature. The resultant cell pellet was re-
suspended in 20ml PBS and centrifuged again. Cells were re-suspended in 5ml PBS and 
a small sample (600µl) was used to quantify cell number using a ViCell automated cell 
counter (BD Biosciences). Cells were once more centrifuged at 1000rpm for 8minutes 
prior to being re-suspended in PBS at 5x106cells/ml and 100µl of cell suspension was 
transferred to 12x75mm round bottom FACS tubes. Primary antibody was added to 
5x105 cells at a dilution listed in table 2.5 in a 100µl final staining volume. Separate IgG 
isotype controls were also included and protein concentration was matched to that of the 
appropriate antibody. Cells were protected from light and incubated for 20minutes at 
4oC before washing three times using a cell lyse/wash assistant (BD Biosciences). If 
unconjugated primary antibody was used, cells were then stained with secondary 
antibody (goat anti-rat alexa fluor 647 conjugated IgG (dilution 1:40, Invitrogen)) for 
20minutes at 4oC and again washed three times. For triple stained samples unconjugated 
anti-endoglin or anti-CD31 antibodies were applied first followed by alexa-647 
conjugated IgG secondary antibody, after the designated washing steps. Thereafter cells 
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were washed again and cKit-PE-Cy5.5 and CD90-PE antibodies were added together. 
To allow exclusion of dead cells DAPI was added at a final concentration of 1µg/ml and 
cells were incubated for a further 5-10minutes at room temperature. FACS analysis was 
performed immediately using a LSRII flow cytometer (BD biosciences). Alexa-647 was 
detected on the 638/660 channel, whereas phycoerythrin (PE), PE-Cy5.5 and DAPI 
were detected on the 488/585, 488/710 and 407/450 channels respectively and both 
FITC and GFP were detected using the 488/520 channel. Data were analysed using 
FACSDIVA software (BD biosciences). 
 
Each analysis included a minimum of 30,000 events and only viable, single cells were 
included. Data was displayed on dot plots and histograms with gates to delineate the 
boundary for negative cells. Gates were positioned using negative isotype and no 
primary antibody controls, as previously.  A minimum of three replicates of each 
sample were analysed. 
 
Primary Antibody Stock Concentration Final Dilution Source 
Endoglin 0.5mg/ml 1µl stock /100µl staining volume eBioscience 
cKit-PE-Cy5.5 0.2mg/ml 1µl (1/2 stock)/100µl staining vol. eBioscience 
CD90-PE 0.5mg/ml 1µl stock /100µl staining volume BD Pharmingen 
CD31 0.5mg/ml 1µl stock /100µl staining volume BD Pharmingen 
CD45-FITC 0.5mg/ml 1µl stock /100µl staining volume eBioscience 
GFP-alexa-488 0.5mg/ml 1µl stock /100µl staining volume Invitrogen 
Secondary Antibody Stock Concentration Dilution Source 
Goat anti-Rat alexa-647 2mg/ml 1µl (1/40 stock)/100µl staining vol. Invitrogen 
Table 2.5. Antibodies used to immunophenotype cardiosphere-derived cells. 
 
2.7. RT-PCR 
2.7.1. Primer Design 
Previously published primer pairs used in this study are highlighted and referenced in 
table 2.6. All other primers were designed using Primer3 software281. The genomic 
DNA (gDNA) and complementary DNA (cDNA) sequences of the genes of interest 
were obtained from the UCSC Genome Browser and to confirm primer specificity 
BLAST searches for primer sequence similarity were performed. 
 
RT-PCR primers were designed to span an intronic sequence between two exons to 
allow easy distinction between products derived from target cDNA template and 
products arising from the presence contaminating gDNA. 
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Table 2.6. Details of primers used for RT-PCR. (Tm is annealing temperature) 
 
2.7.2. RNA Extraction from Mammalian Cells and Reverse 
Transcription 
RNA. Total RNA from cell lysates (approximately 106 cells per sample) was isolated 
using the RNeasy Mini Kit (Qiagen) followed by the RNeasy Micro Kit (Qiagen) to 
purify and concentrate the final yield.  Protocols were followed according to 
manufacturers’ recommendations including the on column DNase digestion step. RNA 
is vulnerable to degradation therefore prior to doing any practical work the laboratory 
bench was cleaned with RNase Zap wipes (Invitrogen), gloves were worn and barrier 
filter tips were used. RNA concentration (in ng/ul) was measured using the Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific) at an absorbance of 260nm (A260). 
Purity of obtained RNA was also assessed; RNA was considered pure when the 
A260/A280 ratio was above 1.9 and the A260/A230 was between 1.8-2.2 (if either ratio 
is appreciably lower than these values this suggests the presence of contaminating 
protein or co-purified contaminants respectively). RNA was stored at -80oC in RNase 
free water until required. 
 
Complementary DNA. cDNA was prepared from extracted RNA using a High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems). Briefly, 1µg RNA in 
10µl DEPC- treated dH2O was added to a reaction mix consisting of 2µl 10X reverse 
transcription buffer, 0.8µl 25X dNTP mix, 2µl 10X random primers, 2µl Multiscribe 
Gene Sequence [5’-3’] Exon cDNA bp 
gDNA 
bp Tm 
oC Ref 
Tgfbr2 F: GGAAGTCTGCGTGGCCGTGTGG R: CTATGGCAATCCCCAGCGGAGG 2-4 299 21349 61 
282
 
Bmpr2 F: CTCAGAATCAAGAACGGCTGTG R: TGAATGAGGTGGACTGAGTGGT 2-4 359 27854 61 - 
Endoglin F: CAATGCCAGCATTGTCACCTCC R: AGAGGCTGTCCATGTCGATGCA 7-11 428 5139 58 
283
 
Alk1 F: GACCTTGGGGAGCTTCAGA R: TGCAGAAGGATCTATAGCAGCA 3-4 281 835 58 - 
Alk5 F: GCACCATCTTCAAAAACAGGGG R: GCCAAACTTCTCCAAACCGACC 2-4 415 12532 61 
284
 
Pai1 F: GCTGTAGACGAGCTGACACG R: ACGTCATACTCGAGCCCATC 4-5 203 903 60 - 
Id1 F: TCCTGCAGCATGTAATCGAC R: GAGAGGGTGAGGCTCTGTTG 1-2 356 582 60 - 
β-Actin F: TGAACCCTAAGGCCAACCGTG 
R: GCTCATAGCTCTTCTCCAGGG 
3-4 396 850 61 282 
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Reverse Transcriptase and made up to a final volume of 20µl with 4.2µl with DEPC-
treated dH2O. The mixture was incubated at 25oC for 10minutes (to allow primer 
extension), 37oC for 120 minutes, 85oC for 5 minutes and cooled down swiftly to 4oC 
degrees and stored at -20oC until required. 
 
2.7.3. RT-PCR of Cell-derived Material and Densitometric 
Analysis 
RT-PCR. Reaction mixtures were made up to a total volume of 50µl in 0.2 ml thin 
walled PCR tubes and consisted of 5µl MgCl2 (25mM), 5µl 10X Buffer IV, 0.4µl Taq 
red hot polymerase (Applied Biosystems), 1µl 20mM dNTPs (New England Biolabs), 
1µl forward primer (20µM), 1µl reverse primer (20µM), 33.6µl dH2O, and 2µl sample 
cDNA. Reactions were carried out using a C1000 thermal cycler (Biorad). 
 
Primer details and the expected sizes of the amplified cDNA sequences are shown in 
table 2.6 and the RT-PCR cycling conditions used are shown in table 2.7. 
Table 2.7. Details of PCR conditions used for gene-specific RT-PCR. 
 
Agarose Gel Electrophoresis. Successful and specific amplification of RT-PCR 
products were confirmed by ethidium-bromide stained gel electrophoresis as described 
in section 2.2.4. 
 
Densitometry Analysis.  Band intensity was measured by scanning ethidium bromide-
stained agarose gels using an Typhoon Trio scanner (GE Healthcare) and performing 
densitometry analysis using ImageQuant TL image analysis software (GE Healthcare) 
which allows fully automatic lane and band detection and quantitation. Results were 
expressed as the densitometry ratio of target gene bands to the β-actin bands. 
 
Reaction Step 
Primer Pairs 
Tgrbr2 and 
Bmpr2 Endoglin 
Alk5  and β-
Actin Alk1 Id-1 and Pai-1 
1 94oC-5mins 95oC-5mins 95oC-5mins 95oC-5mins 94oC-2mins 
2 94oC-15secs 95oC-75secs 95oC-30secs 95oC-30 secs 94oC-15secs 
3 61oC-30secs 58oC-75secs 61oC-45secs 58oC-45secs 60oC-30secs 
4 72oC-45secs 72oC-2mins 68oC-60secs 68oC-60secs 68oC-5secs 
5 72oC-5mins 72oC-7mins 68oC-7mins 68oC-7mins 68oC-5mins 
Cycles (Steps 2-4) 33 33 33 33 33 
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2.8. Protein Analysis 
2.8.1.  Protein Extraction and SDS-PAGE 
Lysis Buffer 
10mM Tris-HCl pH 7.4, 1% Triton X-100, 1/100 dilution of protease inhibitors 
(Sigma), 1/10 dilution pf 10X phosphatase inhibitor (PhosSTOP tablets, Roche) 
 
2X SDS Loading Buffer 
12.5ml 0.5M Tris-base pH 6.8, 10ml glycerol, 20ml 10% Sodium Dodecyl Sulphate 
(SDS), 7ml dH2O, 0.5ml β-mercaptoethanol, 20mg Bromphenol Blue 
 
1X SDS Running Buffer 
14.4g Glycine, 3g Tris-base and 10ml of 10X SDS dissolved in 1 litre of dH2O 
 
Protein Extraction. Approximately 2.5 x 105 cells were washed in PBS, pelleted and 
stored at -80oC until required. To extract proteins a defined volume of lysis buffer 
(typically 50-100µl) was added to each sample followed by repeated trituration. Prior to 
separation via SDS-PAGE a volume of 2X SDS loading buffer was added to each 
sample at a 1:1 2X SDS loading buffer: lysis buffer volume ratio to denature proteins, 
aid loading into wells and allow tracking of the sample during gel electrophoresis. The 
protein samples were denatured at 95°C for 10 minutes in a thermomixer, briefly 
sonicated and centrifuged for 3minutes at 1300rpm. 
 
SDS-PAGE. Approximately 30µl of whole cell lysate was loaded per well of a pre-cast 
10% Tris-HCl polyacrylamide mini-gel (Bio-Rad). The gels were run in 1X SDS 
running buffer for 1hour at 100 volts. Molecular weights of the proteins were 
determined using a pre-stained protein marker (New England Biolabs). Equal loading of 
protein was assessed by using α-tubulin as a loading control (discussed below). 
 
2.8.2. Western Blotting 
Transfer Buffer 
14.4 g Glycine, 3g Tris-base dissolved in 1 litre dH2O 
 
TBST 
150mM NaCl, 50mM Tris-HCl, 0.1% Tween-20 
 
Stripping Buffer 
0.1M Glycine dissolved in dH2O, adjust pH to 2.2 with HCl 
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Protein Transfer to Membrane. Following protein separation by SDS-PAGE, the 
separated proteins were transferred in a wet transfer apparatus (BioRad) to 
polyvinylidene fluoride (PVDF) membrane (GE healthcare) at 4oC in cold transfer 
buffer for 1hour at 100 volts. Prior to transfer the PVDF membrane was activated in 
methanol for 30seconds, dH2O for 5minutes and equilibrated in cold transfer buffer for 
20minutes. Successful transfer and equivalence of protein loading was confirmed using 
Ponceau S stain (Sigma).  Briefly, membranes were incubated with Ponceau S solution 
for 5 minutes at room temperature then rinsed in dH2O to remove background staining 
and allow clear visualisation of the transferred protein bands. To de-stain membranes 
were washed 2 x 10 minutes in TBST wash buffer. 
 
Immunoblotting, Membranes were incubated in blocking buffer (5% Marvel dry 
milk/TBST) for 1 hour at room temperature to avoid non-specific antibody binding. 
This was followed by incubating membranes overnight at 4oC with primary antibodies 
diluted to a specific concentration (see table 2.8 for antibody details) in primary 
antibody diluent (0.5% marvel/TBST). Membranes were then quickly rinsed in TBST 
before being washed 4 x 10 minutes in 5% Marvel/TBST. The membranes were then 
incubated with a secondary antibody conjugated to horse-radish peroxidase (HRP) 
directed against the primary antibody’s species of origin (see table 2.8). The HRP 
conjugated secondary antibodies were diluted to a 1/2,000 concentration in 5% 
Marvel/TBST and left to incubate for 1 hour at room temperature. Membranes were 
again briefly rinsed in TBST before being washed 2 x 10 minutes in 5% Marvel TBST, 
followed by 4 x 10minutes in TBST. 
 
Successful antibody binding was visualised by enhanced chemiluminescence (ECL) 
using the SuperSignal West Pico or Dura ECL Chemiluminescent Substrate kits (Pierce 
Biotechnology), which bind HRP antibodies and produce a light reaction that can be 
detected by exposure to X-ray film. Therefore band signals were detected after exposure 
of Western blot membranes to X-ray film (GE Healthcare) and processing in a Xograph 
Compact X4 automatic X-ray film developer (Xograph Imaging Systems Ltd.).  
 
Membrane Stripping and Re-blotting. To strip the membrane of bound antibodies, it 
was incubated with stripping buffer for 30 minutes at room temperature followed by 3 x 
10 minute washes in TBST. The membrane was then subjected to chemiluminescence 
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treatment and X-ray film developing to ensure successful stripping of bound antibody. 
Following 3 x 10 minute washes in TBST the membrane was ready to be re-blotted 
(beginning at the membrane block step).  
 
Primary 
Antibody Blocking Solution 
Working  
Dilution  
Secondary 
Antibody 
Working  
Dilution 
ECL 
Kit 
Size 
(kDa) 
phospho-Smad 
1/5/8 
(Cell Signalling) 
5% Marvel/TBST 1:500 in 0.5% Marvel/TBST 
α-rabbit 
HRP 
1:2000 
in blocking solution Dura 60 
Smad 1 
(Cell Signalling) 5% Marvel/ TBST 
1:500 
in 0.5% Marvel/TBST 
α-rabbit 
HRP 
1:2000 
in blocking solution Dura 58-60 
phospho-Smad 2 
(Cell Signalling) 5% Marvel/ TBST 
1:500 
in 0.5% Marvel/TBST 
α-rabbit 
HRP 
1:2000 
in blocking solution Dura 60 
Smad2 
(Cell Signalling) 5% Marvel/ TBST 
1:2000 
in 0.5% Marvel/TBST 
α-mouse 
HRP 
1:2000 
in blocking solution Pico 60 
Tubulin 
(Sigma) 5% Marvel/ TBST 
1:1000 
in 0.5% Marvel/TBST 
α-mouse 
HRP 
1:2000 
in blocking solution Pico 50 
Endoglin 
(eBioscience) 
 
5% Marvel/ TBST 1:150 in 0.5% Marvel/TBST 
α-rat 
HRP 
1:1000 
in blocking solution Dura 90 
Table 2.8. Antibodies and conditions of use for western blotting. 
 
2.9. Histological Procedures 
2.9.1. General Solutions 
10 x Phosphate Buffered Saline (PBS) 
80g NaCl, 2g KCl, 14.4g Na2HPO4 and 2.4g KH2PO4 dissolved in 800ml of ddH2O. Adjust 
pH to 7.4 with HCl then add ddH2O to make volume up to 1 litre.  
 
4% Para-formaldehyde (PFA)/PBS Solution 
Add 4g of para-formaldehyde powder to 100ml of PBS and dissolve at 60°C. Divide into 
aliquots and store at -20°C until required. 
 
4% Formaldehyde/PBS Solution 
10.5ml of 38% formaldehyde solution (BDH, AnalaR, VWR International) and make up to 
100ml with 1xPBS. Divide into aliquots and store at -20°C until required. 
 
0.2% Para-formaldehyde (PFA)/PBS Solution 
Add 0.2g of para-formaldehyde powder to 100ml of 1xPBS and dissolve at 60°C. Divide 
into aliquots and store at -20°C until required. 
 
2.9.2. Paraffin Embedded Tissue 
2.9.2.1. Tissue Processing and Sectioning 
Tissue Dissection, Fixation and Paraffin wax embedding. Dissected tissue was 
washed twice in ice-cold PBS (5 minute each) and then fixed in 4% paraformaldehyde 
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or 4% formaldehyde (required for Masson trichrome staining; see 2.7.2.2) overnight at 
room temperature.  The fixative was removed following three 1 hour washes in excess 
PBS with gentle agitation. The tissue was then incubated in 50% ethanol/dH2O for a 
minimum of 2 hours at room temperature with gentle agitation of the tubes. The tissue 
blocks were then left at room temperature overnight in 70% ethanol/dH2O. The tissue 
was then further dehydrated through 3 x 2 hour changes of 100% ethanol at room 
temperature before being left in a glass container containing Histoclear overnight in a 
fume cupboard. The following day, the tissue blocks were equilibrated in a minimum of 
3 x 2 hour changes of molten paraffin wax at 60°C, followed by an overnight incubation 
in molten paraffin wax at 60°C before embedding the tissue in paraffin wax and 
allowing it to set in plastic moulds (RA Lamb). Tissue blocks were stored at 4°C. 
 
Sectioning. Tissue blocks were sectioned using a Leica RM2235 rotary microtome with 
disposable microtome blades at a thickness of 8µm. Transverse or saggital serial 
sections were cut into small ribbons and transferred onto HistoBond adhesive glass 
slides (RA Lamb) bathed in water on a hot plate pre-heated to 37oC to aid in flattening 
sections and remove creases. Slides were left to air dry on the hot plate for a minimum 
of 2 hours and any excess water was carefully removed using the edge of a tissue while 
taking care not to touch the tissue sections. The slides were incubated at 40oC overnight 
to ensure that the sections adhered well to the HistoBond slides. 
 
2.9.2.2. Masson Trichrome Histological Staining 
Working Weigert's Iron Hematoxylin Solution (Sigma) 
Equal volumes of solution A (1% Hematoxylin in 95% EtOH) and solution B (1.2% 
Ferric Chloride and 1% Acetic Acid in distilled water). The working solution is stable 
for approximately 10 days. 
 
Phosphomolybdic/Phosphotungstic Acid Solution 
1 volume of Phosphotungstic Acid Solution, 1 volume of Phosphomolybdic Acid 
Solution and 2 volumes of distilled water. 
 
Sections were dewaxed and hydrated using the method described in table 2.9. Slides 
were then ‘mordanted’ in Bouin's Solution at room temperature overnight in fume hood 
to intensify the final colouration of the tissue. The slides were then washed in running 
tap water to remove yellow colour from sections and then rinsed briefly in distilled 
water.  The sections were stained in working Weigert's Iron Hematoxylin solution 
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for 5 minutes followed by a 5 minute wash in running tap water and a rinse in distilled 
water.  Sections were then stained in Biebrich Scarlet-Acid Fuchsin for 5 minutes and 
then briefly rinsed in distilled water.  Slides were placed in freshly prepared working 
Phosphomolybdic/Phosphotungstic Acid solution for 5-10 minutes (allows for uptake of 
the aniline blue stain).  Sections were finally stained in Aniline Blue solution for 5 
minutes before a brief rinse in distilled water and differentiation in 1% acetic acid for 3-
5 minutes to render the shades of colour more delicate and transparent. Sections were 
rapidly dehydrated through a graded ethanol series and cleared in Histoclear as listed in 
table 2.9  Finally, the stained sections were then mounted under cover slips using 
Histomount mounting medium and left to dry in a fume cupboard overnight. In Masson 
Trichrome stained sections, haematoxylin stains nuclei blue-black, Beibrich scarlet-acid 
fuchsin stains cytoplasm and muscle red while Aniline blue stains collagen blue. 
 
Dewaxing and Rehydration Dehydration and Clearing 
Treatment Incubation Time Treatment Incubation Time 
Slides at 60°C 1 hour 50% Ethanol 5 seconds 
Histoclear 2 x 10 minutes 70% Ethanol 5 seconds 
100% Ethanol 2 minutes 100% Ethanol 5 seconds 
70% Ethanol 2 minutes 100% Ethanol 5 minutes 
50% Ethanol 2 minutes Histoclear 2 x 10 minutes 
30% Ethanol 2 minutes   
Tap water 2 minutes   
Table 2.9. Method for (i) dewaxing and rehydrating paraffin sections prior to staining 
(white) and (ii) dehydrating and clearing sections prior to mounting (grey). 
 
2.9.2.3. X-Gal Staining (Lung Wholemounts) 
0.2% Gluteraldehyde Fixative Solution 
Add 0.2% Gluteraldehyde, 0.02% NP40, 0.005M EGTA, 0.002M MgCl2, and 0.1M 
Phosphate buffer at pH 7.6; make up to a total volume of 20ml with ddH20 
 
X-Gal Staining Solution 
6ml of 0.5M K3 Ferricyanide, 6ml of 0.5M K4 Ferrocyanide, 120ml of 0.5M Phosphate 
Buffer (pH7.2), 1.2ml of 1M MgCl2, 6ml of 1%NaDeoxycholate, 1.2ml of 10% NP40, 
make up to 600ml with dH2O. This staining solution should be stored in the dark at 4°C. 
 
X-gal  
0.25g of X-gal dissolved in 10ml of dimethylformamide and stored at a stock 
concentration of 25mg/ml in the dark at -20°C. Added to pre-warmed staining solution 
at a final concentration of 1mg/ml immediately prior to use. 
 
Wash Buffer 
0.02% NP40 in PBS 
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Lung lobes were dissected and washed in ice-cold PBS prior to incubation in pre-cooled 
0.2% gluteraldehyde fixative solution for 30 minutes at 40C. Post fixation the tissue was 
rinsed in PBS to remove excess fixative, washed thoroughly with wash buffer (3 x 
30minutes) and then stained with pre-warmed 1mg/ml X-Gal staining solution 
overnight at 30oC with gentle agitation.  Following X-Gal staining the lung lobes were 
then washed in PBS (3 x 30minutes) to remove staining solution and fixed in 4% 
formaldehyde/PBS for 3 hours at room temperature. Tissue was washed in excess PBS 
(3 x 60minutes) before being imaged as wholemounts using a  Stereomicroscope (Leica) 
and then processed through alcohol dehydration, embedded in paraffin wax and 
sectioned (see section 2.7.2.1).  
 
2.9.3. Frozen Tissue 
2.9.3.1. Tissue Processing and Sectioning 
Lung and heart tissue was dissected quickly and carefully from adult mice (≥8 weeks) 
immediately after humane killing. Tissue was washed twice in ice-cold PBS and fixed 
in 0.2%PFA/PBS overnight at 4°C with gentle agitation followed by an overnight 
incubation in PBS + 2mM MgCl2 + 30% sucrose solution at 4°C with gentle agitation. 
The dissected tissue was then attached to cork discs using OCT tissue freezing medium 
(Lamb) before being frozen (either snap frozen in liquid nitrogen-cooled isopentane or 
slow frozen using dry ice) and sectioned.  
 
Further modifications of the method were employed as required. To clear the lungs of 
blood, lung tissue was perfused with PBS prior to dissection by inserting an insulin 
syringe into the pulmonary artery through the right ventricle and an incision was made 
in the left atrium to allow outflow of perfusate. For improved section quality, a 1:1 
OCT:PBS mixture was injected through the trachea prior to dissection to inflate the 
lungs and help maintain their morphology.  In this case it was important that the tissue 
was immediately snap frozen in liquid nitrogen-cooled isopentane. Heart tissue was fixed 
directly following washes in ice-cold PBS and prior to slow freezing a 1:1 OCT: PBS 
mixture was injected into the ventricular cavities. To freeze, heart tissue was orientated 
in small dispomoulds (Lamb), embedded in OCT compound and slowly frozen by 
incubating on dry ice for (approximately 15 minutes). Frozen samples were stored at -
80oC until required. 
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Cryo-sectioning frozen tissue blocks: Tissue blocks were sectioned using a Microm 
HM 560 CryoStar cryostat (Thermo Scientific).   Following an equilibration period of 
approximately 30mins at -20oC, 10µm serial sections were cut and mounted on 
polylysine glass slides (VWR International). The slides were left to air dry for a 
minimum of 60 minutes before being transferred to labelled slide mailers and stored at -
80°C until required.  
 
2.9.3.2. Immunohistochemistry using the Vectastain ABC System 
Blocking Solution 
5% rabbit serum diluted in PBS. 
 
Heart and lung cryo-sections were removed from -80°C storage and allowed to reach 
room temperature for 30 minutes inside slide mailers to minimise condensation. 
Subsequently slides were transferred to a slide rack and left at room temperature for a 
further 30minutes. Sections were circled using a hydrophobic barrier pen whilst drying 
followed by a brief 5minute wash in PBS. Sections were then fixed in cold AnalaR 
acetone for 10 minutes and allowed to air dry for 30minutes prior to commencing the 
immunostaining protocol. All the incubation steps were performed in a humidified 
chamber at room temperature unless stated otherwise. 
 
Following fixation, cryosections were washed in PBS for 1 x 5mins prior to a 1 hour 
incubation with blocking solution. Sections were then subjected to treatment with an 
Avidin/Biotin blocking kit according to manufacturer’s instructions (Vector 
Laboratories) to block non-specific binding of Biotin/Avidin System reagents and 
endogenous biotin activity. Briefly the sections were incubated with Avidin D solution 
for 15 minutes and rinsed in PBS prior to a second 15 minute incubation with the Biotin 
solution and finally 2 x 5 minute washes in PBS.  Sections were subsequently incubated 
with primary antibody at a specified dilution overnight at 4oC followed by 3 x 5 minute 
PBS washes (see table 2.10 for antibody details; antibodies diluted in blocking solution). 
The sections were then incubated with a biotinylated rabbit anti-rat secondary antibody, 
diluted to a 1/200 working concentration in blocking solution, for 30 minutes. The 
Vectastain® ABC reagent (Vector Laboratories) was made up according to the 
manufacturer’s instructions and allowed to stand for 30 minutes at room temperature 
before use. Sections were washed for 3 x 5 minutes in PBS, incubated in Vectastain® 
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ABC reagent for 30 minutes and then washed again in three changes of PBS (5 minutes 
each). Antibody binding was visualized using the liquid DAB substrate kit (BioGenex), 
which was prepared according to the manufacturer’s instructions. Sections were rinsed 
under running tap water then counterstained with Mayer’s Haematoxylin (RA Lamb) 
for 2-3 minutes followed by a final wash under running tap water before being 
dehydrated and cleared, according to the steps listed in table 2.9. Finally, slides were 
mounted under cover slips using Histomount mounting medium and allowed to dry 
overnight.  
 
Negative or ‘no primary’ control sections were prepared as described above (primary 
antibodies replaced with blocking solution) to assess specificity of staining.  
 
Primary 
Antibody 
Working 
Dilution Incubation  
Additional 
Treatment 
Blocking 
Solution 
Secondary 
Antibody 
Endoglin (MJ7/18) 
(eBiosciences) 
1/400 
(diluted in 
blocking solution) 
Overnight at 
4oC 
Avidin/Biotin 
Blocking 
5% rabbit 
serum/PBS 
Rabbit anti-rat IgG 
(Vector Laboratories) 
CD31 
(MEC13.3 clone) 
(BD Pharmingen) 
1/25 
(diluted in 
blocking solution) 
Overnight at 
4oC 
Avidin/Biotin 
Blocking 
5% rabbit 
serum/PBS 
Rabbit anti-rat IgG 
(Vector Laboratories) 
Table 2.10. Antibodies and conditions of use for immunohistochemistry (Vectastain 
ABC System) on paraffin embedded tissue sections. 
   
 
2.9.3.3. Immunofluorescence  
Blocking Solution 
5% goat serum, 1% BSA, 0.5% Tween-20 diluted in PBS 
 
PBST 
0.25% triton diluted in PBS 
 
0.2% PFA fixed heart cryosections were removed from the -80°C freezer and allowed to 
thaw for 30minutes at room temperature inside their slide mailers, followed by drying 
for a further 30minutes in a slide rack. Sections were circled using a hydrophobic 
barrier pen (Vector Laboratories) whilst drying. All incubation steps were performed in 
a humidified chamber at room temperature unless stated otherwise. Antibody details, 
conditions and additional treatments are listed in table 2.11. 
 
Sections were blocked by incubating in blocking solution for 2 hours at room 
temperature. The sections were then incubated with primary antibody at the appropriate 
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dilution and temperature (see table 2.11). Following 3x5miute washes in excess PBS 
and 1x5 minute wash in PBST sections were then incubated with the appropriate 
secondary antibody (diluted 1/200 in blocking solution, see table 2.11) for 1 hour at 
room temperature.  Following 3x5 minute washes in excess PBS and 1x5 minute wash 
in PBST, sections were mounted under glass slides using Vectashield with DAPI hard 
set mounting media (Vector Laboratories) and left to dry at 4oC in the dark.  
 
Sections to be stained with biotinylated or CD11b antibodies were also pre-treated with 
a Streptavidin/Biotin blocking kit (Vector Laboratories) as per manufacturer’s 
instructions. Briefly, following incubation in standard blocking solution, sections were 
incubated with Streptavidin solution for 15 minutes, rinsed in PBS and then incubated 
with Biotin solution for 15 minutes (all at room temperature).  
 
For α-actinin staining, the Streptavidin/Biotin blocking step was used in place of 
blocking solution and was followed by treatment with the mouse on mouse (M.O.M.) 
immunodetection kit which enables the specific localisation of mouse primary 
antibodies on mouse tissues. Tissue sections were incubated with M.O.M. mouse Ig 
blocking reagent for 1 hour, washed in PBS (2x2minutes) and incubated in M.O.M 
dilute for 5minutes. Excess M.O.M. diluent was tipped off prior to α-actinin (1/400 in 
M.O.M diluent) being added and sections were incubated for a further 30mins. 
Following 2 x 2minute washes in excess PBS, sections were incubated with M.O.M. 
biotinylated anti-mouse IgG reagent for 10minutes and then washed again in PBS 
(2x2minutes). The tissue sections were then incubated with a 1/200 dilution of 
streptavidin alexa 594 conjugate in M.O.M. diluent for 30min (see table 2.11) and 
washed in excess PBS (3x5minutes), prior to mounting as above. All steps were 
performed at room temperature. 
 
Double Immunofluorescent Staining. Antibodies directly conjugated to a 
fluorochrome were added to sections together (eg SMA-Cy3.3 and anti-GFP-alexa 488). 
For unconjugated antibodies (endoglin, CD31, cKit and CD11b), GFP staining was 
achieved by incubating sections with both the appropriate secondary antibody and anti-
GFP-alexa 488 together, prior to final washes and mounting. For α-actinin staining 
sections were incubated with anti-GFP-alexa 488 following incubation with streptavidin 
alexa 594 and associated washes. 
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Negative or ‘no primary’ control sections were prepared as described above (primary 
antibodies replaced with blocking solution) to assess specificity of staining.  
 
Primary 
Antibody 
Working 
Dilution Incubation Additional Treatment Secondary Antibody 
Endoglin 
(eBiosciences) 
1/100 
 
Overnight at 
4oC - 
anti-rat alexa 594 
(Invitrogen) 
CD31 
(BD Pharmingen) 
1/50 
 
Overnight at 
4oC - 
anti-rat alexa 594 
(Invitrogen) 
α-Actinin 
(Sigma) 
1/400 
 
30minutes at 
room temp. 
Streptavidin/ Biotin Blocking Kit 
MOM Immunodetection Kit 
streptavidin-alexa 594 
(Invitrogen) 
SMA-Cy3 
(Sigma) 1/200 
1 hour at room 
temp. - n/a 
cKit 
(eBioscience) 1/100 
1 hour at room 
temp. - 
anti-rat alexa 594 
(Invitrogen) 
CD11b 
(BD Pharmingen) 1/100 
1 hour at room 
temp. Streptavidin/ Biotin Blocking Kit 
streptavidin-alexa 594 
(Invitrogen) 
GFP-alexa 488 
(Invitrogen) 1/25 
1 hour at room 
temp. - n/a 
Table 2.11. Antibodies and conditions of use for immunofluorescence staining on 
frozen heart sections. All secondary antibodies were diluted 1/200 in blocking solution 
(streptavidin-alexa 594 diluted in M.O.M. diluent for α-actinin staining) and washed in 
PBST. 
 
2.10. Microscopy & Image Analysis 
For light microscopy, cells grown in tissue culture dishes or flasks were viewed using a 
Zeiss Axiovert 200 inverted microscope. Stained tissue sections and wholemounts were 
viewed using a Ziess Axioplan microscope and a Zeiss Stemi microscope respectively. 
For fluorescence microscopy, a Zeiss Axio Imager II was used (with optional apotome 
feature for the generation of higher resolution images) to view both cell and tissue 
slides. The Nikon biostation was used for live cell imaging and a Leica MZ 125 was 
used for mouse surgery and tissue dissection.  
 
Images were recorded with a digital camera and analysed using Axiovision Release v4.8 
or ImageJ (NIH) software packages, 
 
2.11. Statistical Analysis 
Statistical analyses were performed using SPSS software (version 19, SPSS Inc.). The 
Shapiro-Wilk normality test was used to assess if data was normally distributed. If data 
was normally distributed parametric analyses were performed; for multiple group data 
sets one-way ANOVA was used while comparisons between two independent groups 
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were made using the students unpaired t-test. The Mann Whitney statistical test (non-
parametric) was used to analyse non-normally distributed data. Pearson's correlation 
coefficient was also used to assess correlation between two variables. A p value of 
<0.05 was accepted as being statistically significant. 
 
2.12. Mouse Model of Myocardial Infarction and Intramyocardial 
Cell Injection 
Pre-surgery Preparation. Prior to beginning any surgery the entire work area was 
thoroughly cleaned with 70% ethanol and equipment was checked for function. Surgical 
tools, drapes and accessories (sterilised by autoclaving) were assembled and tools were 
re-sterilised where appropriate during batch surgeries by using a hot bead steriliser 
(Harvard Apparatus)). The intubation cannula was checked to ensure that it was patent 
and free from obstruction.  Sterile surgical gowns, face mask and gloves were worn and 
special care was taken to ensure aseptic technique was maintained throughout the 
procedure. A detailed record of each mouse was made prior to surgery including 
identification (denoted by cage number and earclipping), genotype and strain, date of 
birth and pre-operative weight. In addition details of administered drugs and the 
anaesthesia/ventilation regime were included and subsequent notes relating to the 
surgery were added during the recovery period.  
 
Inducing anaesthesia, Intubation and Mechanical Ventilation. The mouse was 
injected (via IP route) with 0.2ml/kg Hypnorm, (a neuroleptanalgesic mixture of 
fentanyl/Fluanisone, Janssen) as a pre-sedative to aid in anaesthesia induction and 
maintenance, and was then placed in an anaesthetic induction chamber (97% O2/3% 
(vol/vol) isoflurane, flow rate ~3 liters min-1) for 1-2minutes prior to shaving the left 
side of the chest and the throat area. The animal was then transferred to an anaesthetic 
nose cone on a surgery panel (directly onto a sterile drape covering a heat blanket 
maintained at 37oC (Harvard apparatus)) beneath a Leica MZ 125 microscope. 
Isoflurane was reduced to 97.5% O2/2.5% (vol/vol) at a flow rate of ~2 liters min-1 and 
an ‘activated charcoal filter gas scavenger’ (Cardiff Aldasorber, Shirley Aldred & Co 
Ltd) was switched on to collect waste anaesthetic gases. The mouse was placed in a 
supine position in preparation for surgery with both forelimbs taped down either side of 
the body with care taken not to overstretch the limbs. A cotton bud was used to clean 
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the shaved regions with hydrex chlorhexidine solution (Ecolab).  The microscope was 
focused over the throat region and a midline ventral skin incision of about 1cm in length 
was made slightly below the position of the cricoid cartilage using blunt scissors and 
rounded forceps. Skin was separated from connective tissue using blunt dissection and 
once the salivary glands were visualised they were split on their natural midline division 
by simultaneously pulling each part sideward with forceps. With this same manoeuvre 
the paratracheal muscles on the midline fascia were spilt to expose the trachea in the 
larynx area (care was taken to avoid pinching the trachea or the adjoining vessels and 
nerves).  Anaesthetic flow was then opened to the ventilator to pre-flush the system with 
isoflurane. To intubate the mouse it was removed from the nose cone and, working 
quickly (to avoid the animal regaining consciousness during this part of the procedure), 
moved to a horizontal position and fixed at its front teeth using suture material. The 
trachea was exposed with forceps in the left hand while sliding the intubation cannula 
carefully into the mouth, then the trachea with the right hand (cannula tip should be 
visible through the displayed larynx and trachea). The cannula was immediately 
connected to the ventilator (Minivent, Harvard Apparatus) which was set at ~200µl min-
1
 / ~150 strokes min-1 and tubing supplying anaesthetic gases to the mouse was secured 
with tape.  Anaesthetic flow to the nose cone was closed and outflow rate was reduced 
to 0.75 liter min-1, while isoflurane concentration was reduced to 1.5-1.8%. The tracheal 
incision was covered with a sterile PBS soaked sponge to protect it and prevent the 
tissue from drying out. 
 
Thoracotomy. The mouse was then positioned for thoracotomy; both forelimbs were 
fixed sidewards, the right hindlimb parallel to the tail and the left hind leg was turned to 
the right side. With blunt scissors and rounded forceps, a 1-1.5cm long skin incision 
was made over the left thoracic region starting from 1cm medial of the left axilla at a 
45o angle cranial-ward to the sternum. The skin was loosened from the connective tissue 
/ muscle layers by blunt dissection and the left pectoralis major muscles were loosened, 
moved towards the right shoulder and fixed with a muscle retractor, while the left rectus 
thoracis and serratus anterior muscles were retracted towards the left side of the mouse. 
Fine scissors were used to carefully cut the sheets of connective tissue that prevent 
retraction, taking care not to damage the muscles or major blood vessels in the vicinity.  
Several intercostal spaces were visible and the following criteria were used to ensure the 
right space was chosen to ensure optimum exposure of the heart (usually between the 
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third and forth ribs); (i) curvature (after first rib that is less curved than the rib above), 
(ii) vessel landmark (a large vessel runs from outside to inside the thoracic cavity; take 
the intercostal space just cranially of this vessel), (iii) lungs (the lower edge of the left 
lung should be one intercostal space distal, or left of the surgeon’s viewpoint, to the 
thoracotomy).  The chosen intercostal muscle layer was perforated approximately 3mm 
from the sterno-costal junction to avoid injury to the left internal mammary artery, by 
pinching with small, rounded forceps. Once a hole was made, the closed tips of the 
forceps were inserted into the thoracic cavity from medial to lateral orientation with the 
tips parallel to the muscle thereby avoiding contact with the lungs. The tips of the 
forceps were then pushed up through the lateral side of the intercostal muscles and 
opened slightly while the overlying muscle was cut with fine scissors to produce 
thoracotomy.  A small piece of sterile PBS soaked sponge was inserted into the thoracic 
cavity to protect the lungs and heart from instruments and a chest retractor (Mini 
Goldstein Retractor, Fine Science Tools) was used to expose the heart.     
 
LAD ligation. The pericardium was opened and removed using two pairs of small, 
round forceps and the upper- and mid- left ventricle with its partly overlapping auricle 
and blood vessels were made visible.  The left anterior descending coronary artery 
(LAD) was then identified as a bright red to orange/pink, pulsatile vessel running from 
below the left auricle to the apex. It has several side branches, which may also be 
visible, but the occlusion was made proximal to these branches to obtain maximal 
reproducibility of infarct size. Once identified, the LAD was enclosed in approximately 
four times its diameter of surrounding myocardium just distal to the left auricle with 7-0 
Prolene suture material (Johnson & Johnson Medical Ltd) while taking care to avoid 
perforating the ventricle cavity.   The suture was closed using a double surgeon’s knot, 
fixed with two extra half-stitches and the suture ends were cut just long enough to 
prevent slipping of the knot.  A successful infarction was characterized by (i) immediate 
change colour of the LAD after occlusion from bright red/orange to dark violet (ii) 
discoloration (pallor) of the LV free wall, (iii) a clear border between ischaemic and 
non-affected area and (iv) reduced or absent motility of the infarct area. 
 
Intramyocardial Cell Injection. Cells were washed and prepared as a single cell 
suspension in PBS (without Ca++) at a concentration of 106 cells per 5µl of PBS. Cells 
were stored on ice prior to being delivered via intramyocardial injection (within 15 
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minutes of preparation) using a 25µl Hamilton Microliter™ syringe and 33 gauge 
needle. Cells were injected into two sites bordering the ischaemic zone of the LV free 
wall (approx 2.5µl per site, see figure 6.1). The injection was superficial to prevent 
perforation of the LV wall and the injection sites were distal to the septum and RV to 
minimise contact with the conduction system. Successful injection was evident by the 
absence of cell backwash and the appearance of a white area in the myocardium. 
 
Wound Closure. The retractor was removed and the thoracic cavity closed by 
enclosing the two separated ribs with two stitches of 5-0 vicryl suture material (round 
bodied needle, Johnson & Johnson Medical Ltd), keeping some distance from the ribs to 
prevent damage to the intercostal vessels and nerves. The internal sponge was removed 
prior to tying the sutures with one double surgeons knot secured with two half-stitches.  
The lungs were re-inflated by closing the ventilator expiratory tube three times very 
swiftly to generate a positive end expiratory pressure (PEEP), which helps the small 
airways to fill with air again. The pectoral muscles were moisturised with sterile PBS 
and gently pulled back into their original positions. The skin incision was closed with a 
continuous mattress suture using 5-0 vicryl suture material (cutting needle, Johnson & 
Johnson Medical Ltd) and the incision over the tracheal region was closed with one or 
two simple interrupted stitches.  
 
Recovery. At this point the isoflurane flow was switched off and flow rate of oxygen 
increased to 2 liters min-1, while a heating lamp was directed towards the mouse and all 
tapes were removed. Effective analgesia was achieved by injecting buprenorphine 
(Reckitt Benckiser Healthcare Ltd) subcutaneously into the scruff at a dose of 0.3mg/kg.  
Once the mouse started to breathe without mechanical aid the intubation cannula was 
removed from ventilator tubing and if the mouse continued to breathe independently the 
cannula was gently and carefully removed, if not artificial ventilation was resumed. The 
mouse was placed on the nose cone on its right side to receive oxygen. Within minutes 
the mouse recovered and became mobile, at this time it was transferred to a pre-warmed 
recovery cage in an incubator maintained at 33oC. The mouse was placed on a soaked 
diet to support recovery and if necessary the mouse received a second dose of analgesia 
24-48 hours following surgery. 
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CHAPTER 3. 
 
Effect of Altered TGFβ 
Signalling on EPC Yield 
from Mouse Bone Marrow 
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3.1. Introduction  
EPCs have therapeutic potential for treating ischaemic heart disease, however in order 
to maximise the positive effects of EPC therapy a greater understanding of the 
fundamental regulatory mechanisms underlying cell-mediated heart repair are required. 
Autologous therapy is favoured to avoid immunological rejection. As the number of 
cells available for autologous therapy is limited it would be advantageous to enrich and 
deliver an optimised cell type.  This study investigated how TGFβ signalling regulates 
the proliferation and differentiation properties of EPCs and whether this could be used 
to manipulate cells ex vivo to increase numbers to optimally high levels. 
 
TGFβ controls the balance of proliferation and differentiation responses in many cell 
types. Evidence from endothelial studies strongly supports the prevailing hypothesis 
that TGFβ signalling through Alk1 versus Alk5 type I receptors represents a major 
angiogenic switch with TGFβ/Alk1 signalling promoting EC proliferation and 
angiogenesis while the TGFβ/Alk5 pathway opposes pro-angiogenic processes 
(reviewed in6). Both endoglin-dependent inhibition and promotion of TGFβ signalling 
has been observed, mediated by Alk5 and Alk1 related Smad signalling, although the 
exact mechanisms involved remain incompletely understood237, 247, 265, 268, 285.  
 
Given the inherent importance of the TGFβ superfamily to both vasculogenesis during 
embryonic development and angiogenesis in adult life, it is likely that components of 
this family play central roles in fundamental mechanisms underlying EPC-mediated 
vascular repair and biology.  
 
In this study I tested the following two inter-related hypotheses: 
 
(i) EPC differentiation and proliferation responses are mediated by the TGFβ/Alk1 
versus TGFβ/Alk5 angiogenic switch. Consequently, inhibition of the TGFβ/Alk5 
signalling pathway in vitro will enhance EPC proliferation and differentiation towards 
the endothelial lineage, leading to an increased yield of cells from mouse BM. To test 
this, EPCs cultured from mouse BM-MNCs were treated with SB431542, a synthetic 
molecule that potently inhibits the kinase activity of Alk5286.   
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ii) Endoglin acts as a critical regulator of the balance between TGFβ/Alk1 versus 
TGFβ/Alk5 responses and the resulting TGFβ–dependent differentiation and 
proliferation of EPCs. Consequently, endoglin deficiency will reduce endoglin 
dependent attenuation of TGFβ signalling resulting in impaired proliferation and 
endothelial differentiation in vitro, leading to a decreased yield from mouse BM.  To 
test this part of the hypothesis, EPC number was assessed in EPC cultures derived from 
Eng+/- mice. 
 
3.2.  Results  
3.2.1.  Characterisation of EPCs in Culture 
Early and late EPCs residing in the MNC fraction of murine BM were isolated using 
commonly accepted methods involving short (7 days)42, 55-56, 60 and long term (several 
weeks)46, 59-61 cell culture (figure 3.1). Ficoll density gradients were used to separate 
BM-MNCs from red blood cells as described in chapter 2.3.1.1.1. After 4 days in 
culture non-adherent cells were removed and discarded while adherent cells were 
cultured further to generate early EPCs by day 7 and these cells were assessed for 
features of endothelial lineage.  Additional cell cultures were maintained over several 
weeks to derive late EPCs. These formed endothelial colonies after 2 to 3 weeks and 
were further expanded to form a confluent cell monolayer with cobblestone morphology 
at 3 to 6 weeks. I assessed these cells for the expression of endoglin and the pan 
endothelial marker CD31. 
 
Early EPCs were assessed for endothelial features through dual binding of the 
endothelial marker GSLI–isolectin-B4287 and uptake of acetylated low-density 
lipoprotein (acLDL)288 (figure 3.2). Although this dual staining assay is not considered 
to be specific to endothelial cells, as it can also stain other cell types including 
monocytes/macrophages, it is widely used as a positive indicator of endothelial 
lineage66, 89, 289.  Adherent cells dual-positive for acLDL up-take and isolectin B4 
binding were counted as early EPCs (figure 3.2) and for simplicity these cells will be 
referred to as short term cultured-EPCs (STC-EPCs) throughout the remainder of this 
thesis. Freshly isolated BM cells subjected to ficoll gradient separation are referred to as 
BM-MNCs and cells cultured for 7 days without further characterisation are referred to 
as STC cells.  
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Figure 3.1. Short- and long-term culture of murine BM-MNCs. (A) Murine BM-
MNCs immediately after seeding onto fibronectin coated dishes in endothelial culture 
conditions. (B) Adherent spindle-shaped cells 7 days after seeding. These cells represent 
STC cells. (C) Emergence of LTC outgrowth colonies 14 days after plating. Colonies 
were defined as a cluster of >30 central cells with spindle shaped cells radiating 
outwards. (D) Formation of cobblestone-like monolayer after 3 weeks in culture. Scale 
bars = 50µM (C) and 100µM (A, B and D). E and F=digital zoom of images C and D. 
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The original staining protocol involved the incubation of cells with 10µg/ml of both 
DiI-acLDL and FITC-GSLI-isolectin-B4 for 1 hour consecutively. However I often 
observed cell death following staining, which complicated quantification of dual 
positive cells (figure 3.3). I hypothesised that the cells were ‘over’-endocytosing acLDL 
substrate leading to cell membrane damage and lysis. To test this possibility, acLDL 
concentration and incubation time were titrated and the lower concentration of 5µg/ml 
(1 hour incubation) showed a notable decrease in cell damage without compromising 
staining intensity (figure 3.4). Therefore in all subsequent experiments cells were 
stained using an optimised protocol with 5µg/ml DiI-acLDL followed by 10µg/ml 
FITC-GSLI-isolectin-B4 (one hour incubation each) (figure 3.2). 
 
 
Figure 3.2. Staining STC-EPCs with DiI-acLDL and FITC-GSLI-isolectin B4 using 
optimised staining conditions. Representative images of short term cultured (day 7) 
cells (A, phase contrast) stained with FITC-GSLI Isolectin-B4 (B, green) and DiI-Ac-
LDL (C, red).  In merged images dual positive cells (STC-EPCs) appear yellow (D). 
Inset images represent unstained cells as negative controls. Scale bar = 20µm. 
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Figure 3.3. Staining STC-EPCs with DiI-acLDL and FITC-GSLI-isolectin B4 using 
the original (non-optimised) staining conditions. Representative phase contrast (A) 
and dual stained (B) images using the pre-optimised staining protocol. The blue arrow 
highlights a damaged cell with abnormal membrane morphology whereas the white 
arrow indicates a typical normal cell.  Scale bar = 20µm. 
 
 
Figure 3.4. Titration of DiI-labelled acLDL to optimise cell labelling. Top panel, 
representative images of STC cells incubated for 1hour with DiI-acLDL concentration 
ranging from 1.25µg/ml to 10µg/ml. Bottom panel, cells incubated with 10µg/ml DiI-
acLDL for 15min to 60min.  Optimum staining of cells (defined as strongest signal with 
minimum cell membrane damage) determined as incubation at 5µg/ml for 1 hour. 
Images taken at X20 magnification. 
 
Additionally, I noted a gradient of weak to strong fluorescence signal following DiI-
acLDL and FITC-GSLI-isolectin-B4 staining which led to a level of uncertainty in 
counting dual positive cells. To confirm the reproducibility of quantifying STC-EPCs 
using this optimised staining protocol multiple randomly selected microscopic fields 
were analysed and counted by myself and three independent observers (figure 3.5). Cell 
counts (total and dual positive cells) were compared between observers and revealed 
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only minor non-significant variations (analysed by ANOVA; total cell number p=0.804, 
STC-EPC p=0.996) suggesting that this is a robust quantitative method. 
 
 
Figure 3.5. Confirmation of cell counting reliability and assessment of inter-
observer variability. 3 independent observers (obs 2-4) and I (obs 1) counted i) total 
cell number and ii) total dual positive cell number (FITC-isolectin B4/DiI-acLDL) in the 
same 4
 
random fields of view. Results were compared and analysed using ANOVA 
which revealed no significant difference between observers (total cell number p=0.804, 
STC-EPC p=0.996) indicating that the cell staining/enumerating method is reliable with 
minimum inter-observer variability. This test verified my counting method. 
 
BM-MNCs cultured over longer periods (up to 6 weeks) were monitored for their ability 
to form colonies. These colonies were termed long term culture EPCs (LTC-EPCs) and 
consisted of clusters of round central cells with spindle-shaped cells radiating from this 
core. To assess the feasibility of using enumeration of outgrowth colonies to quantify 
LTC-EPC number in vitro I titrated cell seeding density (5x106, 4x106, 3x106, 2x106 
and 1x106 cells per well of a 24 well plate) with the expectation of observing a 
proportional increase in colony number with increasing seeding density. Colonies were 
counted in a minimum of three wells per group and experiments were repeated three 
times to confirm results. A cell seeding density of below 3x106 MNCs per well resulted 
in limited and highly variable LTC-EPC colony forming capacity, which reached an 
average of 7.7±3.9 colonies per well at day 12 (figure 3.6). Plating densities of ≥3x106 
MNCs per well, produced substantially elevated numbers of highly proliferative LTC-
EPC colonies, which were comparable between groups (in replicate experiments the 
average outgrowth colony number ranged from 44.7±4.8 to 49.3±3.5 colonies per well). 
However, there was no proportional increase in LTC-EPC colony number as plating 
density increased from 3x106 to 5x106 MNCs per well indicating that this assay was not 
truly quantitative (figure 3.6). Based upon these observations I would argue that the 
colony assay is an unreliable method for assessing LTC-EPC number in vitro. However, 
  Obs 1 Obs 2 Obs 3 Obs 4 
field 
1 
Total 75 66 71 72 
EPC 22 26 22 22 
field 
2 
Total 94 98 98 101 
EPC 42 46 49 47 
field 
3 
Total 45 46 49 46 
EPC 33 25 30 32 
field 
4 
Total 85 85 89 82 
EPC 45 42 42 46 
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this experiment showed that a minimum of 3x106 MNCs per well of a 24well plate are 
required for optimal yield of LTC-EPCs and this seeding density was used in all 
subsequent cell culture experiments. 
 
 
LTC-EPCs which emerge from BM-MNC long term cultures were further cultured as a 
monolayer of outgrowth cells for up to an additional 2-4 weeks (figure 3.1D and F) and 
characterised by immunostaining with specific antibodies against the pan-endothelial 
marker CD31 as well as endoglin, a marker of endothelial and mesenchymal cells. 
Contrary to several studies employing similar methodologies46, 59-61, I found that the 
cells emerging from LTC-EPC colonies were heterogeneous populations with marked 
variation in the expression levels of both CD31 and endoglin (figure 3.7) and were 
therefore not mature EC populations.  Moderate to high endoglin expression was 
observed (65±12%), whilst CD31 expression was seen at much lower levels (35±6%). 
Furthermore, I noted limited proliferation potential in these populations, with cultures 
dying out after only 2-4 passages (approximately equivalent to 30 days in culture). This 
is in stark contrast to published data59, 88, 290 citing a high proliferation rate and potential 
for self renewal, indeed this feature has alone been declared as strong evidence of the 
‘stemness’ profile of LTC-EPCs. I attempted to enrich LTC-EPC number by 
introducing a CD31+ cell purification step following initial colony formation 
(approximately 18 days after plating BM-MNCs) using magnetic beads (see 2.3.1.1.2), 
in a similar manner to Melero-Martin et al104, however little difference was observed in 
proliferation potential. 
 
Figure 3.6. BM-MNC seeding density 
titration and formation of LTC-EPC 
colonies. There is a dramatic increase in 
mean LTC-EPC colony number as BM-
MNC plating density increases from 
1x106 to 3x106 per well. However, final 
LTC-EPC colony number is not 
proportional to plating density. Note that 
in cultures with 3x106 cells/well initial 
plating density, the peak mean LTC-
EPC colony number at day 16 and 
subsequent drop at day 18 is due to 
colonies reaching confluence and 
merging together. Error bars represent 
SEM. 
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Figure 3.7. Immunofluorescent staining of LTC-EPC derived monolayer 
outgrowth with CD31 (A) and endoglin (B) at approximately 24 days from plating 
(passage 2). An anti-rat secondary antibody conjugated to alexa fluor 594 (red) was 
used and nuclei stained with DAPI (blue). Approximately 35±6% of LTC-EPC 
outgrowth stained positively for CD31, while endoglin expression was 65±6% (n=6 
fields of view). Inset images in A &B represent no primary antibody controls. (C) and 
(D) show the positive control sEND-1 cell line immunostained for CD31 and endoglin 
respectively. Inset images in C & D show the NIH-3T3 fibroblast cell line is negative 
for CD31 and endoglin expression and acts as a negative staining control. Scale bars = 
20µm.  
 
3.2.2. Characterisation of Freshly Isolated BM-MNCs by FACS 
Analysis  
EPCs occur at low abundance in fresh BM. These EPCs are defined as mononuclear 
cells with the potential to differentiate into functional ECs both in vitro and in vivo and 
express a combination of stem and endothelial markers. Common surface markers used to 
define EPCs in mouse BM are CD34 and Flk1 (also known as Vegfr2).  I therefore used 
flow cytometry to identify EPCs residing in freshly isolated murine BM using these 
markers. In order to optimise a FACS protocol I first titrated both CD34 and Flk1 
antibodies to minimise non-specific staining and maximise the separation between 
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positive and negative cells (figure 3.8). Additional optimisation steps, which were 
aimed at reducing non-specific staining, included lysing red blood cells, increasing cell 
wash number and pre-treating cells with an fc receptor block (CD16/32, BD 
Pharmingen). All steps were associated with a reduction in non-specific staining as 
assessed through comparison with matched isotype control stained samples (in which 
positive cells represent non-specific staining), however a significant amount of non-
specific staining persisted (figure 3.8). This prohibited clear identification of the low 
numbers of Flk1 positive cells present and I was unable to develop a reproducible 
protocol allowing robust evaluation of EPC populations by FACS analysis. This also 
meant I was unable to use FACS to purify a defined population of EPCs in fresh BM. 
This work was further hampered by problems in removing the cells from fibronectin 
coated dishes for FACS analysis. For these reasons, short-term cultured BM-MNCs 
(either total cell populations (STC) or cells defined by acLDL and lectin staining (STC-
EPCs)) were used for the remaining work described in this chapter. 
 
3.2.3.  Expression of Endoglin in Myeloid Cells  
A major theme of this thesis is to investigate whether endoglin positive progenitor cells 
are capable of vascular repair. I therefore used flow cytometry to determine the 
expression of endoglin in total BM compared with the BM-MNC fraction of wild type 
(WT) mice (figure 3.9). I found that 2.4%±0.13 of WT total BM cells express endoglin 
and this positive population is enriched in the BM-MNC sub-population with a 3 fold 
increase in endoglin expression (7.3%±0.5). In order to investigate the role of endoglin 
in EPCs in vitro I used an Eng+/- mouse line to derive endoglin deficient BM-MNC 
cultures. Endoglin levels are reduced in Eng+/- total-BM and BM-MNC populations 
(1.4%±0.12 and 3.6%±0.32 respectively) compared with the equivalent cells derived 
from WT mice; however the enrichment of endoglin expression by BM-MNCs is 
maintained (2.5 fold increase in endoglin positive cell number in BM-MNCs compared 
with fresh BM). Experiments were repeated 3 times to confirm findings and figure 3.9 
illustrates the results of one representative experiment. 
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Figure 3.8. Representative images of the optimisation stages of murine (NIH) BM-MNC FACS analysis of CD34 and FLK1 vascular 
progenitor markers. Plot A shows side scatter (x axis, signal intensity is proportional to the amount of cytosolic structure in the cell) and forward 
scatter (y axis, signal intensity is proportional to cell size) properties of the cell population. A gate (shown in red) is placed around cells to be analysed 
further (cells not within this region represent cell debris and are not included). Plots B-F represent cell samples stained with FITC-CD34 (x-axis) and 
PE-FLK1 (y-axis), whereas plots G-K represent cell samples stained with FITC- and PE-isotype matched controls. Cells (or ‘events’) placed in the 
lower left quadrant of the dot plot are negative for both markers. Plots B and G show results of analysis with no optimisation. Note the extensive non-
specific staining in the isotype control (G). Plots C (and H) and D (and I) represent optimal titration of CD34 and FLK1 antibodies respectively. Plots 
E (and J) show that lysing contaminating red blood cells in the sample and increasing cell washes post staining substantially reduced non-specific 
staining. As did pre-incubation with a mouse IgG block (plots F and K). However despite these interventions I could not reliably identify a dual 
positive cell population (upper right quadrants of dot plots in E and F) due to the low number of Flk1 positive cells. 
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Figure 3.9. Endoglin expression in WT versus Eng+/- total BM and fractionated 
BM-MNCs. (A) representative dot plots (negative cells = blue, endoglin positive cells = 
pink) and (B) histogram showing that endoglin expression is enriched in BM-MNCs 
and reduced in cells derived from Eng+/- mice. 
 
3.2.4.  Modulating TGFβ Receptor Expression in EPCs  
As endoglin was expressed in approximately 7% of fresh BM-MNCs (figure 3.9) and 
this increased to over 65% after long term culture (figure 3.7), I proceeded to examine 
endoglin expression in STC cells using semi-quantitative RT-PCR. Also, because 
endoglin is a co-receptor for TGFβ signalling I investigated whether BM-MNCs and 
STC cells expressed type I (Alk1 and Alk5) and type II (Tgfbr2 and Bmpr2) TGFβ 
receptors. In addition I tested whether reduced endoglin levels in Eng+/- cells or Alk5 
kinase inhibition would affect the relative expression of these receptors.  
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Semi quantitative RT-PCR compares reaction products removed during cycles within 
the exponential amplification range of the PCR and allows semi-quantification and 
comparison of transcripts from different samples by relative densitometric analysis. 
RNA was prepared from freshly isolated MNCs and STC cells derived from WT and 
Eng+/- mice. Densitometric analysis was performed following RT-PCR and data from 
individual genes were plotted as ratios to the β-actin signal. Experiments were repeated 
three times and the statistical significance of differences between groups were 
determined using one-way ANOVA and unpaired t-tests. 
 
All receptors analysed were expressed by WT BM-MNCs and STC cells (figure 3.10). 
Interestingly, endoglin, Alk1 and Alk5 showed differential expression profiles following 
short term culture, whereas the type II receptors, Tgfbr2 and Bmpr2, showed 
comparable expression to freshly isolated BM-MNCs. In WT samples, endoglin and 
Alk5 expression were significantly up-regulated following culture whereas levels of 
Alk1 transcripts were markedly decreased (figure 3.10). 
 
3.2.4.1. Effect of Reduced Endoglin Levels 
As expected the levels of endoglin expression were significantly reduced in Eng+/- BM-
MNCs compared to WT cells (figure 3.10B and 3.10C). Furthermore up-regulation of 
endoglin expression post-culture was of a lower magnitude in endoglin deficient 
samples than in WT counterparts. Interestingly, there was little difference observed in 
Alk1 and Alk5 gene expression in Eng+/- samples (figure 3.10B and 3.10D-E). 
  
3.2.4.2.  Effect of Alk5 Inhibition 
Western blotting was used to examine the effect of the Alk5 inhibitor on TGFβ 
signalling (see figure 1.5). TGFβ1 treated (5ng/ml for 1hour) STC cells show 
phosphorylation of Smad2 confirming the ability of these cells to activate the 
TGFβ/Alk5 pathway in response to stimulation (figure 3.10A). As expected the 
phospho-Smad2 response was almost completely abolished in STC cells following a 24 
hour pre-treatment with the Alk5 inhibitor (SB431542, 5µM) (figure 3.10A).  
 
RNA samples were derived from WT-STC cells cultured either alone or with the Alk5 
inhibitor (SB431542, 5µM) to determine whether the expression profile of TGFβ 
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receptors was altered. Densitometric analysis revealed no difference in expression of 
Alk5 following kinase activity inhibition, nor was any significant difference detected in 
endoglin, Alk1, Tgfbr2 or Bmpr2 expression (figure 3.10B-E).  
 
This work shows that WT STC cells express TGFβ receptors with increased expression 
of endoglin and Alk5 following culture whereas Alk1 levels are reduced compared to 
uncultured BM-MNCs. Neither endoglin deficiency nor Alk5 kinase inhibition appeared 
to have any effect on Alk1 or Alk5 expression.  
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Figure 3.10. TGFβ receptor 
expression in BM-MNCs 
following short term 
endothelial culture; effects 
of Alk5 inhibition and 
endoglin deficiency.  
(A) phosphorylation of Smad2 
in the presence of TGFβ1 
(5ng/ml, 30minutes) is 
abolished in STC BM-MNCs 
following treatment with 5µm 
SB431542. (B) Representative 
images of receptor expression. 
(C) Endoglin expression is 
significantly upregulated in 
BM-MNCs following STC 
and is reduced in cultured 
Eng+/- cells. (D) Alk1
expression is significantly 
down-regulated following 
culture. (E) Alk5 expression is 
significantly up-regulated 
following culture with 
SB431542 treatment. C, D and 
E show receptor expression 
levels relative to β-actin
expression. * denotes p < 0.05, 
** denotes p < 0.01. 
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3.2.5.  Manipulating Yield of STC-EPCs in vitro 
3.2.5.1. Effect of Reduced Endoglin Levels on STC-EPC Yield 
As endoglin can counter the growth inhibitory effects of TGFβ264, and can affect the 
balance of proliferation versus differentiation responses237, I compared the number of 
STC-EPCs derived from WT and Eng+/- mice. BM-MNCs were seeded into multiwell 
plates (6 wells per genotype) and STC-EPCs were identified via DiI-acLDL and FITC-
GSLI-isolectin-B4 staining and counted after 7 days using 4 randomly selected fields of 
view per well (n=24 images per group). Experiments were performed three times 
independently to confirm results.  Cell counts were normally distributed and statistical 
significance was determined using the unpaired t-test. To standardise results the STC-
EPC number was also expressed as a ratio of total cell count and subjected to statistical 
testing. 
 
Levels of STC-EPCs were significantly reduced in endoglin deficient cultures as 
compared to WT cells in three independent experiments with mean levels ranging from 
27.8%-37% fewer EPCs (figure 3.11A-B, table 3.1). No significant difference in total 
cell count was found between the two groups (figure 3.11A). Additionally there was no 
significant difference found between ac-LDL and GSLI-isolectin-B4 positively stained 
cells when analysed separately indicating that levels of both markers were equally 
affected in Eng+/- STC-EPCs (fig 3.11C). These results suggest that endoglin levels are 
important for EPC differentiation and/or proliferation in short term culture. 
 
To determine the effect of reduced endoglin levels on STC-EPC viability and 
proliferation the colorimetric MTT assay was used. This assay examines the 
mitochondrial metabolic capacity of viable cells. The reduction of tetrazolium salts by 
mitochondrial dehydrogenase into a water insoluble formazan product results in purple 
crystal deposits in the cell medium which are re-suspended in DMSO and the optical 
density (OD) of this solution can be measured. Increased mitochondrial activity of cells 
reflects increased ATP production to fuel cell replication, whereas lower levels of 
reduction are observed in senescent or apoptosing cells.  The MTT assay revealed no 
significant difference between WT (OD 0.195±0.005) and Eng+/- (OD 0.178±0.006) 
STC-EPCs as confirmed by the unpaired t-test (p>0.05) (figure 3.11D). This data 
suggests that endoglin deficient STC-EPCs do not display reduced proliferation or 
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viability and differences observed in cell count may be due to a reduced capacity to 
differentiate towards the endothelial lineage.  
 
Genotype 
Total Cell 
Count  
mean±SEM 
STC-EPC 
Count 
mean±SEM 
%  STC-EPC 
mean±SEM 
Unpaired t-test 
p Value 
% 
Change 
WT  63.29±1.85 34.08±2.57 54±4 
0.008 (-) 27.8%  Eng+/-  63.00±1.61 24.54±2.47 39±4 
WT 65.46±2.21 44.54±1.90 68±2 
<0.001 (-)  27.8% Eng+/- 65.67±1.72 32.46±1.39 49±2 
WT 62.50±3.24 34.00±3.05 54±3 
<0.001 (-)  37% Eng+/- 65.00±2.01 21.46±1.86 34±3 
Table 3.1. Reduced endoglin levels leads to a significantly reduced yield of STC-
EPCs. Table illustrating the results and statistical analyses of 3 independent 
experiments analysing the effect of endoglin deficiency on STC-EPC yield.  The 
statistical significance of differences between groups was determined using unpaired t-
tests. p values <0.05 considered significant. 
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Figure 3.11. Effect of endoglin 
deficiency on STC-EPC 
number in vitro. Histograms 
showing absolute counts of total 
cell and STC-EPCs (A), EPC 
counts proportional to total cell 
number (B). Analysis of 
isolectin+ and acLDL+ cell 
number (C). Effect of endoglin 
deficiency on STC-EPC viability 
using MTT assay (D). 
Representative images of WT (E) 
and endoglin heterozygous (F) 
short term cultured BM-MNCs 
stained with DiI labelled acLDL 
(red) and FITC labelled GSLI-
Isolection-B4 (green) merged 
with phase contrast images to 
allow visualisation of all cells.  
Scale bar = 20µm. 
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3.2.5.2.  Effect of Alk5 Inhibition on STC-EPC Yield 
Endothelial TGFβ signalling through the type I receptor Alk5 is associated with cellular 
growth inhibition and the resolution phase of angiogenesis6. I tested the hypothesis that 
inhibiting this signalling pathway would increase EPC proliferation during short term 
culture by quantifying STC-EPCs following treatment with SB4315452 (5µm versus 
10µm). Data was normally distributed and differences in STC-EPC number between 
groups were initially assessed using one-way ANOVA. Where this analysis suggested 
significant differences existed (p<0.05) unpaired t-tests were then used to calculate 
precise differences between pairs of groups. Experiments were repeated a minimum of 
three times to confirm findings.  
 
Inhibitor treated cultures contained significantly higher levels of dual positive cells than 
untreated cultures (figure 3.12). The increase in STC-EPC number ranged from 20% to 
35.8% in 5µM SB431542 treated cultures and from 24.1% to 39.3% in those cultures 
treated with 10µM SB431542 (table 3.2). Total cell number was also shown to be 
significantly higher in inhibitor treated cultures (figure 3.12A) suggesting either 
increased proliferation of non-endothelial cell types or increased adhesion to the 
fibronectin matrix, which may also be attributable to the inhibition of TGFβ/Alk5 
signalling. This increase in total cell number exemplifies the need to quote STC-EPC 
yield as a ratio to avoid misrepresenting levels of EPC in different treatment groups.  
 
MTT assays revealed significantly increased viability and/or proliferation in STC-EPC 
cultures treated with SB431542 (both 5µM and 10µM) as compared to untreated cells 
(figure 3.12D). However, cell viability was similarly affected in 10µM compared with 
5µM treated cultures.  Overall this part of the study confirmed the hypothesis that STC-
EPC yield could be increased by inhibiting Alk5 signalling and that this may have 
occurred by increasing the viability and/or proliferation of these cells. 
 
3.2.5.3.  Alk5 Inhibition Rescues the Low Yield of STC-EPCs 
Associated with Endoglin Deficiency 
As Alk5 inhibition increased the yield of STC-EPCs I also tested whether SB431542 
treatment would rescue the low yield of STC-EPCs generated from Eng+/- cultures. BM-
MNCs were derived from adult WT and Eng+/- littermate mice and treated with or 
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without 10µM SB431542 for 7 days. STC-EPC number was compared between 
untreated and inhibitor treated groups. Again, the experiment was repeated 3 times to 
confirm results and statistical analysis was performed as previously described (see 
section 3.2.5.1.).  Results (shown in figure 3.13) revealed that Alk5 inhibition partially 
rescued the defect in STC-EPC yield from endoglin deficient cultures. STC-EPC 
number was significantly increased in SB431542 treated cultures from both WT and 
Eng+/- BM (34% to 51.5% and 29.2% to 60.7% increase respectively, table 3.3) with 
levels in Eng+/- inhibitor treated cultures being comparable to WT untreated levels (table 
3.3). 
 
However, total cell counts were not significantly different between SB431542 treated 
and untreated cells in these cultures (Fig 3.13A) in contrast to earlier experiments (Fig 
3.12A). This may be due to the intrinsic variability of the culture method.   
 
Analysis of proliferation and viability using the MTT assay revealed a positive effect of 
Alk5 inhibition in endoglin deficient cultures (Fig 3.13C), in a similar manner to that 
observed previously in inhibitor treated WT cultures (Fig 3.12D).  
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Figure 3.12. Effect of Alk5 
inhibition on STC-EPC number 
in vitro. Histograms showing 
absolute counts of total cells and 
STC-EPCs (A), STC-EPC counts 
(expressed as a ratio of total cell 
number) (B) reveal a significant 
increase in cells of endothelial 
lineage following Alk5 kinase 
activity inhibition.  Analysis of cell 
number using single stains 
(isolectin+ or acLDL+) reveal a 
similar increase in cells of 
endothelial lineage following Alk5 
inhibition (C). Analysing the effect 
of Alk5 inhibitor treatment on 
STC-EPCs using MTT assay (D) 
reveals a significant increase in cell 
viability/proliferation. 
Representative images of untreated 
WT (E) and SB431542 treated 
(5µm (F) vs 10µm (G)) WT STC-
EPCs stained with DiI labelled 
acLDL (red) and FITC labelled 
GSLI-Isolection-B4 (green) merged 
with phase contrast images to 
allow visualisation of all cells. 
Scale bar = 20µm. 
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Total Cells at 
day 7 
mean±SEM 
Anova 
Total cell 
number 
p-value 
STC-EPC 
Count 
mean±SEM 
% STC-EPC 
mean±SEM 
ANOVA 
% STC-EPC 
p value 
% STC-EPC 
Unpaired t-Tests, p Value % Change 
 Unt vs 5µM Unt vs 10µM 5µM vs 10µM 
Untreated 68.13±1.71 
<0.001 
29.71±1.06 44±2 
 
<0.001 
 
<0.001  
 
<0.001 
  
SB-5uM 83.21±2.93 46.08±2.61 55±2 
n/s 
(+) 20% 
SB-10uM 86.46±2.65 49.50±1.62 58±1  (+) 24.1% 
Untreated 90.75±3.06 
<0.001 
30.79±2.41 34±2 
 
<0.001 
 
<0.001  
 
<0.001 
 
 
SB-5uM 109.42±3.08 57.75±3.55 53±3 
n/s 
(+) 35.8% 
SB-10uM 117.04±3.83 63.92±3.74 55±3  (+) 38.2% 
Untreated 73.83±2.68 
 
0.012 
25.08±1.92 34±3 
 
 
<0.001 
 
 
0.006 
 
 
<0.001 
  
SB-5uM 87.33±3.88 41.25±3.02 48±4 
n/s 
(+) 29.2% 
SB-10uM 93.17±6.01 51.42±3.54 56±3  (+) 39.3% 
Table 3.2. Inhibition of Alk5 kinase activity leads to a significantly increased yield of STC-EPCs. Table illustrating the results and statistical 
analyses of 3 independent experiments analysing the effect of Alk5 inhibitor (SB43152 (SB)) treatment on STC-EPC yield. The statistical significance 
of differences between groups was determined using one-way ANOVA (p<0.001) and unpaired t-tests (p values <0.05 were considered significant; n/s 
= not significant). 
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Figure 3.13. Alk5 inhibition improves yield of STC-EPCs 
from Eng+/- BM-MNCs. Histograms showing absolute counts 
of total cell and STC-EPCs (A); EPC counts (expressed as 
fraction of total cell number) (B); and the analysis of 
viability/proliferation using the MTT assay (C). Statistical 
analysis reveals a significant increase in Eng+/- STC-EPC 
number following treatment with 10µm SB431542. * denotes p 
< 0.05, **, p < 0.01. 
 
   107 
 
 
 
 
 
Total Cells at Day7 
mean±SEM 
Number of 
STC-EPC 
mean±SEM 
% STC-EPC/Total 
mean±SEM 
Unpaired t-Test comparing %STC-EPC/Total, 
p Value and % Change 
Eng+/- SB-10µM vs 
Eng+/- Eng+/- vs WT 
WT SB-10µM vs 
WT  
Eng+/- Untreated 98.29±2.32 26.96±1.82 28±2 
 
<0.001 
 
(+) 60.7% 
 
<0.001 
 
(-) 82.1% 
 
<0.001 
 
(+) 41.2% 
Eng+/- A5i-10µM 88.25±3.58 39.38±2.30 45±2 
WT Untreated 96.20±2.83 48.25±1.80 51±2 
WT SB-10µM 93.46±3.84 66.71±2.30 72±2 
Eng+/- Untreated 107.21±3.37 33.92±1.70 32±1 
 
<0.001 
 
(+) 50% 
 
<0.001 
 
(-) 56.3% 
 
<0.001 
 
(+) 34% 
Eng+/- SB-10µM 100.46±1.87 48.21±1.50 48±1 
WT Untreated 92.38±2.17 48.08±1.24 50±1 
WT SB-10µM 93.46±2.94 62.75±2.20 67±1 
Eng+/- Untreated 133.67±7.16 31.29±2.28 24±2 
 
0.01 
 
(+) 29.2% 
 
<0.001 
 
(-) 37.5% 
 
<0.001 
 
(+) 51.5% 
Eng+/- SB-10µM 134.46±6.74 41.04±3.05 31±2 
WT Untreated 119.21±4.53 38.79±1.48 33±1 
WT SB-10µM 117.46±3.81 57.5±2.16 50±2 
Table 3.3. Inhibition of Alk5 kinase activity rescues the low STC-EPC phenotype associated with Eng+/- genotype. Table illustrating the results 
and statistical analyses of 3 independent experiments analysing the effect of the Alk5 inhibitor SB43152 (SB) on the yield of STC-EPCs from WT and 
Eng+/- BM-MNCs. The statistical significance of differences between groups was determined using one-way ANOVA and unpaired t-tests (p values 
<0.05 were considered significant). 
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3.2.6.  Effect of Alk5 Inhibition on TGFβ Signalling Responses  
TGFβ signalling is reported to regulate the activation of ECs via a fine balance between 
the Alk5 and Alk1 pathways6. To give a greater insight into the effect of Alk5 inhibition 
in STC-EPCs at the signalling level semi-quantitative RT-PCR was used to elucidate 
Alk1 and Alk5 signalling responses.  Alk1 specifically induces the expression of Id1, 
which promotes EC proliferation and migration219-220 and Alk5 specifically stimulates 
expression of Pai1, which is a negative regulator of EC migration in vitro and 
angiogenesis in vivo219-220. Expression levels of Id1 and Pai1 in WT BM-MNC and STC 
cells with or without Alk5 inhibitor treatment (7 days 10µM) were assessed as a readout 
of the endogenous level of TGFβ signalling activity in STC cells and results were 
subjected to statistical analyses as previously described in section 3.2.4. 
 
No change in Id1 expression was observed in STC cells compared with total BM-MNCs 
although levels were slightly decreased in Alk5 inhibitor treated cultures (figure 3.14A). 
Pai1 expression was markedly increased in STC cells and a significant decrease in 
expression was observed following inhibitor treatment (figure 3.14B). These results 
suggest that both TGFβ/Alk1 and TGFβ/Alk5 signalling is depressed in SB431542-
treated cultures. 
 
 
Figure 3.14 The effect of Alk5 inhibtion on downstream TGFβ signalling responses. 
Expression levels of Id1 (A) and Pai1 (B) mRNA were determined by semi-quantitative 
rtPCR and used as readouts of Alk1/TGFβ and Alk5/TGFβ signalling respectively in 
BM-MNCs, STC cells and STC cells treated with 10µM SB431542. Densitometric 
analysis of PCR band intensity was determined using ImageQuant TL software. Id1 
expression levels were signicantly reduced in SB431542 treated STC-EPCs. Pai1 levels 
were almost undetectable in fresh BM-MNCs, dramatically increased in STC-EPCs and 
significantly reduced following Alk5 kinase actvity inhibition.  
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3.3.  Discussion 
3.3.1.  Challenges of Isolating and Quantifying Murine BM- 
derived EPCs 
Despite extensive investigation over the past decade the phenotype and function of 
EPCs are topics that remain complex and under heavy debate.  The controversy 
surrounding EPC definition is confounded by a myriad of studies reporting a variety of 
isolation methods and phenotypes with interchangeable and confusing terminology. At 
the time that the present study was conceived the methods described in this thesis were 
widely regarded to isolate populations of EPCs; however it is now generally accepted 
that cells of diverse lineages and functions are being investigated and ambiguously 
placed under the single term EPC25-26. A major limitation of this study was the inability 
to isolate a more defined population of putative EPCs.  
 
In this study mouse STC-EPCs were defined as BM-MNCs that attached to fibronectin-
coated culture dishes within 1-4 days of culture and displayed the ability to take-up 
acLDL and bind GSLI-isolectin-B4 on day 7. Defining STC-EPCs using these criteria 
has been adopted extensively by many studies characterising EPCs24, 56, 291-293. However 
it has been shown that neither acLDL uptake nor lectin binding are specific to cells of 
endothelial lineage. During endothelial culture conditions monocytes have been shown 
to express many endothelial-associated proteins and are likely to express scavenger 
receptors that bind acLDL89. Similarly GSLI-isolectin-B4 binds many epithelial and 
haematopoietic cell types in addition to ECs89. Additionally, in human blood cultures, 
fibronectin is known to isolate and enrich monocytes for differentiation into 
macrophages294. Thus in recent years Yoder et al89 among others have called for 
scrutiny to be applied to papers in which EPCs are being defined on the basis of 
lectin/acLDL binding to adherent MNCs as the sole criteria. However despite the 
relatively recent acceptance that ‘early EPCs’ actually represent pro-angiogenic 
monocytic cells which exhibit several endothelial features but do not differentiate into 
mature ECs, the presence of these cells in the circulation are associated with 
cardiovascular health and they are thought to have therapeutic benefit. Thus, TGFβ 
signalling in early EPCs is still likely to be of importance. Nevertheless, there is a need 
to identify which cell types contribute to neovascularisation, what roles they play and 
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how to optimally manipulate them in order to allow us to develop effective cell-
mediated therapies. 
 
Colony forming assays have also been used to identify and isolate EPCs. First described 
by Asahara et al24 the original assay was later adapted by Hill and colleagues45 to 
identify EPC colonies that emerged from non-adherent cultured human PB-MNCs. 
However in recent years the true lineage and fate of these colony forming cells has been 
called into question (discussed in section 1.5.1).  Adherent cultured human PB-MNCs 
also form a different type of colony that have been called OECs59, late EPCs88 or 
ECFCs46. The characteristics of these cells are described in more extensive detail in 
section 1.5.1 but briefly hallmarks include a high proliferation potential, expression of 
endothelial markers and the ability to form vessels in vivo which can anastomose with 
host vasculature following transplantation into pre-clinical animal models. Despite 
several enthusiastic attempts at culturing OECs from mouse BM-MNCs I struggled to 
maintain self-renewal capacity and consistently observed low CD31 expression and 
high endoglin expression (which is also expressed by mesenchymal cells as well as 
monocytes and macrophages) therefore I did not progress to testing the angiogenic 
ability of these cells. It has since been suggested that mouse-derived OECs have limited 
proliferative and angiogenic capacity (personal communication, Dr Joyce Bischoff) and 
in general do not display the same functional characteristics as human derived OECs, 
however exceptions have been cited290. Interestingly OECs can be successfully derived 
from mouse lung EC preparations295. We too have cultured ECs from mouse lungs but 
due to a limited proliferative capacity and the tendency of cells to reach senescence at 
early passage number we found it necessary to introduce an immortomouse allele (H-
2KbtsA58), which permits cells to bypass the G1 cell cycle check-point under certain 
conditions and hence allows for the derivation of longer lasting primary endothelial cell 
lines296.  
  
3.3.2. The Effect of Manipulating TGFβ Signalling on STC-EPC 
Yield in vitro 
3.3.2.1. Effect of Alk5 Kinase Inhibition 
The development of EPC-mediated therapeutic angiogenesis is impeded due to the low 
frequency of these cells, their tendency to readily differentiate in culture and their 
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limited proliferation potential. Ex vivo expansion of EPCs provides an alternative means 
to expand the number of pro-angiogenic cells for direct application or intravenous 
infusion.  The TGFβ superfamily is known to control the balance of proliferation and 
differentiation responses in many cell types and EPCs are likely to be amongst these. 
Synthetic kinase inhibitors are useful tools for investigating the roles of growth factor 
signalling within cells in vitro. SB431542 is a synthetic compound that inhibits Alk5 
kinase activity286 and was added to the culture media in this study to assess the 
inhibition of Alk5 signalling on EPC biology.  
 
Inhibition of the type I TGFβ receptor Alk5 using SB431542 led to a significant 
increase in STC-EPC number. Increased proliferation/ viability (as indicated by MTT 
assay data (figure 3.12)) may at least partially explain this observation.  This is in 
agreement with the role of TGFβ/Alk5 signalling in the canonical TGFβ signalling 
pathway in which it opposes EC migration and proliferation (see figure 1.5). 
Furthermore, an increase in EPC proliferation is supported by several studies which 
have shown that Alk5 inhibition in mouse ES derived ECs lead to increased cell growth 
and integrity297-299. SB431542 treatment also significantly enhanced VEGF-induced 
formation of EC sheets from foetal mouse metatarsals in culture300. Therefore it appears 
rational to assume that inhibition of Alk5 kinase activity does indeed increase the 
proliferative potential of adherent MNCs that display endothelial properties to generate 
STC-EPCs. However the MTT assay only measures metabolic activity of total cells in 
the well over a limited time (24 hours) and this only indirectly relates to proliferation 
therefore a more direct method of assessing cell proliferation in culture (such as Ki67 
staining) would be necessary to definitively prove that Alk5 inhibition increases STC-
EPC proliferation. 
 
Another possible explanation of my findings is that TGFβ ligand contained within 
culture media serum could have affected BM-MNC differentiation. While Alk5 
inhibition may have allowed STC-EPCs to maintain an endothelial-like phenotype, 
TGFβ1 ligand stimulation could have induced differentiation into a more mesenchymal-
like phenotype as this ligand is known to promote epithelial or endothelial to 
mesenchymal transition (EMT or EndMT)301-302. EPCs have been shown to differentiate 
into mesenchymal cells that express smooth muscle actin303-304. Diez et al299 
investigated whether TGFβ signalling may contribute to EPC acquisition of a 
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mesenchymal phenotype. The authors reported that EPCs (commercially sourced human 
CD133+ progenitor cells) differentiate into SMC-like cells through an EndMT-like 
process and that TGFβ1 plays an important role in this process and in EPC fate 
generally. Alk5 inhibition (SB431542 treatment) increased numbers of BM-derived ECs 
but the authors found no direct effect on EPC proliferation or apoptosis (assessed using 
FACS based cell cycle analysis). Instead, Alk5 inhibition led to a partial block in the 
acquirement of mesenchymal markers thus facilitating the retention of an endothelial 
phenotype. James et al298 have also described an increase in human ESC-derived ECs 
following inhibition of the TGFβ/Alk5 pathway. Initially, although a small number of 
ECs could be isolated from human ESC cultures, these could not be expanded without 
the majority of cells adopting a non-endothelial phenotype. SB431542 treatment of 
human ESC cultures resulted in increased cellular proliferation (indicated by a higher 
percentage of phospho-histoneH3+ mitotic ECs) and a preservation of vascular 
phenotype. The authors have shown that Id1 expression is sustained in these cells and 
suggest that this maintenance of high expression levels preserves an immature 
proliferative phenotype. Id1 expression has been shown to inhibit growth arrest and 
differentiation in multiple cell types305. However, in my study STC-EPCs showed a 
significant decrease in endogenous Id1 expression in the presence of the Alk5 kinase 
inhibitor (Fig 3.14). The different outcomes may be due to differences between the role 
of Id1 in human embryonic cells in the James et al298 study versus murine adult cell 
types in this study. Moreover, James and colleagues were using a highly homogenous 
cell population and serum free culture conditions to enhance vascular differentiation and 
they also FACS sorted Id1high and Id1low CD31+ cells, correlating increased expansion 
with high levels of Id1 whereas the readout of Id1 expression in my own cultured 
MNCs was derived from a heterogeneous cell population, cultured in high serum 
conditions which was likely to affect TGFβ signalling as well as crosstalk with other 
pathways. Furthermore Alk5 has been shown to be important for Alk1 recruitment into 
the TGFβ receptor complex and Alk5 kinase activity is essential for efficient Alk1 
activation and mediation of Id1 expression219, 221 which could at least partially explain 
the reduced Id1 levels observed in SB431542 treated STC-EPC cultures described in 
this chapter.  
 
Bringing together my own observations and those of related studies it is likely that the 
inhibition of Alk5 kinase activity can be used to expand EPCs ex vivo whilst 
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maintaining their endothelial-like phenotypes.  However, further work would be 
required to establish the effect of Alk5 inhibition on STC-EPC proliferation (for 
example by FACS-based cell cycle analysis or Ki67 staining) and its effect on transition 
to a mesenchymal cell phenotype (by assessing changes in EndMT associated gene 
expression such as twist and snail as well as mesenchymal markers including αSMA or 
calponin). Additionally, it would be necessary to test the functional relevance of these 
findings in vivo to evaluate if the use of an Alk5 inhibitor is safe and whether it has 
therapeutic potential.  
 
3.3.2.2. Effect of Endoglin Deficiency  
As discussed in chapter 1.9.3 the precise role of endoglin in TGFβ/BMP signalling 
cascades remains unclear. In vitro studies suggest that endoglin functions within the 
endothelium to potentiate TGFβ/Alk1 signalling and antagonise the TGFβ/Alk5 
pathway237, 264 and as such acts as a positive facilitator of endothelial proliferation and 
migration. However, contradictory in vitro findings have found that Eng-/- ECs display 
increased proliferation269 270.  Furthermore, it has been shown that in response to both 
BMP9 and BMP10 ligands endoglin (and Alk1) promote endothelial cytostasis238-239, 241. 
In a number of different cell types, including ECs and monocytes, endoglin has been 
shown to oppose a variety of TGFβ1-dependent responses, including the inhibition of 
cell proliferation and migration, as well as modulating cellular apoptosis, adhesion and 
the expression of ECM components306. In this chapter I have shown that endoglin 
deficiency results in a significant decrease in the number of STC-EPCs cultured from 
BM-MNCs. Cell counting revealed no difference between the total numbers of WT and 
Eng+/- cells, nor were differences in viability/proliferation detected between these two 
groups using the MTT assay. These results suggest that the decrease in STC-EPC 
number is not directly, or entirely, due to the inhibition of cellular proliferation as was 
proposed in the original study hypothesis. However, despite observing a general 
increase in endoglin expression following culture of BM-MNCs to STC-EPCs it is 
unknown which cell types within the heterogeneous STC-EPC population express 
endoglin and to what extent each distinct cell type is affected by reduced protein levels. 
Cells of endothelial nature (STC-EPC) account for just 50% (approximately) of the STC 
population (see table 3.3) therefore it is possible that cells that either do not express 
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endoglin or are unaffected by a reduction in endoglin expression could be masking an 
inhibitory effect on proliferative capacity.  
 
Linda van Laake et al275 published seminal research identifying endoglin as a crucial 
component in circulating cell-mediated vascular repair. Human circulating MNCs 
deficient in endoglin expression (derived from HHT1 patients) were less able to 
promote cardiac repair than WT control cells due to a proposed deficiency in the 
SDF1/CXCR4 homing gradient276. The authors did not detect any effect of endoglin 
deficiency on MNC attachment, apoptosis, proliferation or TGFβ signalling in vitro, 
however they did not exclude the possibility that these processes may be defective and 
contribute to the underlying pathological mechanism in vivo. Interestingly following 
short term culture of human MNCs (using a similar approach to that described in this 
thesis), no difference in STC-EPC number (defined using lectin and acLDL co-staining) 
was found between WT and endoglin deficient (HHT1 patient) cells275. This stark 
difference to my own results may be explained by the source of MNCs used for culture. 
In my study mouse BM-MNCs were used, which may contain more primitive 
endothelial precursors than human peripheral blood. Endoglin is expressed by a number 
of BM mononuclear cell types including EPCs, MSCs and HSCs. It is possible that 
these cells in the BM are potentially more sensitive to a change in endoglin levels and 
more likely to reveal functional differences following in vitro culture. Therefore, my 
study may represent the effect of endoglin deficiency on several distinct types of 
endothelial progenitor cell at varying early stages of differentiation, whereas the van 
Laake study is restricted to analysing circulating MNC cell-types at a more advanced 
stage of differentiation. Additionally peripheral blood is more likely to be contaminated 
with ECs sloughed from mature vessel walls that enter the circulation and could skew 
results.   
 
Alternative explanations of my findings include an EPC specific increase in apoptosis or 
a reduced capacity to differentiate towards an endothelial phenotype. Endoglin null 
mice die at mid-gestation due to cardiovascular abnormalities and impaired 
angiogenesis232-234, however endothelial differentiation and vasculogenesis appear 
normal in these embryos up to embryonic age E9.5, suggesting that endoglin is not 
essential for endothelial differentiation during early development.  In addition to ECs, 
both HSCs257-258, 307-308 and mature haematopoietic cells are known to strongly express 
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endoglin265, 309, which is thought to be required for haemangioblast specification and 
early haematopoietic commitment308, 310. Eng-/- mouse ESCs show impaired 
myelopoiesis and definitive erythropoiesis308, whilst Eng-/- blast colony forming cells 
(BL-CFCs, regarded as the in vitro haemangioblast equivalent) also show impaired 
haematopoiesis, but endothelial differentiation is not affected310.  My results do not 
support the view that endothelial differentiation is unrelated to endoglin function, but it 
is possible that distinct TGFβ family signalling pathways that differentially utilise 
endoglin lead to alternative outcomes in adult progenitor cells compared to their 
developmental counterparts. In the adult mouse it has been reported that HSCs can give 
rise to true endothelial progeny311-313 and that early EPCs or EC-like cells are derived 
from heterogeneous haematopoietic cells53-54, 56, 62-63. By using acLDL and iso-lectin to 
label STC-EPCs I was unable to differentiate between true endothelial and EC-like cells 
and attempts to further characterise a more specific population of EPCs by FACS were 
thwarted by technical problems (discussed above in 3.2.2).  In BL-CFCs, whilst 
endoglin loss does not impair endothelial differentiation, there is a defect in 
haematopoietic cell formation310. Therefore it is feasible that there are reduced numbers 
of haematopoietic stem/progenitor cells available to differentiate into EC-like cells in 
Eng+/- mice compared with WT.  This would be difficult to assess because the 
composition of the BM-MNC population is heterogeneous and it is likely that multiple 
cell types, identified by overlapping surface marker expression are subsequently 
regarded as EPCs but actually represent distinct lineages. This heterogeneity may also 
explain the variability in results observed in replicate experiments described in this 
chapter. 
 
I observed no difference in the expression of either Alk5 or Alk1 transcripts in STC cells 
derived from WT or Eng+/- mice.  This is of interest because levels of Alk5 have been 
shown to be reduced in ECs derived from endoglin heterozygote mouse embryos237. 
Additionally, Xu et al314 have reported vascular defects associated with a reduction of 
Alk5 expression in VEGF-induced microvessels of endoglin heterozygous mice.  Lebrin 
et al proposed the following model: in ECs with reduced endoglin levels, Alk5 
signalling is increased. In order to compensate for this “over activity of Alk5 signalling” 
leading to inhibition of EC growth, ECs adapt by down-regulating Alk5 expression204. 
That no such down-regulation was observed in my cultures suggests that this 
compensatory adaptation is not present. This could also account for the decreased STC-
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EPC number in my endoglin deficient cultures due to the inhibitory effects of Alk5 
(expressed at WT levels). This proposal is further supported by my observation that 
Alk5 kinase inhibition leads to increased STC-EPC yield in Eng+/- cultures. In addition 
van Laake et al275 did not detect a decrease in Alk5 expression in endoglin deficient 
MNCs using real time-PCR therefore it is possible that this compensatory mechanism 
proposed for terminally differentiated ECs has not been acquired by more primitive 
cells of endothelial lineage. Another important consideration is the heterogeneous 
nature of STC cell cultures, approximately 50% of cells showed endothelial 
characteristics (see table 3.3) in comparison to the homogenous endothelial populations 
used in endothelial cell studies and this may have masked possible EPC-specific 
differences in Alk5 expression.  To give a greater insight into the role of the canonical 
endothelial TGFβ pathway in endothelial progenitors it would be of immense benefit to 
sort these progenitors based on surface cell markers, perform lineage tracing and to 
examine EPCs at various differentiation stages. 
 
SB431542 treatment in multiple cell types, including cultured BM-MNCs, has resulted 
in enhanced cellular growth due to increased proliferation and/or increased 
differentiation towards the endothelial lineage. Hence, the observation that Alk5 
inhibition using SB431542 rescued the low yield of STC-EPCs in endoglin deficient 
cultures suggests that endoglin too is important in modulating vascular progenitor cell 
fate. I therefore looked in more detail at the effect of reduced endoglin in endogenous 
vascular repair. This is discussed in the next chapter. 
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CHAPTER 4. 
 
Endothelial Progenitor Cells 
and Endogenous Endothelial 
Repair 
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4.1. Introduction 
Given the role of endoglin in enhancing the yield of EPCs in vitro shown in the 
previous chapter I set out to investigate whether endoglin depletion had an effect on 
vascular repair in vivo.  
 
Gene ablation of endoglin in the germ line results in early embryonic lethality232-234, 
precluding analysis at later developmental and postnatal stages.  Recent advances in 
mouse genetics has led to the development of conditional knock-out mice permitting 
spatio-temporal control over gene activation at any time during prenatal or postnatal 
development.  The Cre/loxP site-specific recombination system is commonly used to 
generate conditional gene deletion315.  In this system Cre-recombinase excises a region 
of genomic DNA essential for the production of a functional gene product. LoxP (locus 
of X-over P1) sites are 34 base-pair (bp) sequences absent from the mammalian 
genome, which act as recognition sites for Cre-recombinase316.  Two loxP sites are 
introduced to flank the target DNA sequence and binding with Cre-recombinase leads to 
inversion or excision of the intervening ‘floxed’ DNA sequence depending upon loxP 
site orientation (figure 4.1).  Temporal control over gene deletion is achieved through 
the use of inducible Cre-recombinases. Fusion of Cre-recombinase with mutated 
hormone-binding domains of nuclear receptors permits inducible activation of the 
enzyme in the presence of synthetic exogenous ligands. The CreERT2 fusion protein is 
obtained by fusing Cre-recombinase to a mutated ligand binding domain of the human 
oestrogen receptor ERα, which is activated by the synthetic oestrogen-like agonist 
tamoxifen but not by endogenous oestrogen317-318.  Consequently expression of the 
CreERT2 fusion protein allows efficient tamoxifen dependent Cre-mediated 
recombination at loci flanked by loxP sites.  Gene ablation can be directed within target 
cells by using transgenic mice expressing Cre-recombinase under the control of a tissue 
or cell specific promoter. Vascular endothelial cadherin (VE-Cadherin or Cdh5) is an 
endothelial specific adhesion molecule that is essential for endothelial cell-cell 
interaction319. In this chapter I have used a tamoxifen inducible Cdh5(PAC)-CreERT2 
transgenic mouse model270, 320 (courtesy of Ralf H. Adams, CRUK London) to achieve 
inducible gene knockdown specifically in vascular endothelial cells. 
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Figure 4.1. Cre-mediated loxP recombination reactions.  Cre recombinase catalyzes 
intra-molecular excision or inversion. Cre-recombinase binds the loxP sequences 
flanking the target sequence and facilitates cleavage of DNA. If two loxP sites are in 
homologous orientation (A) recombination will preferentially produce excision and 
circularisation of the target sequence. Cre can also catalyze the re-integration of the 
target DNA into a single loxP site but this is kinetically unfavourable and occurs rarely. 
Recombination between inverted loxP sites (B) leads to a 50:50 probability of segment 
inversion.  (Figure adapted from321). 
 
A bifloxed endoglin allele (Engfl/fl) has been generated in my host laboratory278 (figure 
4.2). Exons 5 and 6 are flanked by loxP sites and Cre-mediated recombination results in 
deletion of these exons, as well as a frame shift in exon 7 which introduces a premature 
stop codon into the sequence. Consequently, if translated, the knockout allele generates 
a non-functional peptide consisting of the extracellular domain encoded by exons 1-4 
and two additional amino acids encoded by exon 7. To confirm that Eng∆ex5-6 is a null 
allele Allinson et al278 have shown that offspring derived from Engfl/∆ex5-6/Engfl/∆ex5-6 
breeding show a similar phenotype to conventional endoglin knock-out mice displaying 
embryonic lethality at mid-gestation278.  
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Figure 4.2. Schematic of the Engfl/fl;Cdh5(PAC)-CreERT2 inducible knock-out 
mouse model. Tamoxifen treatment activates Cdh5(PAC)-CreERT2 recombinase 
leading to endothelial specific recombination between loxP sites and deletion of 
endoglin exons 5 and 6, resulting in a frame shift mutation, giving rise to a null allele 
encoding a truncated, non functional protein. 
 
Early characterisation of the Engfl/fl;Cdh5(PAC)-CreERT2 conditional knock-out mouse 
model reported an initial high level of endoglin depletion in the pulmonary vasculature 
three weeks following tamoxifen administration however in two out of  three mutants an 
apparent re-establishment of expression was observed (figure 4.3) (personal 
communication, Dr Marwa Mahmoud). This rescue suggests a role for circulating EPCs 
in vascular repair and maintenance. Additionally, an in vivo angiogenesis assay using 
subcutaneously implanted Matrigel matrix plugs revealed evidence of a potential 
invasion of endoglin positive cells into the Matrigel of mutant mice (figure 4.3) 
(courtesy of Zhen Zhai, unpublished data). Although it is possible that these results 
reflect an incomplete knockdown of endoglin in the ECs, it is also possible that 
systemic endothelial specific endoglin depletion is sufficient to stimulate large scale 
proliferation and migration of BM-derived circulating EPCs that are unaffected by the 
Cdh5(PAC)-CreERT2 line and can contribute to endogenous endothelial replacement. 
Endothelial turnover is normally a very slow process, in the order of 3 years322. An in 
vivo model in which this process is enhanced would provide an important new tool for 
investigating vascular repair. For example, injection of labelled EPC sub-populations 
and pre-treated cells into mutant mice would permit in vivo visual tracking of these cells 
and would establish to what extent they are capable of differentiating into mature ECs, 
incorporating into the vasculature and contributing to repair. Such a large scale or 
‘hyper’ repair model could be used to screen proposed therapeutic strategies and may be 
extremely beneficial in elucidating the optimal repair cell type and associated 
mechanisms of repair. 
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Figure 4.3. Preliminary evidence for endothelial replacement following endoglin 
depletion. (A-C) Immunohistochemical staining for endoglin (brown stain) on skin 
sections confirm efficient loss of endoglin protein following tamoxifen treatment (B) as 
compared to matched controls (A) however several mutants (n=3/5) show a possible 
invasion of endoglin expressing cells into growth factor enriched Matrigel pellet (C). 
The Matrigel-skin boundary is indicated by dashed lines. (Images courtesy of Dr 
Zhenhua Zhai).  (D-F) Efficient knockdown of endoglin (brown stain) in the pulmonary 
vasculature was seen in mutant lungs harvested 3 weeks after tamoxifen treatment (D) 
however other mutant  lungs (n=2/3) harvested at 5 weeks showed clear endoglin 
expression (E) that was comparable to the level of endoglin expression seen in matched 
control lungs. (Images courtesy of Dr Marwa Mahmoud). 
 
To test this novel repair/replacement model endoglin protein expression was analysed in 
heart, lung and BM tissues following endoglin depletion (by tamoxifen injection) in 
Engfl/fl;Cdh5(PAC)-CreERT2 mice. Animals were humanely killed and tissues analysed 
at weekly intervals over a 6 week period.  
 
As an additional way of determining the specificity and efficiency of Cre-recombinase 
expression and activation in vivo, mice also carried a Rosa26 Cre-reporter (Rosa26R) 
allele279. The Rosa26R lacZ reporter line carries a bi-floxed STOP cassette in front of 
the bacterial gene lacZ, driven by the ubiquitously expressed Rosa26 promoter (Rosa26 
is now known to be Thump domain-containing protein 3 gene). The lacZ gene expresses 
β-galactosidase upon Cre-mediated excision of the STOP cassette, therefore detection of 
β-galactosidase provides a readout of Cre-recombinase activity (figure 4.4). With the 
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standard chromogenic substrate X-Gal, β-galactosidase is visualized in tissue as an 
intense blue precipitate.  
 
 
Figure 4.4. Cre-mediated recombination of the Rosa26R allele. The expression of 
LacZ is driven by the ubiquitously expressed Rosa26 promoter and is conditional on the 
removal of the preceding loxP flanked neo expression cassette stop codon by Cre-
mediated excision. Subsequent expression of the LacZ gene product, β-galactosidase, 
can be detected by X-gal staining and used to map expression of Cre-recombinase in 
murine tissue or primary cell types.  
 
Two tamoxifen treated Engfl/∆ex5-6;Cdh5(PAC)-CreERT2;R26RT/+ adult mice (referred to 
as endoglin–inducible knockout (Eng-iKO) mutants) were culled and their tissues 
harvested for analysis at each time point. Additionally each time point included a 
tamoxifen treated Engfl/∆ex5-6 matched control lacking Cdh5(PAC)-CreERT2 and a Engfl/fl 
mouse as a further control. An additional group of control mice did not receive 
tamoxifen treatment and were analysed to exclude the possibility of secondary or toxic 
effects of tamoxifen. The average age of mice involved in this study was 22.5 weeks 
(±1.0 week) with a range of 16.7 to 31.3 weeks. 
 
The purpose of this study was to test whether tamoxifen administration reproducibly 
leads to endoglin depletion and whether this is followed by active endothelial 
replacement that would increase over time. This represented a pilot study with 2 
experimental animals used for each of 6 time points over 44 days.  
 
   123 
4.2. Results 
4.2.1. Conditional Endoglin Knock-Out Mouse Model 
4.2.1.1. Efficiency of Cdh5(PAC)-CreERT2 Expression and Activation 
in Lung Tissue 
Recombination was induced in a group of 12 adult Engfl/∆ex5-6;Cdh5(PAC)-CreERT2 
;Rosa26RT/+ mice by administering 7 intraperitoneal (IP) injections of 2mg tamoxifen 
over 9 days (total of 14mg delivered). The mice were humanely killed at different time 
points and the middle lobe of the right lung of each mouse was removed and stained 
with X-Gal to determine the efficiency and reproducibility of Cre-mediated 
recombination. Efficiency of Cdh5(PAC)-CreERT2 activation was graded according to 
X-Gal staining intensity (see figure 4.5 for grading criteria). All mutant mice showed 
high levels of positive X-Gal staining throughout the lobe (graded +++ or ++++) across 
all 6 time points with the exception of a single mouse from group 4 (identified as AN3) 
which was given a grading of ++ due to patches of unstained tissue (figure 4.5A).  
Positive staining was observed throughout the pulmonary vasculature and is indicative 
of strong Cdh5(PAC)-CreERT2 expression (figure 4.5C). Correlation with endoglin 
depletion will be discussed below (section 4.2.3). As expected, lobes from both 
tamoxifen treated and untreated control mice showed no evidence of X-Gal staining 
(figure 4.5B). 
 
4.2.1.2. Expression of Cdh5(PAC)-CreERT2 in Bone Marrow 
Cdh5 (VE-Cadherin) is expressed in mature ECs but in only a small fraction of BM-
MNCs. To confirm Cdh5(PAC)-CreERT2 expression in BM cells of Engfl/∆ex5-6 
;Cdh5(PAC)-CreERT2;Rosa26R mice I adopted a FACS-based method to detect β-
galactosidase expression. Fluorescein di-β-D-galactopyranoside (FDG) is a fluorogenic 
substrate of β-galactosidase, which releases a fluorescent product (FITC) when cleaved 
and is quantified using flow cytometry323-324.   
 
FDG staining and subsequent FACS analysis revealed very low levels of lacZ 
expression (0.43%±0.12) in BM cells from tamoxifen treated Cdh5(PAC)-CreERT2; 
Rosa26RT/+ mice, which was similar to that displayed by BM from tamoxifen treated 
controls (0.53%±0.07) (figure 4.6A and B).  The widely expressed Rosa26-CreERT2 line 
with an incorporated Rosa26R lacZ allele was used as a positive control and showed 
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approximately 50% recombination in BM (figure 4.6D), while conversely the NIH WT 
negative control showed no expression. These results show that the inducible 
Cdh5(PAC)-CreERT2 enzyme is not active in the vast majority of BM cells following 
tamoxifen induction, implying that BM cells would retain the functional Engfl allele and 
would not undergo recombination to Eng∆ex5-6 null allele in the Eng-iKO animals. These 
findings do concur with results from similar Cdh5-Cre deleter lines (see section 4.3.2.) 
indicating that the low Cre expression in BM cells in Cdh5(PAC)-CreERT2 mice, as 
observed here, is a true finding. 
 
 
Figure 4.5. Efficient activation of Cdh5(PAC)-CreERT2 by tamoxifen in murine 
pulmonary vasculature. Application of tamoxifen (7 intraperitoneal injections of 2mg 
tamoxifen over 9 days) to Engfl/∆ex5-6;Cdh5(PAC)-CreERT2;Rosa26RT/+ mice leads to 
efficient Cre activation in vascular endothelium as indicated by blue X-Gal staining of 
lung lobes (A). Groups (1 to 6) are categorised according to time period from first 
tamoxifen injection to time of tissue harvest. Grading of stain intensity is assigned 
beneath mouse identity (+ = negligible staining, ++ = low level or patchy lacZ 
expression, +++ = majority of vessels exhibiting intense staining, ++++ = maximum). 
X-Gal stained tamoxifen treated and untreated negative controls (B). Section of 
wholemount X-Gal stained lung lobe showing lacZ expression throughout the vascular 
network (C). Abbreviations: dpi = days post first injection. 
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Figure 4.6. LacZ expression in Murine BM Cells from Cdh5(PAC)-CreERT2  mice. 
Flow cytometry histograms showing lacZ expression as a percentage of total fresh bone 
marrow cells (A-D). Low activity of Cdh5(PAC)-CreERT2 (as determined by staining 
with the ß-galactosidase substrate FDG) was detected in BM cells of mutant mice (A),  
which is comparable to that observed in Engfl/∆ex5-6 controls (B). High expression of 
Cdh5(PAC)-CreERT2 detected in the BM of the ubiquitously expressed Rosa-CreERT2 
line (C) and wild type mice (D). All mice received 7 x (2mg) tamoxifen injections (via 
intraperitoneal route) over 9 days prior to FACS analysis. 
 
4.2.2. Endoglin Depletion Results in an Increase of Endoglin 
Expression in Bone Marrow Cells 
To identify alterations in endoglin expression in the BM of mutant mice following 
tamoxifen treatment it was important to establish the normal expression profile of 
endoglin in control mice. To do this flow cytometry was used to analyse freshly 
harvested BM cells from Engfl/∆ ex5-6 (n=7) and Engfl/fl (n=7) mice lacking Cdh5(PAC)-
CreERT2.  Mean values of endoglin expression (represented as percentage of total BM ± 
SEM) were calculated.   
 
Unlike the endoglin expression profile of NIH strain mice (see figure 3.9), the normal 
expression profile of BM cells from mice used in this study (mixed genetic background) 
revealed both bright and dim endoglin positive populations. The dim population occurs 
when the antigen expression for a subset of cells is poorly resolved and can appear as a 
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continuous population from those cells not expressing the antigen.  Engbright subsets 
were 0.53±0.04% and 1.44±0.12% in the BM from Engfl/∆ex5-6 and Engfl/fl mice 
respectively, while Engdim sub-populations were 7±0.6% and 12.4±0.8% (see figure 4.7 
for representative dot plots). As expected, the number of endoglin positive BM cells 
(either Engdim or Engbright) was reduced by approximately 50% in the Engfl/∆ex5-6 mice 
compared with Engfl/fl controls (figure 4.7). 
  
 
Figure 4.7. Endoglin expression in BM is up-regulated in tamoxifen treated Eng-
iKO mutants. Representative dot plots A-D show mean values of endoglin expression 
as a percentage of total bone marrow cells (red box correlates to Engbright sub-
population, green box correlates to Engdim sub-population). Tamoxifen treated endoglin 
mutant mice show up-regulated levels of endoglin (n=12) (A) as compared to Engfl/∆ex5-6 
tamoxifen treated controls (n=7) (B).  Dot plot C represents endoglin expression in BM 
of Engfl/fl mice (=7) and (D), an isotype matched control.  
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Due to the low level of Cdh5(PAC)-CreERT2 induction observed in BM cells (refer to 
section 4.2.1.2) I did not expect to see endoglin knock down in mutant mice. 
Surprisingly, analysis revealed an up-regulation of endoglin expression in several Eng-
iKO mutant mice compared with Engfl/∆ ex5-6 controls (figure 4.7). Expression of the 
Engbright sub-population ranged from 0.58% to 0.93% in mutant mice (figure 4.8) and 
from 5% to 10.8% for the Engdim sub-population (figure 4.9).  Cell counts were not 
normally distributed and Mann Whitney statistical tests were used to assess the 
significance of differences between mutant mice and Engfl/∆ ex5-6 matched controls (table 
4.1 summarises statistical analyses). Three technical replicate FACS analyses were 
performed for each BM cell population. Six out of twelve mutant mice had a higher 
percentage of Engbright cells than controls, while three out of twelve reached statistical 
significance in the Engdim sub-set. These mutants were distributed throughout the 6 
week period and too few mice were analysed to see a difference related to time from 
commencement of endoglin depletion. Additionally, an insufficient number of mutant 
mice were analysed at each time point to determine a reliable pattern of expression. 
However the data indicate both the number of endoglin positive cells and the level of 
endoglin expression increased in the BM of Eng-iKO mice.  
 
These results appear independent of any secondary effects of tamoxifen administration 
as both tamoxifen treated and untreated control mice presented with similar levels of 
expression (table 4.1). However only 1 Engfl/fl and 1 Engfl/∆ex5-6 untreated animal was 
included in this analysis (versus 6 tamoxifen-treated controls of each genotype) 
therefore further investigation using a wider cohort of control mice (without tamoxifen 
administration) would be required to absolutely discount this possibility. 
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Figure 4.8.  FACS analysis of the Engbright sub-population in BM cells of Eng-iKO 
mice. Red bars correspond to tamoxifen treated Eng-iKO mice categorised according to 
time interval from tamoxifen treatment to tissue harvest. Blue bars correspond to 
endoglin positive cells in BM from tamoxifen-treated Engfl/∆ex5-6 (n=7) and Engfl/fl (n=7) 
mice. Horizontal bars identify significant results of Mann Whitney tests between 
individual mutant mice and Engfl/∆ex5-6 levels. *= p<0.05, **= p<0.01. Error bars 
represent ±SEM.  Abbreviations; dpi = days post first injection.  
 
Figure 4.9.  Expression of the Engdim sub-population in BM cells of Eng-iKO mice. 
Red bars correspond to tamoxifen treated Endoglin mutants with groups categorised 
according to time interval from tamoxifen treatment to tissue harvest. Blue bars 
correspond to tamoxifen-treated Engfl/∆ex5-6 and Engfl/fl controls. Horizontal bars identify 
significant results of Mann Whitney tests between individual mutant mice and Engfl/∆ex5-
6
 levels. * = p<0.05. Error bars represent ±SEM.  Abbreviations; dpi = days post first 
injection. 
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Eng-iKO       Mutant Engbright (%) 
Mann 
Whitney 
p Value 
% Change Eng
dim 
(%) 
Mann 
Whitney 
p Value 
% 
Change 
Group110pi BB2 0.7 N.S. (+) 32.1 5.275 N.S. (-) 24.6 
 BB3 0.875 0.029 (+) 65.1 5.2 N.S. (-) 25.7 
Group216dpi DF1 0.9 0.007 (+) 69.8 9.225 0.047 (+) 31.8 
 ZL2 0.75 0.028 (+) 41.5 8.475 N.S. (+) 21.1 
Group323dpi DE2 0.925 0.01 (+) 74.5 10.775 0.018 (+) 53.9 
 DI4 0.775 N.S. (+) 46.2 8.225 N.S. (+) 17.5 
Group430dpi AN3 0.6 N.S. (+) 13.2 8.975 N.S. (+) 28.2 
 AO2 0.825 0.019 (+) 55.7 10.075 0.04 (+) 43.9 
Group537dpi ZE1 0.575 N.S. (+) 8.5 5 N.S. (-) 28.6 
 ZX2 0.875 0.011 (+) 65.10 6.6 N.S. (-) 5.7 
Group644dpi ZW1 0.625 N.S. (+) 17.9 8.675 N.S. (+) 23.9 
 ZW5 0.575 N.S. (+) 8.5 9 N.S. (+) 28.6 
Engfl/∆ex5-6   0.53 n/a n/a 7 n/a n/a 
Engfl/fl  1.44 n/a n/a 12.4 n/a n/a 
Engfl/∆ex5-6,  no tamoxifen  0.58 n/a n/a 5.4 n/a n/a 
Engfl/fl,            no tamoxifen  1.25 n/a n/a 9.7 n/a n/a 
Table 4.1. Statistical analyses of Engbright and Engdim populations (displayed as 
percentage of total BM cells) in Eng-iKO mutant mice. The results of Mann Whitney 
tests between individual mutants and tamoxifen-treated Engfl/∆ex5-6 control populations 
for both Engbright and Engdim populations are shown, as well as percentage changes in 
expression. Both tamoxifen-treated and untreated Engfl/∆ex5-6 and Engfl/fl control 
populations are listed for comparison (red). p<0.05 is considered significant; N.S. 
denotes not significant (p>0.05), and n/a is not applicable. 
 
4.2.3. EPCs Do Not Contribute to Endothelial Repair in Endoglin 
Knock-Out Mice 
Immunohistochemistry using an anti-endoglin antibody was performed on heart and 
lung cryosections from all mutant mice and controls to determine the efficiency of 
endoglin depletion following tamoxifen treatment and to assess the contribution of BM-
derived progenitor cells to endothelial replacement. To accurately confirm efficient 
endoglin knockdown in mutants following tamoxifen induction I first established the 
normal expression profile of endoglin in heart and lung tissues. Figure 4.10 shows 
representative images of staining for endoglin in heart and lung tissue from Engfl/∆ex5-6 
and Engfl/fl control mice.  
 
Analysis of Lung Tissue in Endoglin Knock-Out Mutants 
Lung tissue from mutant mice was examined at each time-point and endoglin expression 
was graded according to staining intensity (for grading criteria see figure 4.11). If 
endothelial repair/replacement had occurred then I would have expected to see low 
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expression of endoglin protein at early time-points in the study, followed by increasing 
levels as BM derived EPCs replaced the endoglin-negative resident ECs. However, no 
clear temporal pattern was observed. In particular, group 6 animals (analysed at day 44) 
did not show a clear increase in endoglin expression compared with other groups 
analysed at earlier time points. Overall, negligible positive staining (grading +) was 
observed in 6 out of 12 mutants indicative of extensive endoglin knock-down. In 5 out 
of 12 mutants there was a reduction in expression compared to Engfl/∆ ex5-6 mice however 
notable levels of expression were still detected (grade ++) and only 1 out 12 mutants 
displayed clear endoglin expression at levels that were comparable to those seen in 
matched controls (grade +++). 
 
Within group 1 (mice culled 10days following the first tamoxifen injection, days post 
injection (dpi)) animal BB2 was awarded a higher grade of staining intensity than its 
mutant counterpart (BB3) due to patches of positive staining that were restricted to one 
lobe only.  Group 2 mutant mice were analysed at 16dpi and showed consistent low 
levels of endoglin expression throughout the capillary network and major vessels with 
several intermittent patches of negative staining, which were visible at a higher extent in 
ZL2 than in DF1. Analysis of group 3 mutant mice one week later revealed greater 
inconsistency, while DI4 showed negligible endoglin expression DE2 displayed patches 
of positive staining throughout the capillary network. Similarly whereas AN3 of group 4 
displayed extensive positive staining, AO2 showed much lower expression. Of group 5 
mutant mice ZE1 showed a high degree of endoglin knock down and ZX2 retained a 
high degree of endoglin expression that was comparable to matched control mice. 
Group 6 mutant mice were both negative for endoglin staining.  
 
Analysis of Heart Tissue in Endoglin Knock-Out Mutants 
Analysis of endoglin stained heart sections from mutant mice revealed extensive knock 
down of endoglin expression at all time-points (figure 4.12). Only 3 out of 12 Eng-iKO 
mutants showed considerable levels of expression following tamoxifen treatment. Both 
ZL2 (group 2, analysed 16 days post tamoxifen) and AN3 (group 4, analysed 30 days 
post tamoxifen) exhibited low levels of endoglin positive staining and were awarded 
grade ++ intensity rating, whereas examination of ZX2 (group 5, analysed 37 days post 
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tamoxifen) revealed endoglin expression comparable to that seen in Engfl/∆ ex5-6 matched 
controls (+++).  
 
This study failed to demonstrate endothelial replacement following endoglin depletion 
in a significant number of animals (see table 4.2. for summary of findings). Overall 
there was a good correlation between the endoglin levels in heart and lung tissues, but 
there appeared to be more efficient endoglin knockdown in cardiac compared with 
pulmonary vasculature. Three (ZL2, AN3 and ZX2) out of 12 Eng-iKO mutants 
demonstrated moderate levels of endoglin protein expression in both heart and lung 
tissue, suggesting that endoglin knockdown was less efficient in these mice. In fact, 
ZX2 had expression levels comparable to Engfl/∆ ex5-6 controls.  
 
 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
BB2 BB3 DF1 ZL2 DE2 DI4 AN3 AO2 ZE1 ZX2 ZW1 ZW5 
X-GAL +++ +++ +++ +++ +++ ++++ ++ ++++ ++++ +++ ++++ ++++ 
Eng LUNG ++ + ++ ++ ++ + ++ + + +++ + + 
Eng 
HEART 
+ + + ++ + + ++ + + +++ + + 
Engbright (%) 
BM 
0.7 0.875 0.9 0.75 0.925 0.775 0.6 0.825 0.575 0.875 0.625 0.575 
Engdim (%) 
BM 
5.275 5.2 9.225 8.475 10.78 8.225 8.975 10.08 5 6.6 8.675 9 
AGE (weeks) 17 17 16.7 25 17 16.6 23.9 23.9 26.9 27.1 28.1 28.1 
SEX f f f m m f f m m f m m 
Table 4.2. A summary of the effect of systemic endothelial restricted endoglin 
depletion on endoglin expression in the BM and endothelial replacement in cardiac 
and pulmonary vasculature. X-Gal staining intensity of lung lobes is consistently high 
indicating extensive Cdh5(PAC)-CreERT2  expression in mutant mice (++ = low level or 
patchy lacZ expression, +++ = majority of vessels exhibiting intense staining, ++++ = 
maximum staining). Expression of endoglin in lung tissue was notably knocked down in 
mutants but shows intra and inter animal variability and heart tissue shows extensive 
knock-down  (+ = negligible endoglin expression, ++ = low level or small patches of 
positive staining, +++ = expression comparable to Engfl/∆ex5-6 controls). Engbright and 
Engdim sub-populations displayed as percentage of total bone marrow. Age of mice at 
time of first tamoxifen injection and sex also shown (m = male, f = female).  
 
Overall, there was no clear outcome from this study. It is possible that high endoglin 
expression may be attributable to poor Cdh5(PAC)-CreERT2 expression and/or 
induction or it could be due to BM cell-dependent endothelial replacement.  
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Figure 4.10. Endoglin expression in lung (A-F) and heart (G-L) tissue of Engfl/fl and 
Engfl/∆ex5-6 mice. Immunohistochemical staining for endoglin and CD31 (indicated by 
brown DAB stain) revealed endoglin expression is present throughout the vasculature of 
heart and lung tissues. Endoglin staining is reduced in Engfl/∆ex5-6 tissue (D and J) 
compared with Engfl/fl (A and G).  Positive expression of the pan-endothelial cell marker 
CD31 is shown in both Engfl/fl and Engfl/∆ex5-6 genotypes for lung (B and E) and heart 
tissue (H and K). Negative staining is shown in no primary control stained sections (C, 
F, I and L). All mice were injected with 14mg tamoxifen over 9 days. Scale bars = 
20µm. 
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Figure 4.11.  Efficient knock-down of endoglin expression in the pulmonary 
vasculature of Eng-iKO mutant mice. Extensive knock-down of endoglin expression 
(brown stain) is evident in all tamoxifen recipient groups (second to bottom panels) 
compared with tamoxifen untreated (top panel) and treated (see figure 4.10) matched 
controls. Mouse identity and extent of knock-down is graded above each panel; (red, + 
= negligible endoglin expression, ++ = low level or small patches of positive staining, 
+++ = expression comparable to Engfl/∆ex5-6 controls). As expected, positive CD31 
staining in adjacent sections revealed no difference in mutant mice as compared to 
matched controls. Scale bars = 50µm. 
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Figure 4.12.  Efficient knock-down of endoglin expression in the heart vasculature 
of Eng-iKO mutant mice. Extensive knock-down of endoglin expression (brown stain) 
is evident in all tamoxifen recipient groups (second to bottom panels) compared with 
tamoxifen untreated (top panel) and treated (see figure 4.10)  Extent of knock-down is 
graded adjacent mouse identity; (red, + = negligible endoglin expression, ++ = low level 
or small patches of positive staining, +++ = expression comparable to Engfl/∆ex5-6 
controls). Positive CD31 staining revealed no difference in mutant mice as compared to 
matched controls. Scale bars = 50µm. 
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4.3. Discussion 
The purpose of this pilot study was to test whether endoglin depletion in ECs leads to 
active endothelial replacement by circulating endoglin positive cells originating from 
the BM.  Considerable endoglin expression in pulmonary vasculature of several mutant 
mice corroborated the trend of endoglin re-expression initially described by Dr Marwa 
Mahmoud (unpublished data) however the level of expression was relatively low and 
extensive endoglin knock-down, with little to no detectable expression of endoglin was 
evident in a number of additional mutant mice sampled across all time-points (one week 
to six weeks following tamoxifen induction). The majority of mutants analysed also 
showed highly efficient endoglin knock-down in the endothelium of the heart. I 
concluded that the patterns of endoglin expression in lung and heart tissue of mutant 
mice do not support the hypothesis that circulating EPCs of myeloid origin could 
replace endoglin negative vascular ECs in adult mice. 
 
4.3.1. Heterogeneity of Endothelial Specific Endoglin Knock-
Down in the Pulmonary Vasculature 
The mechanism explaining the inter-animal variability of endoglin knock-down 
observed in the pulmonary vasculature of mutants is unclear however it is highly 
unlikely to be due to reversal of Cdh5(PAC)-CreERT2-mediated genetic excision. 
Although this reaction is reversible in theory, for kinetic reasons, intermolecular 
recombination occurs at very low frequency (figure 4.1)321. Several possibilities could 
explain the observed variation including the possible suppression of CreERT2 activity in 
lung endothelium or a dose dependent mechanism which dictates that a higher dose of 
tamoxifen is necessary to bring about efficient deletion in lung endothelium than is 
necessary for heart tissue. Indeed a low local concentration of tamoxifen due to blood 
flow patterns may explain variability of endoglin depletion observed between lung lobes 
of a single animal. Several additional relevant factors have been associated with 
CreERT2-mediated recombination efficiency including genetic background, sex, weight 
and age of mice325. Of particular note is the effect of age, Monvoisin et al observed that 
the degree of Cre-mediated genetic recombination correlates inversely with age and 
identified significant differences between 8 week and 24 week old mice325. The reason 
for this is unknown but the authors postulate that it could be due to alterations in the 
chromatin status of older cells preventing recombination or the activity of Cre or the 
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CreERT2 fusion protein being suppressed in older animals. It is plausible therefore to 
expect a greater degree of knockdown with less variation if using young adult, age 
matched mice. It is of note that the mice with the highest levels of endoglin expression 
(ZL2 and ZX2) were also amongst the oldest mice in the study, at 25 weeks and 27.1 
weeks respectively. This would be consistent with a reduced level of Cre mediated 
recombination leading to moderate levels of residual endoglin protein expression in 
these individuals, but it is surprising that this difference was not also observed in the X-
Gal stained lung lobes which were also used a readout for Cre activity. It may be that 
the Rosa26 (Thumpd3) locus is less susceptible to chromatin re-organisation with age 
than the endoglin locus. 
 
4.3.2. Cdh5(PAC)-CreERT2 Mediated Recombination and 
Endoglin Expression in BM Cells 
The low incidence of recombination in BM cells of mutant mice (0.43%±0.12) is in 
accordance with a similar VECadherin-CreERT2 deleter mouse which describes 
0.4%±0.01% recombination (over control) in BM cells325. Another mouse line showing 
constitutive VE-Cadherin-Cre expression shows lacZ Cre reporter activity in 50–60% of 
BM cells. However, this high level is thought to represent the progeny of progenitor 
cells that expressed VE-Cadherin-Cre during early development326. In contrast, the 
inducible Cdh5(PAC)-CreERT2 BM lacZ positive cell populations described in this 
chapter (and in reference325), represent adult BM cells in which CreERT2 expression 
driven by the VE-Cadherin promoter is activated only once tamoxifen is administered. 
The levels of Cre expression shown in figure 4.6 are consistent with the reported 
expression of VE-Cadherin in healthy adult BM of less than 1 per cent327. While many 
studies report the expression of VE-Cadherin as a property of BM-derived EPCs more 
detailed analysis has shown that EPCs begin to express VE-Cadherin once they have 
committed to terminal endothelial differentiation88 and it is unlikely that more primitive 
BM-resident cells would strongly express VE-Cadherin.  
 
Following endothelial specific endoglin depletion a small but significant up-regulation 
of endoglin protein expression was observed in Eng-iKO BM cells compared with 
matched controls. An increase in an Engbright subpopulation was detected from as early 
as week one and an increase in Engdim cells from week two.  The expansion of endoglin 
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expressing cells in response to systemic endoglin loss would be consistent with a role 
for circulating BM-derived EPCs in vascular repair in endoglin knock-out mice. 
However, there was no temporal pattern in endoglin protein expression in lung or heart 
tissues to indicate such a repair mechanism was occurring.  
 
Interestingly I detected both ’bright’ and ‘dim’ endoglin positive BM cells in this study, 
whereas analysis of endoglin expression in BM in chapter 3 (figure 3.9) did not reveal 
such sub-populations. This may be due to different strains of mice being used in these 
two chapters (chapter 3 analysis represents NIH pure line whereas in chapter 4 I used 
mice of mixed genetic background). In addition different flow cytometers were used in 
these two analyses. BM from NIH mice was analysed using a FACS Calibur machine 
(Becton Dickinson) whereas in the later study I used a LSRII flow cytometer (Becton 
Dickinson), which may offer better resolution.  Although the work described in this 
chapter has not explored the role of endoglin in the BM, the detection of ’bright’ and 
‘dim’ endoglin positive cells could represent heterogeneous sub-populations of cells or 
mark progenitor cells in the BM at various stages of differentiation.  Endoglin is used as 
a marker for both EPCs and terminally differentiated ECs and onset of expression may 
represent a transitional phenotype between the primitive EPC and mature EC.  A role 
for endoglin in haemangioblast specification during development has been identified310 
and it has been suggested that an adult equivalent of the embryonic haemangioblast may 
be the likely source of EPCs in haematopoietic tissues, although this has yet to be 
proven. It is possible that the expanded endoglin expressing population observed in the 
current study represents such an adult haemangioblast. Endoglin is also expressed on a 
sub-population of pro-erythroblasts in healthy adult BM328 and marks adult long-term 
repopulating HSCs257. It may be beneficial to isolate bright and dim endoglin positive 
populations and test their capacity to contribute to vessel formation in vivo, as well as 
capacity for differentiation along both the endothelial and haematopoietic lineages.  
 
4.3.3. Is a Secondary Pathological Stimulus Required to Induce 
EC Replacement? 
The lack of evidence for endothelial replacement in Eng-iKO mutant mice may be 
explained by the stable nature of endothelial cells which have an estimated turnover 
time of more than 1000 days322. A secondary pathological stimulus, such as acute MI, 
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may be required to fully activate an endothelial repair mechanism. Such a stimulus 
would increase the turnover rate of the microvascular endothelium and promote active 
angiogenesis, in which EPCs proliferate, mobilise and home to sites of ischaemia.  
 
Despite the initial enthusiasm surrounding EPC based pro-angiogenic therapies the 
delivery of mixed populations of poorly defined cells has resulted in only modest 
benefit in clinical trials134-136. While it is likely that the identification and use of a more 
defined functionally active repair cell will improve the clinical outcomes, the 
combination of EPCs with MSCs has also been shown to augment neovascularisation in 
vivo106-107. Similarly, cardiosphere-derived cells (CDCs), a mesenchymal cell type 
expanded from cardiac tissue has been shown to promote heart repair following MI159. 
These cells also express endoglin, which may act as a functional marker of cardiac 
repair cells. This hypothesis was tested in vitro and in vivo in a murine MI model by 
depleting endoglin in donor CDC repair cells using inducible knockout technology and 
is described in chapters 5 and 6 of this thesis. 
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CHAPTER 5. 
 
The Role of Endoglin in 
Cardiosphere-derived Cells 
in vitro 
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5.1. Introduction  
The discovery of endogenous cardiac-resident stems cells (CSCs) capable of 
differentiating into multiple cell lineages has led to intense investigation into their 
therapeutic potential of (as discussed in section 1.7.4). The isolation of specific cardiac 
stem cell sub-populations directly from cardiac tissue has also been described162. Cells 
spontaneously migrate from heart biopsy tissue in culture. The resultant population 
contains distinct cell types expressing stem cell-associated (cKit, Sca1, Abcg2), 
endothelial (CD31, CD34) and mesenchymal (CD90) markers. The transition of this 
outgrowth cell population to form cardiospheres reportedly enriches CSCs and increases 
repair potency158. Cell expansion as cardiosphere-derived cells (CDCs) is also possible 
with cells retaining their multipotent and self-renewal capacity159, 162, 175. CDCs have 
been shown to have therapeutic potential in the treatment of ischaemic heart disease in 
experimental models and phase I clinical trials (as discussed in section 1.7.4). Of 
particular interest CDC transplantation into pre-clinical models has been shown to 
induce an angiogenic response (discussed in section 1.7.3).  
 
Interestingly the majority of human CDCs express endoglin, which is also expressed by 
ECs, EPCs, HSCs and MSCs (see section 1.9.3.). The role of endoglin has been most 
extensively studied in ECs and here it acts to regulate the balance of TGFβ signalling 
through the Alk1 and Alk5 pathways. However, the role of endoglin in CDCs has not 
yet been determined. This is important to address as endoglin may represent a key 
surface marker that can be used to define these cardiac repair cells, whilst also 
facilitating their pro-angiogenic potential by mediating TGFβ family signalling.  The 
study described in this chapter aims to address the role of endoglin in CDCs by testing 
the effect of endoglin loss on in vitro properties related to tissue repair (cellular 
proliferation and migration) and the activation of Smad1/5/8 and Smad2 TGFβ 
signalling pathways. Endoglin expression was depleted in the experimental cells in vitro 
using the inducible Cre-recombinase strategy described in section 4.1 (see figures 4.1 
and 4.2). 
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5.2. Results 
5.2.1.  Derivation and Characterisation of Cardiosphere-derived 
Cells 
5.2.1.1.  Optimisation of CDC Culture  
CDCs were derived using an adapted version of a protocol described by Smith et al159 
(figure 5.1A). Briefly mouse neonatal hearts are enzymatically digested, minced and 
tissue fragments are plated on fibronectin-coated dishes as explants and cultured (figure 
5.1B). After several days a layer of stromal-like cells grows from the adherent explant 
tissue (figure 5.1B), over which small round ‘phase bright cells’ migrate (figure 5.1C). 
Once confluent, all explant derived cells (EDCs, including both stromal-like and phase 
bright cells) are removed via gentle trypsinisation, plated on low-adherence poly-D-
lysine and cultured in a specific growth factor enriched low serum media for several 
days. Over this time clusters of cells aggregate and proliferate to form spheres, and 
these cellular structures are termed cardiospheres (figure 5.1D and E). Cardiospheres 
are loosely adherent and easily removed via gentle trituration, re-plated on a fibronectin 
matrix and cultured as a monolayer of CDCs in basal medium supplemented with 20% 
FCS (figure 5.1F and G).  Several studies report that EDCs can be harvested repeatedly 
from the same tissue fragments, however I observed that explants became progressively 
more rounded with less-defined margins and eventually degraded to a degree which 
precluded using the same tissue to produce a second generation of EDCs.  
 
Several stages of the culture protocol were adapted in order to obtain optimal 
cardiosphere and CDC yields. I observed that early adherence of myocardial fragments 
was essential to ensure sufficient growth of EDCs and that the initial plating of tissue 
explants in the presence of media was required to prevent heart tissue becoming 
desiccated. Likewise addition of media at defined intervals during the culture period 
was also advantageous in preventing explants from drying out.  Andersen et al have 
stated that cardiosphere yield is correlated with EDC plating density174 therefore to 
enhance cardiosphere number I titrated EDC seeding density on poly-D-lysine coated 
dishes and assessed the number and size of cardiospheres formed. I found that EDC 
seeding density positively correlated with increased cardiosphere number and size up to 
105 cells per well (24 well plate). Therefore, this seeding density was used in all 
subsequent cultures (figure 5.2A). In addition, I tested the effect of varying the 
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concentration of growth factors in cardiosphere specific media (CGM). Two different 
formulations of CGM were compared and they were denoted as high growth factor 
media (high-GF-CGM; bFGF 80ng/ml, EGF 20ng/ml and thrombin 50ng/ml) and low 
growth factor (low-GF-CGM; bFGF 20ng/ml, EGF 10ng/ml and thrombin 25ng/ml) 
supplemented media. Cardiosphere number was compared between these two groups 
and found to be significantly increased in high-GF-CGM cultures (p=0.008, figure 
5.2B). Also, addition of fresh high-GF-CGM at day 4 of cardiosphere culture (6 day 
total culture period) appeared to have a positive effect on cardiosphere growth (p=0.05, 
figure 5.2B).  
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Figure 5.1. Cardiosphere and CDC culture. (A) Schematic depicting different stages 
of CDC culture. (B) Neonatal mouse heart explant at day 4 showing spontaneous 
outgrowth of EDCs (stromal-like cells (white arrows) and phase bright cells (red 
arrows) with inset image showing a similar explant just 12 hours after plating).  (C) At 
day 14 EDC outgrowth reaches confluence and is harvested for cardiosphere culture. 
The myocardial tissue gradually diminishes as the number of outgrowth EDCs 
increases. (D) EDCs are plated in cardiosphere-culture conditions. At day 2, cells 
appear to migrate towards each other to form cellular foci. (Note white arrows 
highlighting small fragments of contaminating myocardial tissue which cardiospheres 
occasionally form around). (E) Fully formed cardiospheres at day 6. (F) CDCs at 
passage 2, plated on fibronectin for expansion. (G) CDCs at passage 6. Scale bars = 
100µM. 
 
Spontaneous beating of embryonic mouse cardiospheres has previously been 
described158, though in the present study while the beating of myocardial explant tissue 
was often noted, this was only rarely observed in cardiospheres. It has been suggested 
that beating cardiospheres are due to  the presence of ‘contaminating’ heart tissue 
fragments174 therefore I included a sedimentation step following harvest of phase bright 
cells to ensure that minimal amounts of cardiac tissue were present in subsequent 
cardiosphere cultures (briefly, following EDC harvest, cells in suspension are left to sit 
for 1-2min prior to being transferred to a second tube while the myocardial tissue 
fragments sink to the bottom of the first tube and are discarded). However despite this 
intervention very small fragments of tissue sometimes did persist in cardiosphere 
culture and it appeared that EDCs migrated towards these and formed cardiospheres 
around them (figure 5.1D, white arrows indicate myocardial tissue present in the centre 
of a cardiosphere in formation). It is possible that these pieces of myocardial tissue 
enhance cardiosphere formation, although such contamination may be undesirable if 
this protocol is used to prepare CDCs from human heart tissue biopsies for clinical 
applications as injecting tissue fragments may increase the risk of micro-thromboli 
formation, and injecting myocardial tissue that retains intrinsic contractility may 
interfere with the electrophysiology of the recipient heart. It may be possible to filter out 
these fragments using an appropriately sized filter mesh, however I opted not to do this 
in the current study to prevent marked deviation from other published culturing 
methods159, 163. CDCs represent a heterogeneous cell population and so to minimise the 
‘contamination’ of cultures with stromal-like cells, which could become detached 
during the gentle trituration used to isolate cardiospheres, a second sedimentation step 
was included during the cardiosphere harvesting stage as suggested by Anderson et al174. 
This involves allowing cardiospheres to sink to the bottom of a greiner tube while the 
supernatant, which contains any contaminating non-cardiosphere cells, is discarded. 
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Figure 5.2. Optimising culture conditions to maximise cardiosphere yield and 
evaluation of CDC expansion. (A) There is a positive correlation between 
cardiosphere number and EDC seeding density up to 105 cells per well. Inset graph, 
there also appears to be a positive correlation between cardiosphere size and EDC 
seeding density indicating that cardiospheres may be partially formed by cellular 
aggregation. (B) A higher concentration of bFGF (80ng/ml versus 20ng/ml), EGF 
(20ng/ml versus 10ng/ml) and thrombin (50ng/ml versus 25ng/ml) in cardiosphere 
specific growth media results in a significant increase in cardiosphere number per well 
(p=0.008), as does replacing CGM-high media with fresh CGM-high media to 
cardiosphere cultures at day 4 (p=0.05). Experiments were repeated three times and the 
statistical significance of differences between groups was determined using one-way 
ANOVA (p=0.001) and unpaired t-tests. (C) Cell growth of 4 separate CDC cultures 
expressed as number of population doublings between each passage (average time 
between passaging is 3-5 days). ** denotes p < 0.01. 
 
Using an optimised culture protocol, approximately 93%±2 of neonatal cardiac explants 
adhered to fibronectin coated plates and of these 92%±1 produced an EDC outgrowth 
which included phase bright cells in 51%±13 of cases. EDCs typically became 
confluent within 14±2 days and yielded approximately 1.2-2.4x106 cells per heart.  
EDCs were seeded in poly-D-lysine coated 24 well plates at a density of 105 cells per 
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well and started to move together in foci during cardiosphere culture within 24 to 48 
hours. By day 6 approximately 159±2.6 complete cardiospheres had formed per well. 
Cardiospheres were expanded as monolayers of CDCs that required passaging about 
every 3-5 days. Approximately 2-4x106 CDCs at passage 2 were harvested per neonatal 
mouse heart. All data described above were generated from at least 3 independent 
experiments. 
 
5.2.1.2.  Isolating Progenitor Cells from Different Regions of the 
Neonatal Mouse Heart  
It has been reported that atria of the human heart contain higher numbers of progenitor 
cells than the ventricles329-330. Furthermore, Davis et al have shown that human atrial 
biopsies cultured as explants produce a markedly increased yield of EDCs than cardiac 
tissue taken from other regions162. I investigated whether this was also true for neonatal 
mouse hearts (aged between 4 to 6 days) by culturing explants of atrial and ventricular 
tissue separately and monitoring subsequent transition of resultant EDCs to 
cardiospheres. The aim of this study was to determine conditions that would enable an 
optimal yield of cardiac resident progenitors to be harvested. End-point measurements 
were (i) percentage of productive explants (defined as explants producing both stromal-
like and phase bright cells), (ii) EDC yield (normalised to total explant number to 
account for the significantly larger amount of ventricle tissue available), (iii) 
cardiosphere number and (iv) cardiosphere size.  The experiment was repeated three 
times and differences between atrial and ventricular measurements were statistically 
analysed using the unpaired t-test. Both atrial and ventricular tissue was cultured for the 
same time period (explant culture period was 14±2 days and cardiosphere culture was 6 
days). The average number of explants analysed per experiment was 106±19 atrial 
fragments versus 231±13 ventricle explants. Cardiospheres were enumerated from 6 
wells (105 EDCs plated per well of a 24 well plate) per group. 
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Figure 5.3. Evaluating the potential of atrial versus ventricular tissue to generate 
cardiospheres. (A) A summary of 3 independent experiments showing percentage of 
productive explants (blue bars) and EDC yield (red line) derived from atrial (A) versus 
ventricular (V) tissue. Percentage of productive explants is comparable between groups, 
whilst a greater yield of EDC outgrowth is obtained from ventricular explant culture.  
(B) A summary of 3 independent experiments showing cardiosphere number (blue bars) 
and size (cardiosphere diameter (µM), red line) derived from atrial (A) versus 
ventricular (V) tissue. Whilst cardiosphere yield was higher from atrial tissue cultures, 
these cell clusters were significantly smaller than their ventricular counterparts 
(cardiosphere diameter (µM) measured using Axiovision Rel. v4.8 software (Zeiss)). 
All pups used in this study were between 4 to 6 days old. Data analysed using the 
unpaired t-test. ** denotes p < 0.01. 
 
In the first of the three experiments no difference was observed between atrial and 
ventricular cultures (figure 5.3). However in the second and third experiments 
significant differences were found between these two groups in all parameters tested 
with the exception of the percentage of productive explants, which remained 
comparable in all three experiments (figure 5.3A). EDC yield (normalised to total 
explant number and expressed as cell number per explant) was significantly increased in 
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ventricle derived cultures (figure 5.3A), in contrast to findings reported by Davis and 
colleagues162. Furthermore, whilst cardiosphere number was significantly increased in 
atria-derived cultures these cellular structures were markedly smaller than those derived 
from ventricular tissue (figure 5.3B). Given the variable outcomes of this experiment, 
and also that neonatal hearts offer relatively small tissue samples, in all subsequent 
experiments whole hearts were used to derive CDCs.  
 
5.2.1.3.  The Expression of Endothelial, Mesenchymal and Stem cell 
Markers in Passage 2 Murine CDCs. 
Ex vivo expanded CDCs (passage 2) were characterised using immunocytochemistry 
staining and fluorescent microscopy with specific antibodies against endoglin and 
CD31. This analysis revealed high endoglin and low CD31 expression levels in CDCs 
(figure 5.4).  
 
To allow high throughput immunophenotyping of CDCs in passage 2 cells, I used flow 
cytometry to analyse the expression of endoglin and CD31 as well as the stem cell 
marker cKit, and the mesenchymal cell marker CD90. Figure 5.5 graphically displays 
the results of one representative experiment showing the following approximate 
expression levels: 90.2±1.2% endoglin+, 30.2±0.5% cKit+, 22.1±0.3% CD90+ and 
25.8±1.1% CD31+ (figure 5.5).  These values are similar to those published in similar 
studies159. The majority of cKit and CD90 positive cells also co-expressed endoglin 
(approximately 82.5% and 94.6% respectively, figures 5.5C and 5.5D), whilst cKit+ 
CDCs were largely distinct from the CD90+ subpopulation (figure 5.5B). cKit is 
expressed by a large proportion of CD31+ cells whereas CD90 expression is largely 
absent from CD31+ cells (table 5.1).  
 
Table 5.1 summarises the mean percentage values of all cell populations analysed in 6 
independent experiments and reveals that there is a degree of inter-culture variation. 
Endoglin expression ranges from 68% to 92.2%, cKit expression peaked at over 50% in 
two of the analyses (see experiments B and E in table 5.1) whereas it ranged from 13.9 
to 30.2% in the remaining experiments, which is more in keeping with published 
data159. CD90 also peaked at over 50% in one analysis (see experiment D in table 5.1) 
but remained relatively constant otherwise (11.9% to 22.1%), whilst the expression of 
CD31 ranged from 19.5% to 37.9% in 5 independent immunophenotyping profiles of 
passage 2 CDCs. Interestingly  CD31 expression appeared to be appreciably lower in 
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CDCs as measured using immunocytochemistry (figure 5.4, n=1) compared with flow 
cytometry (n=5). This may be related to the higher sensitivity of FACS analysis which 
can detect antigen expression even at very low intensities. Furthermore, 
immunohistochemistry using an anti-CD31 antibody was only performed once and 
additional staining of independent cultures would be needed to confirm findings. The 
mice used were all neonates of C57Bl/6 strain and aged between 4 and 6 days (see table 
5.1). Furthermore media and culture techniques were consistent between cultures 
therefore the observed variability in marker expression is presumably due to stochastic 
events or unknown variables (discussed in greater detail in section 5.3.1.). 
 
 
Figure 5.4. Immunofluorescent staining of passage 2 CDCs and primary mouse 
lung ECs. CDCs stained with anti-endoglin (A) and anti-CD31 (C) specific antibodies. 
Positive control mouse lung ECs stained with endoglin (B) and CD31 (D). Anti-rat 
secondary antibodies conjugated to alexa594 (red, A and B) and alexa488 (green, C and 
D) were used and nuclei stained with DAPI (blue). Inset images representative of no 
primary controls (A and C) and a negative control NIH-3T3 fibroblast cell line (B and 
D). N.B. CD31 positive CDCs (C) appear to be forming tubules/linear aggregates, 
however the presence of coronary vessel fragments cannot be discounted. This staining 
for CD31 was performed only once and additional replicate experiments would be 
required to confirm findings. Scale bars = 20µm. 
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Figure 5.5.  Flow cytometric analyses of murine CDCs at passage 2. (A) Summary of the percentage of CDCs expressing endothelial (CD31, endoglin), 
mesenchymal (CD90, endoglin) and stem cell (cKit) markers from one representative experiment. Dot plots showing populations of CDCs that co-express 
cKit and CD90 (B), cKit and endoglin (C) and CD90 and endoglin (dual positive cells in upper right quadrant). CDCs expressing cKit are largely distinct from 
CD90+ cells and the majority of cKit+ or CD90+ cells also co-segregate with endoglin. Histograms E to G show isotype control samples (PECy5.5-IgG, PE-
IgG and AF594-IgG respectively). Data is derived from 3 replicate samples and presented as mean percentage ± SEM. 
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Age of 
Pups 
(Days) 
Eng+ cKit+ CD90+ CD31+ 
cKit+/ 
CD90+ 
Eng+/ 
cKit+ 
Eng+/ 
CD90+ 
CD31+/ 
cKit+ 
CD31+/ 
CD90+ 
A* 6 90.2±1.2 30.2±0.5 22.1±0.3 25.8±1.1 1.4±0.1 29.6±0.5 20.9±0.2 24.9±0.3 1.6±0.1 
B 4 73.1±4.9 53.6±1.0 16.4±0.4 37.9±2.3 1.7±0.2 45.8±1.6 12.4±0.7 36.1±1.4 2.0±0.3 
C 5 70.5±0.8 13.9±0.8 15.6±1.7 19.5±0.9 0.7±0.2 13.3±0.9 9.2±0.2 11.7±0.9 5.7±1.5 
D 4 68.0±4.2 21.2±1.0 49.1±0.6 20.2±2.1 1.8±0.2 20.4±0.5 32.0±1.4 17.5±1.3 8.0±1.2 
E 4 88.5±0.6 56.5±0.6 18.3±0.2 n/a 0.8±0.2 54.4±0.9 16.5±0.2 n/a n/a 
F 5 68.0±0.8 23.7±0.7 11.9± 33.2±1.0 0.68±0.1 23.6±0.3 7.1±0.2 22.4±1.2 3.0±0.1 
Table 5.1. Summary of 6 independent FACS analyses performed with murine CDCs at passage 2. * denotes experiment illustrated in figure 5.5. 
Data is derived from 3 replicate samples and presented as mean percentage ± SEM. (n/a; CD31 stained samples were not included in this experiment).
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5.2.1.4. CDCs Do Not Represent a Haematopoietic Cell Population 
Flow cytometry demonstrated that passage 2 CDCs were predominantly negative for the 
haematological marker CD45 (2.1±23%, figure 5.6).  This result indicates that 
haematological-derived cells do not form a major component of ex vivo expanded 
cardiac-derived progenitor cells.  
 
 
Figure 5.6. CDCs at passage 2 are predominantly negative for CD45. (A) Flow 
cytometric analysis reveals a very low population of CDCs express the pan-leukocyte 
marker CD45 (anti-CD45 specific antibody conjugated to FITC), whereas CD45 is 
expressed by almost all cells isolated from adult bone marrow. (B) A representative dot 
plot showing the CD45+ population against side scatter. Data is derived from 3 replicate 
samples and presented as mean percentage ± SEM. 
 
5.2.1.5 Dynamic Expression of Endothelial, Mesenchymal and Stem 
Cell Markers following Extended CDC Expansion 
Dramatic differences were observed in the phenotypic profile for endoglin, cKit, CD90 
and CD31 following extended in vitro CDC expansion. Using flow cytometric based 
immunophenotyping I analysed the same preparation of CDCs at passages 2, 4 and 6 
and compared the marker profiles. This experiment was independently performed 3 
times and although results were variable there was a noticeable trend towards a down 
regulation of cKit, CD31 and endoglin expression, whereas the number of CD90 
positive cells increased in higher passage CDCs.  Figure 5.7 shows representative FACS 
plots depicting this trend, while table 5.2 summarises the results of all 3 experiments as 
a percentage of positive events for all cell populations analysed. Of particular 
importance cKit levels fell to negligible levels following multiple passages and endoglin 
expression was also markedly decreased. 
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Figure 5.7. Flow cytometric analyses of CDCs showing the down-regulation of 
endoglin, cKit and CD31 and up-regulation of CD90 following extended culture. 
CDCs were expanded until passage 6 and cells were sampled and analysed for the 
expression of endoglin, cKit, CD90 and CD31 at passage 2 (A, D, G and H), passage 4 
(B, E, H and K) and passage 6 (C, F, I and L). Histograms D and E show that cKit 
expression is appreciably decreased from passage 2 to passage 4 (from 21.1% to 4.7%) 
and decreases further by passage 6 (2.7%). A similar trend was observed for CD31 
expression with levels decreasing from 20.2% at passage 2 (J) to 2.1% at passage 4 (K) 
and falling to 1.7% at passage 6 (L). Endoglin is also markedly decreased following 
culture (passage 2, 68% (A), passage 4, 55.2% (B), passage 6, 15% (C) while CD90 was 
upregulated from 49% at passage 2 (G) to 92% at passage 6 (I). Data is derived from 3 
replicate samples and presented as mean percentage ± SEM. 
 
 
Eng+ 
%±SEM
 
cKit+ 
%±SEM
 
CD90+ 
%±SEM
 
CD31+ 
%±SEM
 
D* 
P2 68±4.2 21.2±1 49.1±0.6 20.2±2.1 
P4 55.2±2.8 4.7±0.4 78.2±0.4 2.1±0.5 
P6 15±4.2 2.7±0.6 92±0.5 1.7±0.8 
E 
P2 88.5±0.6 56.5±0.6 18.3±0.2 n/a 
P4 50±3.7 2.6±0.2 45.9±0.4 n/a 
P6 36.6±1.5 2.3±0.6 47±0.5 n/a 
F 
P2 68±0.8 23.7±0.7 11.9±0.2 33.2±1 
P4 58.6±3 2.8±0.6 7.7±0.3 3.6±0.5 
P6 49.4±5.6 2.3±0.3 9.1±0.1 0.8±0.2 
 
Table 5.2 Summary of 3 independent FACS analyses performed with murine CDCs at 
passages 2, 4 and 6. CDC cultures used for passage 2 (P2) FACS analysis in experiments D, E 
and F (table 5.1.) were further expanded and analysed for marker expression at passage 4 (P4) 
and 6 (P6). * denotes experiment illustrated in Figure 5.7. Data presented as mean percentage ± 
SEM, derived from 3 replicate samples. 
 
5.2.2. Endoglin Depletion in Engfl/fl;Rosa-CreERT2 CDCs 
5.2.2.1. Determining an Effective Dose of 4-Hydroxy-Tamoxifen to 
Achieve Efficient Endoglin Knock-Down in Engfl/fl;Rosa-
CreERT2 CDCs 
To achieve efficient knock-down of endoglin in CDCs I prepared cells from Engfl/fl; 
Rosa-CreERT2 mice. The Engfl/fl mouse model and inducible Cre-recombinase gene 
knock-out strategy is described in section 4.1. (figures 4.1 and 4.2). To achieve endoglin 
loss in CDCs a Rosa-CreERT2 transgene was used, which expresses tamoxifen-activated 
Cre recombinase under the regulation of the ubiquitously expressed Rosa26 promoter. 
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The conversion of tamoxifen to its active metabolite, 4-hydroxy tamoxifen (4OH-
tamoxifen), normally occurs in the liver in vivo therefore it is necessary to treat cells in 
vitro with 4OH-tamoxifen to activate Rosa-CreERT2.  
 
To determine the lowest effective dose and optimal treatment time of 4OH-tamoxifen I 
performed a series of dose titration experiments and determined the efficiency of 
endoglin deletion at the protein level using immunofluorescent staining. The percentage 
of endoglin positive cells within the total cell population is reduced following exposure 
to hydroxy-tamoxifen (table 5.3.). 
 
4OH-Tamoxifen Dose Treatment Time Endoglin Positive Cells (% ± SEM) 
Untreated Control n/a 92.9±3.2 
1µM 48h 76.8±7.1 
1µM 96h 55.4±8.4 
2µM 96h 23.2±5.0 
5µM 96h 27.0±5.6 
 
Table 5.3. Endoglin deletion in Engfl/fl;Rosa-CreERT2 CDCs following treatment 
with 4OH-tamoxifen; effect of 4OH-tamoxifen dose and incubation time. Endoglin 
expression was assessed using an anti-endoglin specific antibody and an alexa594 
conjugated secondary (see figure 5.8 for representative images of staining).  Cells 
stained positive for endoglin expression were counted in each of 12 fields of view per 
condition tested and results are presented as a percentage of positive cells per total cell 
number per field of view±SEM. 2µM 4OH-tamoxifen treatment for 96 hours is the 
lowest dose required to achieve efficient Cre activation and endoglin gene deletion in 
Engfl/fl;Rosa-CreERT2 CDCs. 
 
An initial dose of 1µM 4OH-tamoxifen with an exposure time of 48 hours was tested as 
we had previously shown this to be the most effective regime in the deletion of endoglin 
in a primary mouse lung EC line. However, I found this method to be insufficient, 
resulting in only a ~23% reduction in endoglin expression (table 5.3.). An increase in 
incubation time to 96hours significantly increased efficiency of deletion (approximately 
45%) indicating that endoglin protein expression was stable in these cells, however this 
rate of deletion was still insufficient to create an endoglin null phenotype therefore I 
performed a 4OH-tamoxifen dose titration experiment (ranging from 1µM to 5µM) with 
a 96hour exposure time (table 5.3). The lowest effective dose was identified as 2µM 
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(approximately 77% deletion) which was comparable to higher doses (approximately 
73% deletion achieved using 5µM 4OH-tamoxifen). For representative images see 
figure 5.8 and results are summarised in table 5.3. 
 
In tandem to using immunofluorescence to assay endoglin protein expression and 
deletion, I also investigated whether Cre enzyme activation was induced following 
4OH-tamoxifen treatment using CDCs derived from Rosa-CreERT2;Rosa26R mice. 
These cells express the Rosa26R lacZ reporter transgene and subsequent X-Gal staining 
was used to provide a read-out of Cre recombinase activity (see figure 4.4).  Cells were 
treated with 1-5µM 4OH-tamoxifen for 96hours prior to staining (figure 5.9). LacZ 
expression was inversely proportional to that of endoglin expression and showed 
maximum Cre activation with 2µM 4OH-tamoxifen treatment, which is in agreement 
with endoglin protein data. However, not all cells expressed lacZ suggesting that either 
4OH-tamoxifen was not taken up by all cells or that the Rosa26 promoter was not active 
in all cells and this Cre line could not therefore allow depletion of endoglin in 100% of 
CDCs  at passage 2. Nevertheless this line was the best available for the study and was 
used to generate knock-down of endoglin in approximately 80% of CDCs. 
 
Verification of endoglin knockdown at the DNA level was also analysed using PCR. I 
showed that following treatment with 2µM 4OH-tamoxifen exons 5 and 6 of the 
endoglin gene are successfully deleted in Engfl/fl;Rosa-CreERT2 CDCs which ultimately 
leads to the expression of a truncated and non-functional protein (figure 5.10). 
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Figure 5.8.  Endoglin gene deletion in Engfl/fl;Rosa-CreERT2 CDCs following treatment with 4OH-tamoxifen. Immunofluorescent anti-endoglin 
staining of passage 2 Engfl/fl;Rosa-CreERT2 CDCs; untreated cells (A) versus treatment with 1µM (B), 2µM (C) or 5µM (D) 4OH-tamoxifen for 
96hours. An anti-rat secondary antibody conjugated to alexa594 (red) was used and nuclei were stained with DAPI (blue). Inset image in (A) 
represents a no primary antibody control. 2µM 4OH-tamoxifen treatment is the lowest dose required to achieve maximum Cre activation and efficient 
endoglin gene deletion. Scale bar = 20µm. 
 
Figure 5.9. Titration of 4OH-tamoxifen and X-Gal staining of Engfl/fl;Rosa-CreERT2 CDCs carrying the Rosa26R reporter gene. X-Gal staining 
to detect LacZ expression (blue) in passage 2 cells treated with 1µM (B), 2µM (C) or 5µM (D) 4OH-tamoxifen for 96hours. Cells were counterstained 
with eosin (pink). 2µM 4OH-tamoxifen treatment is revealed as the lowest dose required to achieve maximum Cre activation. Untreated cells (A) show 
no LacZ expression. Scale bar = 20µm. 
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Figure 5.10. Assessing endoglin gene deletion in Engfl/fl;Rosa-CreERT2 CDCs. (A) 
Schematic of the Engfl/fl;Rosa-CreERT2 inducible knock out model showing the position 
of the primers used to assess endoglin gene deletion at the genomic DNA level.  Two 
PCR reactions using primers F6/R7 and F4/R7 amplify two different regions of the 
endoglin gene, which can be used to distinguish  between endoglin floxed and delete  
alleles (for further details of primers and PCR programmes see section 2.2.).  F6/R7 
primers detect the floxed allele and F4/R7 primers detect the delete allele. Primers 
F12/R13 detect DNA in both endoglin floxed and delete alleles and serve as a positive 
control. (B) Lanes 1-4 show PCR products from genomic DNA isolated from untreated 
Engfl/fl; Rosa-CreERT2 CDCs (lane 1) and  from cells treated with 4OH-tamoxifen for 96 
hours (lane 2=1µM, lane 3=2µM and lane 4=5µM). A reduction in the amount of F6/R7 
PCR product is evident in cells treated with 4OH-tamoxifen and F4/R7 PCR products 
are only present in treated cells. Lane 5 is a negative control (no DNA template) and 
lane 6 contains positive control genomic DNA with both floxed and delete endoglin 
alleles present. 
 
5.2.2.2. The Effect of Endoglin Depletion on CDC 
Viability/Proliferation 
Tamoxifen is known to have toxic effects which may affect subsequent analysis of 
cellular function therefore I performed a MTT assay to analyse viability/proliferation 
properties of CDCs following transient (96hour) exposure to 4OH-tamoxifen. Treated 
cells were re-plated in 96well plates and assayed for metabolic activity as previously 
described (section 3.2.5.1.). No significant difference was observed between untreated 
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and treated cells (range of 1µM-5µM 4OH-tamoxifen tested) as confirmed using 
ANOVA testing (figure 5.11A). These data indicated that 4OH-tamoxifen treatment of 
CDCs is safe without significant toxicity.  
 
Additionally I have shown that 4OH-tamoxifen treatment and endoglin depletion does 
not significantly affect cellular viability following serial passaging as cells were 
analysed using the MTT assay for up to three passages following endoglin deletion and 
no difference in viability was found (figure 5.11B). Therefore, in all subsequent 
experiments endoglin depletion was achieved by treating passage 2 CDCs with 2µM 
4OH-tamoxifen for 96hours. 
 
 
  
 
 
 
Figure 5.11. Achieving 
endoglin knockdown in 
Engfl/fl;Rosa-CreERT2 
CDCs by treating cells 
with 4OH-tamoxifen 
treatment has no effect 
on cell viability. (A) 
Engfl/fl; Rosa-CreERT2 
CDCs were incubated 
with or without 4OH-
tamoxifen (1µM, 2µM or 
5µM) for 96hours. The 
MTT assay revealed no 
significant difference in 
viability/ proliferation 
properties in untreated 
versus treated cells.  (B) 
No difference in viability 
was observed in untreated 
versus treated (2µM for 
96hours) CDCs following 
subsequent passaging. 
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5.2.3. Endoglin Depletion has a Modest Adverse Effect on CDC 
Proliferation and Migration 
Effective tissue repair is a complex process that involves a series of coordinated events 
including cell proliferation and migration. These properties were tested in WT versus 
Eng-iKO passage 2 (P2) CDCs in vitro to determine whether endoglin is important for 
proliferation or migration of CDCs.  Passage 1 Engfl/fl; Rosa-CreERT2 CDCs were 
treated with (Eng-iKO) or without (WT) 2µm 4OH-tamoxifen for 96hours, prior to 
passaging cells again (P2) and performing the analyses. Obtaining Eng-iKO and WT 
cells from the same starting culture allowed me to control for cell heterogeneity (see 
table 5.1) and tamoxifen was carefully washed away prior to passaging cells (P2) to 
remove any residual non-specific effects. 
 
To analyse cellular proliferation CDCs were seeded into multiwell plates and the growth 
curves of WT versus Eng-iKO cells were created using mean cell counts calculated 
from 3 wells per group (and from 4 fields of view per well) at 6 hourly intervals over a 
72 hour period (using the method described in section 2.5.1).  Endoglin depletion was 
associated with a declining cell growth rate (figure 5.12A), and at the 60 hour time point 
this difference became statistically significant (p=0.046). At 72 hours I observed the 
maximum significant difference in mean cell count between WT and Eng-iKO cells 
(p=0.009). Cell cultures were approaching confluence at this stage which precluded 
analysis at later time-points. The average cell doubling time was revealed to be 
markedly higher in Eng-iKO CDCs compared to WT controls (27.6±0.8 hours versus 
33.4±4 (p=0.07), figure 5.12B). 
 
The migration assay is described in section 2.5.3. This involved creating scratch 
‘wounds’ in sub-confluent monolayers of endoglin WT and Eng-iKO passage 2 CDCs 
using a sterile pipette tip. Cell migration was measured by calculating the extent of 
‘wound’ closure over 33 hours. Digital microscopy was used to record images at 3 
hourly intervals (3 fields of view per well per time point, 3 wells per group) and 
‘wound’  closure was determined at each time point by calculating migrated 
distance/total ‘wound’ distance using Axiovision Rel. v4.8 software (Zeiss) (for 
representative images see figure 5.13). Eng-iKO cells exhibited a slower rate of 
migration compared to control WT cells (figure 5.14A). At the end of the 33hour period 
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endoglin depleted CDCs had migrated a significantly shorter distance, covering 10% 
less of the wound area than WT control cells (74.2±1.8% versus 84.7±2% (p=0.001), 
figure 5.14B).  
 
These results suggest that endoglin loss has a significant, yet modest effect on CDC 
proliferation and migration. 
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Figure 5.12. Inhibitory effect of endoglin depletion on CDC proliferation. (A) CDCs (Wild-Type, blue) or (Eng-iKO, red) were seeded at 30-40% 
confluence in multiwell plates and phase contrast microscopy was used to record images at 6hourly intervals for 72hours. Cell number was counted at 
each time point (each data point represents the mean value derived from a minimum of 9 fields of view).  Analysis revealed a significant reduction in 
Eng-iKO CDC count from 60h onwards with maximum reduction observed at 72h. (B) The mean doubling time of cells was calculated and found to be 
markedly higher in Eng-iKO cells (27.6±0.8 hours versus 33.4±4 hours, p=0.07). Experiments were independently performed three times to confirm 
results and statistical significance was determined using the unpaired t-test. Error bars = SEM. (* p<0.05, ** p<0.01). 
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Figure 5.13 Representative images of CDC scratch-‘wound healing’ assay comparing control and Eng-iKO CDCs. Control (top panel) and Eng-
iKO (bottom panel) CDCs were grown to 80-90% confluence, wounded with a scratch and maintained in full CDC medium to facilitate cell migration. 
The migration and proliferation of cells into the ’wounded area’ resulted in gradual sealing of the scratch. Cell migration into the ‘wounded’ area was 
recorded by phase contrast microscopy over a 33 hour time course at 3 hourly intervals (6 hourly interval representative images shown). Scale 
bar=0.5mm. 
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Figure 5.14. Inhibitory effect of endoglin depletion on CDC migration. (A) Representative scratch-migration assay displaying significant reduction 
in migration rate (p=0.001) in Endoglin depleted CDCs over a 33h time course. ‘Wound’ closure was determined at 3 hourly intervals by calculating 
migrated distance/total original ‘wound’ distance using Axiovision Rel. v4.8 software (Zeiss). Each data point represents the mean value calculated 
from a minimum of 9 fields of view.   (B) Graphical display of decreased ’wound’ closure by endoglin knock down CDCs at 33 hours (p=0.001). Data 
are presented as percentage of original wound area ± SEM. Experiments were repeated independently three times to confirm results and statistical 
significance was determined using the unpaired t-test. * denotes p < 0.05. 
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5.2.4. The Effect of Endoglin Depletion on TGFβ Signalling  
5.2.4.1. The Effect of Endoglin Depletion on TGFβ Receptor 
Expression in CDCs  
The expression of TGFβ pathway receptors in CDCs were assessed at the RNA level 
using semi-quantitative RT-PCR and results were compared between WT and Eng-iKO 
CDCs. I detected the expression of all the receptors analysed (Tgfbr2, Bmpr2, Alk1, 
Alk5 and endoglin) in both WT and endoglin depleted cells (figure 5.15). I observed a 
moderate increase in Tgfbr2 and a slight decrease in Alk1 transcript levels, as well as 
confirmed a marked reduction in endoglin expression in Eng-iKO samples. 
Unfortunately due to time restraints the analysis was only performed once precluding 
statistical testing. rtPCR using the house-keeping gene β-actin was used as a loading 
control, while ‘no RNA’ template reactions and mouse lung endothelial cells were 
included as negative and positive controls, respectively.  
 
 
 
Figure 5.15. RT-PCR analysis of TGFβ receptor expression in CDCs with and 
without endoglin depletion. Representative images of TGFβ receptor expression in 
WT (lane 1) and Eng-iKO (lane 2) passage 2 CDCs. Lane 3 is a negative control (no 
RNA template) and lane 6 contains positive control RNA derived from primary mouse 
lung ECs. The intensity of Tgfbr2 expression, following 4OH-tamoxifen treatment 
expression appears marginally increased whereas endoglin expression is significantly 
reduced.  
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5.2.4.2. Analysis of Downstream Smad Activation in Wild-Type 
versus Endoglin Depleted CDCs 
To determine how loss of endoglin affects TGFβ signalling in CDCs, I examined the 
phosphorylation of Smad2 and Smad1/5 (downstream targets of TGFβ/Alk5 and 
TGFβ/Alk1 signalling respectively) in WT versus Eng-iKO cells using western blotting 
and antibodies that specifically recognise the phosphorylated forms of these Smad 
proteins. Both WT and Eng-iKO cells were treated with or without TGFβ1 (5ng/ml) or 
BMP9 (1ng/ml) ligands for 30, 60 or 120 minutes and cell lysates (containing total 
protein extracts) were subjected to western blotting (see section 2.8 for further 
methodological details). In WT cells TGFβ1 ligand stimulated an appreciable increase 
in Smad2 phosphorylation in a time-dependent manner (figure 5.16B) whilst phospho-
Smad1/5/8 expression was elevated to a lesser extent and transiently peaked at 
60minutes (figure 5.16A). The reciprocal pattern was observed in BMP9 treated cell 
samples which showed a time-dependent increase in Smad1/5 phosphorylation (figure 
5.16A) and a transient peak of phospho-Smad2 levels at 60 minutes, which was greatly 
diminished in cell samples stimulated with BMP9 for 120 minutes (figure 5.16B).  
 
To determine the effect of endoglin knock down on downstream TGFβ signalling 
pathways, phospho-Smad responses in response to TGFβ or BMP9 ligands were 
compared in WT and  endoglin depleted CDCs. Whilst phospho-Smad1/5 levels 
appeared to be relatively unchanged in Eng-iKO CDCs (figure 5.16A), phospho-Smad2 
levels were dramatically increased in all endoglin depleted samples (figure 5.16B). 
Western blots were stripped and re-probed (see section 2.8 for details) with antibodies 
against total Smad1 and Smad2 proteins and α-tubulin, which acted as loading controls. 
Endoglin protein levels were extremely low in Eng-iKO cell samples confirming 
efficient knockdown (figure 5.16). 
 
   167 
Figure 5.16. Endoglin loss in CDCs leads 
to increased Smad2 phosphorylation in 
response to TGFβ1 and BMP9 
stimulation. Whole cell protein extracts 
from wild type and endoglin knock-out 
CDCs were subjected to western blotting to 
establish levels of phosphorylated smad1/5 
(A) and phosphorylated Smad2 (B). Cells 
were stimulated with TGFβ1 (5ng/ml) or 
BMP9 (1ng/ml) ligands (prior to preparing 
lysates) where indicated for times specified 
(30, 60 or 120 minutes).  Endoglin loss 
leads to an increase in TGFβ/Alk5 
signalling (Smad2 phosphorylation) in 
response to TGFβ1 and BMP9 ligand 
treatment. Phosphorylation of Smad1/5 is 
not notably different. Blots were stripped 
and re-probed with specific antibodies 
against Smad2 or Smad1/5 and α-tubulin 
was included as a loading control. Blots 
were also probed using an anti-endoglin 
antibody to confirm that endoglin is 
depleted in Eng-iKO CDCs. 
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5.3. Discussion 
5.3.1. Heterogeneity of Murine CDCs; Significance and Practical 
Implications 
FACS based immunophenotyping of CDCs revealed marked inter-culture variation in 
endothelial (CD31, endoglin), mesenchymal (CD90, endoglin) and stem cell-related 
(cKit) marker expression in cells expanded to passage 2. The functional significance of 
this observation was not tested but it is prudent to consider that variations in the specific 
composition of this heterogeneous population could have important effects on the 
functional capacity of these cells.  For example, do high cKit expressing cultures 
possess increased repair potential?, and if the CD90 sub-population is indeed 
responsible for providing physical or paracrine support to the cKit  sub-population (as 
proposed by Smith et al159) is there a threshold level of expression for efficient function?  
These proposals remain to be explored, however we are currently investigating methods 
to increase CDC expression of cKit and Sca-1 expression (including preconditioning 
cells in hypoxic conditions) prior to testing their ability to contribute to repair 
(specifically their pro-angiogenic potential) following heart injury, as well as 
performing lineage tracing experiments using Col1a2-CreERT2 mice to deduce what 
proportion of CDCs are derived from the collagen producing cells of the heart (the 
fibroblast lineage)331.  
 
The post-cardiosphere CDC expansion step aims to generate a clinically feasible 
number of cells for transplantation from small amounts of tissue159.  However, the stark 
difference in CDC antigenic profile or ‘phenotypic drift’ following extended ex vivo 
expansion (up to 6 passages) suggests that CDCs may have a limited useful lifespan. 
For example the loss of cKit expression in later passages indicates the stem cell 
component of the population may be diluted by less useful cell types and late passage 
CDCs may have a reduced potential for heart repair. Further investigation would be 
required to test this hypothesis. However, careful profiling of the heterogeneous CDC 
population along with functional testing may aid in the identification of an optimal 
mixture of ex vivo expanded cardiac-derived progenitor cells and may also help to 
elucidate key mechanisms of tissue repair.    
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As there is intrinsic variability between cultures of CDCs, I have continuously 
endeavoured to reduce inter-culture variation by following a strict culture protocol (see 
section 2.3.1.2). Davis et al175 claim that even subtle variations in technique can 
markedly alter CDC phenotype, for example this group claim that the inclusion of an 
EDC filtration step (suggested by Andersen et al174 to remove contaminating 
myocardial tissue from subsequent culture steps) can result in the enrichment of 
fibroblasts. Another possible point of variation is the sex of donor pups  used to derive 
CDCs. Differences in stem cell mechanics and repair efficiency have been attributed to 
gender, with female muscle-derived stem cells332 and BM-MSCs333 displaying increased 
tissue regeneration capacity in comparison to male-derived cells. This would suggest 
that stem cell gender could in principle affect CDC phenotype.  Conversely, Drowley et 
al334 have found that sex of donor muscle-derived stem cells had no significant effect on 
cell engraftment, angiogenesis or cardiac function following experimental MI.    Due to 
the difficulty of sexing young pups I did not record the gender of pups used in this study 
(although this could be done by PCR) therefore it is possible that this may have played a 
role in CDC variability. However, given the conflicting published findings this issue 
remains open to debate. In addition, the age of the neonatal mice used may have 
influenced phenotypic variability between independent CDC cultures. In this thesis, 
mice aged between 3 and 6 days were used to derive CDCs in a bid to maintain 
consistency.  However notable differences in the expression of stem, endothelial and 
mesenchymal markers were observed in cultures derived from mice of the same age 
(see table 5.1) indicating that variability in outcomes may be due to stochastic events or 
unknown variables. Finally differences in FCS (which was not batch-tested) contained 
within the culture media may have influenced cell phenotype and inter-culture variation. 
 
5.3.2. Suitability of using Murine Neonatal Cardiac Tissue to Derive 
and Study Progenitor Cells 
There is a recognised inverse relationship between increasing stem cell age and 
decreased functional capacity. Therefore it has been suggested that stem cells derived 
from younger patients may be better adapted in times of stress, such as during/post 
ischaemia, and thus offer superior repair potential.  Indeed, Madhur et al335 found that 
BM-MSCs from younger adult donors displayed significantly improved functional 
benefit following transplantation into rats following MI. Given the effect of increasing 
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age on adult stem cells it is likely that significant differences will also exist between 
neonatal stem cells and their adult counterparts. Markel and colleagues336 found that 
neonatal BM-MSCs exhibited functional and key cell signalling differences compared 
to their adult derived counterparts.  Of particular importance, whilst a noted decrease in 
neonatal IL6 (compared to adult) suggested that neonatal stem cells may assist in 
decreasing adverse local inflammatory responses following MI, a decrease in neonatal 
VEGF production (compared to adult) inferred that these cells may be stunted in their 
ability to stimulate angiogenesis and stem cell survival. Markel et al337 later reported 
that neonatal and adult BM-MSCs are distinctly different with respect to the level of 
tissue protection and repair potential following experimental MI. Adult stem cell 
transplantation resulted in a significantly greater improvement in myocardial function 
than was achieved using neonatal cells. The authors suggest that a critical age may mark 
when stem cells become fully primed for repair. It remains unclear whether neonatal 
cells have distinct roles or differing efficacy in cardiovascular repair compared to their 
adult counterparts or indeed whether or not any such differences would be cell type or 
source tissue dependent. However it is known that whilst some human neonatal tissue 
(umbilical cord, foetal membrane and placenta) represent plausible sources of clinically 
relevant stem cells, derivation of human neonatal cardiac resident stem cells is not 
clinically feasible or ethical. Despite this, the practical consideration of ease of culture 
of neonatal CDCs compared with adult CDCs allows an opportunity to try and define 
the mechanisms that improve stem cell treatment efficacy, irrespective of age, to better 
inform work using more clinically relevant cell populations. 
 
5.3.3. The Effect of Endoglin Depletion on CDC Function and 
TGFβ Signalling in vitro 
One of the major aims of this chapter was to investigate the effect of endoglin depletion 
on properties of CDCs that relate to tissue repair and TGFβ signalling. 
 
Interestingly I found that whilst endoglin depletion had no effect on passage 2 CDC 
viability/proliferation using the MTT viability assay there was a modest, yet significant, 
negative effect on CDC proliferation detected using a simple cell counting method. The 
reasons for these disparate results are likely the time differences involved in the assays 
as well as the manner of assessment. Whereas the MTT assay only measured metabolic 
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activity and therefore indirectly cell proliferation for up to 24 hours, simple cell 
counting, which represents a more direct method of assessment, did not detect a 
significant difference in cell number until 60hours had elapsed. This together with the 
reduced migratory potential of passage 2 Eng-iKO CDCs as assessed using the scratch 
assay (which measures a combination of proliferation and migration) agrees with my 
original hypothesis stating that endoglin is a positive mediator of cardiac resident stem 
cells and suggests that endoglin depletion may impair the repair potential of these cells.  
 
Unexpectedly, despite endoglin’s reported role in promoting activation of the Alk1 
pathway237 I found that endoglin knockdown in unstimulated CDCs had little effect on 
Smad1 phosphorylation. Furthermore, although endoglin depletion has been shown to 
reduce TGFβ1 and BMP9 induced Smad1 responses in many cell types237, 338-339, little 
difference was observed in phopsho-Smad1 levels in CDCs treated with either ligand 
following endoglin depletion while the Smad2 response was markedly increased in 
response to TGFβ1 and moderately increased following BMP9 stimulation of Eng-iKO 
cells.  These results are in contrast to those of Santibanez et al340 who have reported that 
endoglin enhances Smad2 activation by stabilising Smad2 protein levels and 
potentiating TGFβ signalling in ECs. However my findings do agree with those of 
Finnson and colleagues339 who found that endoglin inhibits TGFβ-induced Smad2 
phosphorylation in human chondrocytes. These studies illustrate the cell type-specific 
and context dependent roles of endoglin. In CDCs it appears that endoglin represses 
Alk5/Smad2 signalling whereas endoglin loss has little effect on the Smad1 response. 
This may be due to an adaptive response which sees an increase in Alk1/Smad1 
signalling in response to reduced endoglin levels. This proposed model is in contrast 
with the adaptive process suggested by Lebrin et al204 who show reduced Alk5 
expression in endoglin depleted cells. However no difference in Alk5 expression was 
observed in Eng-iKO CDCs, whereas a slight decrease in Alk1 expression was found 
using semi-quantitative RT-PCR (figure 5.15). 
 
In endoglin knockout embryos, activation of Smad2 is abolished within the endothelium 
but treatment with TGFβ1 results in phosphorylated Smad2 levels that exceed those 
observed in WT mice341. My results also show an increase in Smad2 phosphorylation in 
Eng-iKO TGFβ1 treated CDCs suggesting that following endoglin depletion 
Tgfbr2/Alk5 complexes on the surface of CDCs can be activated by exogenous TGFβ1 
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treatment. However unstimulated mutant cells also showed equivalent or modestly 
increased levels of phosphorylated Smad2 compared to WT CDC samples.  This may be 
related to the reported activation of Smad2 in the endocardium of hearts from endoglin 
mutant embryos341, proposedly due to Alk4 or Alk7 compensatory signalling pathways 
which have also been implicated in the activation of Smad2 in Alk5 mutants342.  It 
would therefore be interesting to assess whether increased levels of Alk4 are present in 
Eng-iKO CDCs.  
 
Technical issues may also be of importance in the analysis of TGFβ signalling 
responses. Variable endoglin expression in CDC cultures (approximately 70-90%, table 
5.1) may at least partly explain my findings and greater differences in Smad1 
phosphorylation may be observed in cultures pre-selected for endoglin expression using 
FACS sorting. Similarly high levels of stimulating ligand may be present in the culture 
media (supplemented with 20% FCS) thus generating a high basal Smad 
phosphorylation response (as is evident in figure 5.16) which could theoretically mask 
the effect of exogenous ligand application or endoglin loss. To remove this possibility 
one option would be to titrate the FCS contained within the media, however this may 
adversely affect cell growth/function therefore another viable option would be to pre-
treat cells with an Alk5 kinase inhibitor or Noggin to lower basal Smad2 and Smad1/5 
responses respectively prior to western blotting. 
 
As discussed previously the role of endoglin within TGFβ signalling and angiogenesis 
remains incompletely understood, however it is accepted that this role is likely to be cell 
type specific and context dependent. The significance of my findings require further 
investigation, including a more detailed study of the effect of ligand time/dose 
concentration on Smad1/5 and Smad2 phosphorylation, and the expression of a panel of 
downstream genes such as Id1 and Pai1 that are upregulated specifically by Alk1/TGFβ 
and Alk5/TGFβ, respectively.  In addition as both BMP9-induced Smad1 and Smad2 
phosphorylation have been identified to be mediated via Alk1/Bmpr2 and/or Alk1/Actr2 
signalling240 it would also be important assess what proportion of CDCs express Alk1 
using FACS. Finally, as previously mentioned, it would be advantageous to sort the 
endoglin positive CDCs using flow cytometry to provide a pure population for 
investigating the effect of endoglin knock-down on cell signalling and function. 
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Paracrine mechanisms are thought to be responsible for a large proportion of CDC 
mediated cardiac repair187. This may in part be due to a pro-angiogenic mechanism. 
Therefore in addition to testing the effect of endoglin depletion on cellular responses 
associated with angiogenesis, such as proliferation and migration, it will also be 
important to evaluate the effect of endoglin loss on pro-angiogenic cytokine production. 
Endoglin heterozygote ECs display increased collagen production and decreased NO 
synthase expression and VEGF secretion, which results in reduced angiogenic 
responses343.  It is possible that endoglin loss could impair CDC-mediated therapeutic 
angiogenesis in a similar manner. Although time restraints excluded this analysis from 
the present study it would be of major interest to investigate the effect of endoglin loss 
on pro-angiogenic cytokine production in CDCs.  
 
Endoglin loss in CDCs results in perturbed cellular proliferation, migration and there 
was also a notable effect on TGFβ and BMP signalling through Smad2. Although the 
effects were modest they may nevertheless be important during heart repair and may 
also affect pro-angiogenic signals that would require further investigation. In order to 
determine whether this would be a fruitful avenue to pursue, I first performed a 
functional test in a pilot group of animals to examine whether endoglin depletion had 
any effect on the ability of CDCs to promote heart repair, either directly on donor cell 
retention and differentiation, or indirectly via pro-angiogenic effects. To this end, I 
developed a murine model of MI and performed intramyocardial CDC transplantations 
to compare the extent of any heart repair mediated by WT versus and Eng-iKO cells. 
This study is discussed in chapter 6. 
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CHAPTER 6. 
 
Investigating the Role of 
Endoglin in CDC-Mediated 
Heart Repair in vivo 
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6.1. Introduction 
Therapeutic angiogenesis following cardiac ischaemic injury aims to re-establish an 
adequate blood supply to the affected myocardium to minimise further damage caused 
by cardiac cell death. Transplanted cardiospheres and/or CDCs exert their cardio-
protective effects, in part, by augmenting neovascularisation via either direct vascular 
differentiation or paracrine enhancement of angiogenesis159, 187.  As discussed in section 
1.9, TGFβ family signalling is pivotal to blood vessel formation and homeostasis and 
endoglin has a critical role in the regulation of both vascular remodelling and 
angiogenesis344. Previous work has shown that reduced endoglin levels in circulating 
mononuclear cells (Eng+/- cells derived from HHT1 patients) affects their homing ability 
and subsequently leads to impaired neovascularisation and accentuated deterioration of 
cardiac function following MI275-276. In chapter 5 I demonstrated that endoglin depletion 
results in impaired CDC proliferation and migration in vitro as well as perturbed 
canonical TGFβ signalling. I propose that the high level of endoglin expressed by CDCs 
is critical to their pro-angiogenic activity. Establishing an important functional role for 
endoglin in a cardiac derived stem cell population will enable the exploitation of the 
pro-angiogenic properties of this receptor in the development of stem cell therapies and 
will aid our understanding of the mechanisms underlying cell-mediated heart repair.   
 
To confirm the ability of murine WT-CDCs to promote neovascularisation and improve 
cardiac function in vivo I first established a surgical mouse model of permanent 
coronary artery occlusion combined with direct intramyocardial CDC transfer. To 
investigate the subsequent effect of endoglin loss on donor cell mediated cardiac repair 
process following MI, transplanted CDCs were derived from Engfl/fl;Rosa-CreERT2 mice 
which enabled endoglin to be knocked out in vitro (Eng-iKO CDCs) using Cre/loxP 
recombination (as described in section 4.1.).  
 
Pre-clinical models of MI have been described in several animal species with the pig 
ameroid model thought to most closely resemble human physiology and the clinical 
phenotype345. However the expense and practical demands of large animal surgery 
significantly limits the use of such studies to test novel therapeutic approaches. Cardiac 
surgery in mice is extremely technically challenging due to their small size and fast 
heart rate, however they are of particular interest because of the increasing availability 
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of useful transgenic and knock-out mouse strains. A rodent MI model was first 
developed over 3 decades ago346 and later a murine model of ischaemia/reperfusion was 
described347. Distinct pathohistological differences have been observed between the 
reperfused and permanent coronary artery occlusion models of MI348-349. Briefly, less 
myocardial damage is observed in reperfused hearts compared to their non-reperfused 
counterparts due in part to a higher inflammatory cell influx and enhanced angiogenic 
response following the restoration of blood flow348. Reperfusion is currently the 
preferred clinical therapy for MI patients therefore the ischaemia/reperfusion technique 
provides a more clinically relevant model of heart injury. However the permanent 
occlusion model is still useful for some basic science studies. For example, the greater 
and accelerated inflammatory response associated with reperfusion may directly 
interfere with delivered cells (e.g. the greater number of macrophages may increase 
phagocytosis and removal of donor cells) and would have important implications 
regarding the timing of experimental intervention. Moreover, following reperfusion the 
healing response is made more complex due to the effect of ‘reperfusion injury’, 
whereas the response of permanent occlusion is mainly dependent on the effect of 
ischaemia on the heart. Therefore the permanent occlusion model is arguably more 
suited to ‘proof of principle’ studies that aim to identify important genes or proteins that 
may aid the development of novel therapies such as proposed in this study.  
 
As described in chapter 1 (section 1.2), the cardiac healing response following MI 
results in significant structural and functional changes. This frequently results in 
detrimental ventricular remodelling, which ultimately leads to deterioration of cardiac 
function. Global left ventricular (LV) function is often used as a measure of LV 
remodelling in many pre-clinical studies assessing the repair potential of novel 
therapies. In the current study, cine cardiac MRI was used by my colleague Dr Ben 
Davison to assess cardiac functional parameters of my mouse models. The 1 and 4 week 
time points following infarction were chosen because the maximum angiogenic 
response has been observed 1 week following infarct275 and at 4 weeks LV remodelling 
and fibrosis is essentially resolved in mice12. 
 
Following the initial healing process, the surviving myocardium can be divided into 
tissue bordering the infarct and remote myocardium. The infarct border zone 
corresponds to the tissue adjacent to the area of ischaemia and fibrosis, in which 
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myocytes are initially in a state of reversible injury. Due to a reduction in border zone 
capillary density this region constitutes an area at risk even after the completion of the 
healing process350.  Therapeutic strategies aim to salvage this jeopardised tissue and 
decrease the level of myocardial necrosis and infarct extension. In this study CDCs were 
injected directly into the infarct border zone immediately following coronary artery 
occlusion. After 4 weeks, the effect of CDC transfer (with and without endoglin 
expression) on neovascularisation was assessed by quantifying vessel density in the 
ischaemic border zone using immunofluorescent staining. 
 
6.2.  Results 
6.2.1. Establishing the Mouse Surgical Myocardial Infarction 
Model  
I established a mouse model of acute MI at Newcastle University using a protocol 
described by van Laake et al351 (see section 2.12 for detailed protocol). Briefly adult (12 
to 14 weeks old) mice from a C57Bl/6 genetic background were intubated and 
mechanically ventilated with 2% isoflurane/98% oxygen. The left anterior descending 
(LAD) coronary artery was exposed following left side thoracotomy in the fourth 
intercostal space and was occluded using a 7-0 prolene ligature just below the inferior 
border of the left atria. Successful infarction was characterised by immediate blanching 
of the LV free wall, which forms a clear border between ischaemic and non-affected 
myocardium (figure 6.1), as well as reduced motility of the infarcted area. Sham-
operated control mice were also subjected to left-side thoracotomy without coronary 
artery occlusion.  
 
 
Four weeks following experimental MI mice were humanely killed and the hearts were 
removed and processed to prepare paraffin sections for Masson trichrome staining (see 
section 2.9.2.2.). This stain illustrates the structural changes associated with ventricular 
remodelling including LV chamber dilatation with thinning of the free wall, extensive 
collagen deposition and established fibrosis with mature scar formation (figure 6.2). 
   178 
 
Figure 6.1. Image of a murine heart 24 hours following the occlusion of the LAD 
coronary artery. (A) MI was achieved by placing a 7-0 prolene ligature (blue) around 
the LAD coronary artery below the inferior border of the left atria. (B) The position of 
the LAD coronary artery has been digitally enhanced (black) to aid visualisation. (C) 
The ischaemic myocardium (pale zone) represents the area at risk and extends over the 
interventricular septum to the basal-posterior region. The inner and outer boundaries of 
the ischaemic border zone are delineated by dashed black lines and white X’s mark the 
CDC injection sites (see section 6.2.2.1.).  
 
 
Figure 6.2. Remodelling and fibrosis of infarcted mouse heart. (A) Masson 
trichrome staining of sham-operated control heart showing normal morphology. (B) 
Mouse heart 4 weeks post-MI; note the extensive remodelling and thinning of the left 
ventricular free wall and extensive collagen deposition/fibrotic regions (blue staining) 
plus small islands of viable myocardium within the scar tissue (red)).Abbreviations: rv, 
right ventricle; lv, left ventricle. Scale bar = 10µM.  
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To demonstrate that we were able to identify and quantify changes in LV function using 
cardiac cine MRI we measured LV functional parameters in small cohorts of infarcted 
(n=10) and sham-operated (n=8) mice 4 weeks following surgery. 
 
 
 
Figure 6.3. Cine MR images of a sham operated mouse heart (A to C, diastole; D to F, 
systole) and 4 weeks following coronary artery occlusion (G to I, diastole; J to L, 
systole). Images of the sham-operated heart show normal wall thickness and motion 
whereas following MI increased left ventricular volume as well as wall thinning and 
akinesis in the anterolateral and apical regions is evident (red arrows).  Abbreviations: 
lvc, left ventricular cavity; rvc, right ventricular cavity; lvw, left ventricular wall; rvw, 
right ventricular wall; la, left atrium; ra, right atrium; pm, pulmonary muscle. Images 
courtesy of Dr Ben Davison. 
 
Representative MRI images (figure 6.3) clearly show the increased dilatation of the LV 
4 weeks following LAD coronary artery occlusion, with marked myocardial wall 
thinning in comparison to sham controls (figure 6.3G-L, red arrows indicate regions of 
myocardial akinesis in the anterolateral and LV apical walls). MRI-assessed LV 
functional parameter measurements for both sham control and infarcted mice (4 weeks 
post-MI) are shown in table 6.1. Mean myocardial mass and LV volume indices were 
significantly greater in the MI group (myocardial mass index, 4.9±0.1 versus 3.9±0.2 
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(p<0.001); end diastolic volume index (EDVI), 5±0.5µl/g versus 2.3±0.1µl/g (p<0.001); 
end systolic volume index (ESVI), 3.8±0.5µl/g versus 0.76±0.05µl/g (p<0.001)), 
whereas stroke volume index (SVI), ejection fraction (EF) and cardiac output index (CI) 
were all significantly reduced compared to sham operated mice (SVI, 1.2±0.04µl/g 
versus 1.6±0.1µl/g (p=0.008); EF, 26.6±2.8% versus 67.1±0.9% (p<0.001); CI, 
0.5±0.02ml/min/g versus 0.64±0.05ml/min/g (p=0.05). N.B. to account for the 
significant difference in pre-operative body weight (p=0.02) between sham and MI 
mice, which is due to dissimilar proportions of male and female mice included in each 
group, indices measurements (data normalised to pre- operative body weight) were 
calculated for all parameters. Cardiac MRI was able to identify changes related to LV 
remodelling following MI and thus was used to assess the effect of cell transplantation 
in this disease model.   
 
 
SHAM 
n=8 
INFARCT  
n=10 
t-test 
p Value 
Sex 
Age at Infarct (weeks) 
Pre-operation Weight (g) 
5M 3F 
12.4±0.5 
29±1.3 
3M 7F 
12±0.4 
25.2±0.9 
n/a 
n/s 
0.020 
Mean HR(bpm) 409±9.5 416±12.1 n/s 
CO(ml/min) 18.2±0.8 12.6±0.7 <0.001 
CI (ml/min/g) 0.64±0.05 0.5±0.02 0.050 
Mean myocardial mass (mg) 111.9±1.7 122.3.7±2.9 0.011 
Mean mass index (mg/g) 3.9±0.2 4.9±0.1 <0.001 
EDV (µl) 66.4±1.6 116.7±11.5 0.001 
EDVI (µl/g) 2.3±0.1 5±0.5 <0.001 
ESV (µl) 21.8±0.9 85.1±12.5 <0.001 
ESVI (µl/g) 0.76±0.05 3.8±0.5 <0.001 
SV (µl) 44.6±1.5 30.4±1.3 <0.001 
SVI (µl/g) 1.6±0.1 1.2±0.04 0.008 
EF (%) 67.1±0.9 26.6±2.8 <0.001 
Infarct Size (% LV) n/a 36.2±1.8 n/a 
Table 6.1. Functional analysis of global left ventricular function in sham-operated mice 
(n=8) and 4 weeks following LAD coronary artery occlusion (n=10). Data is presented 
as mean ± SEM. Statistical differences between sham and infarct groups were calculated 
using the Student’s t test for all parameters, p-values < 0.05 are considered statistically 
significant and are highlighted in red. Abbreviations: HR, heart rate; CO, cardiac 
output; CI, cardiac index; EDV, end diastolic volume; EDVI, end diastolic volume 
index; ESV, end systolic volume; ESVI, end systolic volume index; SV, stroke volume; 
SVI, stroke volume index; EF, ejection fraction; LV, left ventricle. n/a = not applicable, 
n/s = not significant (p > 0.05). MRI data analysis performed by Dr Ben Davison. 
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Post-surgical survival rates were deduced from a cohort of 28 infarcted mice that were 
sacrificed 4 weeks following surgery. In this experimental group, my peri-operative 
(within 24 hours) survival rate was 100%, while 4 week survival was 86% (figure 6.4), 
which is superior to survival rates reported in similar studies (approximately 50-
63%)352. Additionally, I observed a 100% survival rate in a smaller cohort of mice (n=6) 
that were permitted to live for 12 weeks following MI demonstrating that this model is 
compatible with high survival rates over extended periods. 
 
 
Figure 6.4. Survival of mice at 4 weeks following MI. Survival data shows high 
survival rates (86%) reflecting good surgical technique. Sham operated control survival 
was 92%. (MI, n = 28; Sham, n = 12).   
 
In summary I established a reliable model of experimental MI to test the ability of 
CDCs to contribute to heart repair in vivo and using an inducible endoglin knock-out 
mouse model I subsequently tested the effect of endoglin loss on the repair potential of 
these cells.  
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6.2.2. Investigating the Role of Endoglin in CDC Mediated 
Cardiac Repair  
6.2.2.1. Wild-Type CDC Mediated Heart Repair following MI 
To test the ability of CDCs to contribute to heart rescue following ischaemic injury, 
cells (at passage 2) were injected directly into the ischaemic border zone immediately 
following surgical MI. In order to allow donor cell tracking in cardiac rescue 
experiments CDCs were genetically tagged with enhanced green fluorescent protein 
(eGFP) using the CAG-farnesylated-eGFP line (unpublished line kindly given by 
Professor Alexander Medvinsky, Edinburgh University). In this line eGFP expression is 
driven by the ubiquitous CAG promoter which is a combination of the chicken β-actin 
and the CMV promoters, whilst the farnesyl group anchors eGFP to the cell membrane. 
The majority of passage 2 CDCs derived from Engfl/fl;Rosa-CreERT2;CAG-farnesyl-
eGFP mice express eGFP (92.5±1.7%), which was readily detected by FACS analysis 
(Figure 6.5A, B). However, endogenous eGFP expression was difficult to detect using 
fluorescent microscopy (Figure 6.5C). Therefore staining was performed using anti-
GFP antibody conjugated to alexa488 (Figure 6.5D). This antibody was also required to 
detect endogenous eGFP in cryosections of heart tissue from Engfl/fl;Rosa-
CreERT2;CAG-farnesyl-eGFP mice. 
 
It was important for the work described in this chapter to specifically identify which 
cardiac cell lineages express eGFP to enable the identification of cell types that are 
derived from donor cells following the transplantation of CAG-farnesyl-eGFP CDCs. 
Therefore colocalisation experiments were performed on cryosections of the CAG-
farnesyl-eGFP mouse heart to examine the co-expression of eGFP with CD31 (a 
specific marker of endothelial cells), α-actinin (a marker of cardiomyocytes) and α-
SMA (a marker of vascular smooth muscle or myofibroblasts). I found that only a small 
proportion of ECs in the heart express eGFP (figure 6.6 C and D), whilst expression in 
cardiomyocytes is strong and uniform (figure 6.6G). Interestingly, I observed 
perivascular eGFP expression (figure 6.6H) although only some vascular smooth 
muscle cells expressed eGFP (figure 6.6E and F). These findings suggested that using 
this line, only a subpopulation of eGFP positive cells would be detected following 
transplantation and differentiation into ECs or SMCs, although the majority of CDCs 
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that had differentiated to cardiomyocytes would be detectable. Further details on 
tracking and identification of transplanted CDCs in vivo are described in section 6.2.4.   
 
 
 
 
Figure 6.5. Expression of eGFP in passage 2 CDCs derived from CAG-farnesyl-
eGFP mice. (A) Flow cytometric analysis reveals that the majority of passage 2 CDCs 
from Engfl/fl;Rosa-CreERT2;CAG-farnesyl-eGFP mice express eGFP (92.5±1.7%), 
whereas negligible GFP expression is detected in CDCs derived from C57Bl/6 mice 
(1.6±1%). (B) A representative histogram showing the CDC eGFP positive population. 
Data was derived from 4 replicate samples and is presented as mean percentage ± SEM. 
(C-E) Representative fluorescent microscopy images of passage 2 CDCs from 
Engfl/fl;RosaCreERT2;CAG-farnesyl-eGFP mice showing endogenous eGFP expression 
(C), following immunostaining with a specific anti-GFP antibody conjugated to alexa 
488 (D) and sEND-1 an endothelial cell line that served as a negative control (E, inset 
image, no primary control). The negligible endogenous eGFP expression in (C) 
demonstrates the need to use an anti-GFP antibody to track transplanted CDCs in vivo. 
Scale bar = 20µm. 
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Figure 6.6. Expression of eGFP in cardiac and vascular cell types in pulmonary 
and cardiac tissue harvested from the CAG-farnesyl-eGFP mice. (A and B) 
pulmonary tissue co-stained with alexa 488 conjugated-GFP antibody (green) and alexa 
594 conjugated-CD31 (red). Representative images show endothelial GFP expression in 
some large blood vessels (A, co-expression appears yellow and is highlighted with a 
white arrow) but not in others (B, endothelial cells not expressing GFP highlighted with 
purple arrows).  (C and D) Co-expression of eGFP and CD31 in the myocardium.  A 
small proportion of capillary-associated ECs in the heart co-express CD31 and eGFP (C, 
highlighted with white arrow) although the majority of vessels failed to demonstrate co-
expression (D, GFP negative capillaries highlighted with purple arrows). (E and F) Co-
expression of eGFP (alexa 488, green) and SMA (Cy5.5, orange) in the myocardium. 
GFP co-expresses with a small proportion of SMA positive cells (E, dual positive cell 
highlighted with white arrow) whilst other SMA cells were GFP negative (F, SMA 
positive/GFP negative cell highlighted with purple arrow). (G) Co-staining of 
myocardium with alexa 488 conjugated-anti GFP (green) and alexa-594 conjugated-anti 
α-actinin (red) antibodies show that cardiomyocytes strongly express GFP. (H) 
Myocardium co-stained with alexa 488 conjugated-anti GFP (green) and alexa-594 
conjugated-anti CD31 (red) antibodies. Representative image shows perivascular 
expression of GFP (endothelial cells highlighted with white arrows, GFP positive cells 
in close association with vascular ECs highlighted with purple arrows).  Scale bar = 
2µM. 
 
In CDC transfer experiments a total of 106 cells were transplanted into each animal. 
CDCs were re-suspended in 5µl of PBS and delivered via intramyocardial injection into 
two sites bordering the ischaemic zone of the LV wall. Successful injection was evident 
by the absence of cell backwash and the appearance of a white area in the myocardium. 
To ensure that CDC viability was not adversely affected by injection using a 25µl 
Hamilton Microliter™ syringe and 33 gauge needle I performed an MTT viability assay 
on CDCs that had been passed through the syringe needle. This needle has an internal 
diameter of 110µm whilst the average diameter of a murine CDC at P2 is 15.4±1.5µm. 
CDCs were harvested and re-plated onto a 96 well plate either directly or following 
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passage through the syringe/needle either once or else 5 times. Following a 24hour 
culture period cell viability was assessed using a previously described protocol (see 
section 3.2.5.1). Passing cells through the needle once had no effect, whereas repeated 
trituration (x5) significantly reduced cell viability (figure 6.7).  Additionally, as the 
MTT assay measures the effect of trituration on viability only after a period of in vitro 
culture (24 hours), I also used the ViCell automated cell viability analyser (which uses a 
standard trypan blue assay) to measure viability directly following passage through the 
Hamilton syringe. The ViCell analyser indicated there was no immediate difference 
between the viability of cells that passed through the syringe once and those that were 
not (92.8%versus 94.2%).  The concern raised from low cell viability in the MTT assay 
following repeated (5X) trituration is two-fold; (i) low cell viability would impair our 
ability to test the repair capacity of these cells and (ii) lysed cells are known to release 
potassium, therefore injecting a sufficiently large number of lysed/damaged cells could 
lead to hyperkalaemia resulting in cardiac arrest.  Therefore care was taken to ensure 
that cells were passed only once through the needle prior to injection.  
 
 
Figure 6.7. Evaluating CDC viability using the MTT assay following cell passage 
through a syringe. CDC viability is not significantly affected by passing cells through 
a 25µl Hamilton syringe/33G needle once (p=0.129). However, repeated trituration (x5) 
significantly reduces cell viability. Student’s t-test used to assess statistical significance, 
*p<0.05 **p<0.01. (B) Representative bright field images of cells following no, 1 or 5 
passes through the syringe/needle. Note that following only 1 pass the cells look healthy 
with intact membranes whereas there is evidence of increased cell debris following 
repeated trituration (highlighted with red arrows) with some cell lysis present (white 
arrow, difficult to detect in phase bright image). 
 
 
To further reduce the risk of increased mortality associated with intramyocardial cell 
injections I ensured that the injection volume was small and constant (a total of 5µl split 
between 2 sites), the injection was superficial preventing perforation of the LV wall and 
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also that the injection sites were distal to the septum and right ventricle to minimise 
contact with the conduction system. Additionally I injected the cells into akinetic 
myocardium close to the ischaemic border zone, which also reduced cell backwash 
following injection. Despite these efforts I saw a considerable increase in mortality with 
mice experiencing cardiac arrhythmias immediately following cell injection 
(approximately 33% of mice (12/36) went into ventricular fibrillation and died 
immediately following intra-myocardial cell injection). In addition to this cell injection 
related mortality I also experienced severe problems associated with mechanical 
ventilation and anaesthesia. For several months prior to beginning this study I observed 
that whilst under isoflurane induced anaesthesia mice experienced spontaneous 
respiration that was not synchronised with mechanical ventilation although this did not 
adversely affect mortality rates (100% peri-operative survival, 86% survival at 4 weeks 
(see figure 6.4)). This issue did however become progressively worse and eventually led 
to increased mortality at a time that coincided with the MI surgeries and cell transfers 
described in this study reducing the numbers of mice per group (see section 6.3 for a 
fuller discussion of this problem).   
 
6.2.2.2.  Left Ventricular Functional Analysis Post MI Reveals that 
WT-CDCs have a Cardioprotective Effect   
Directly following LAD coronary artery occlusion a small group of mice received WT 
CDCs via intramyocardial injection into the infarct border zone (n=6), whilst a second 
group of infarcted mice received vehicle (PBS) only (n=3). An additional control group 
consisted of sham-operated mice (n=4). Discounting perioperative mortality including 
the first 24hours following surgery, the 4 week survival rates of each group were 
comparable (sham operated, 100%; MI+ PBS 100%; MI plus WT CDC transplantation 
87%).  
 
LV function was assessed in these mice by MRI analysis at 1 week and 4 weeks 
following surgically induced MI. Figure 6.8 shows representative cine cardiac MR 
images 4 weeks following sham-operation (figure 6.8A-F), MI with PBS injection 
(figure 6.8G-L) and MI with WT-CDC infusion (figure 6.8M-R), whilst figure 6.9 
graphically displays measurements of selected parameters of cardiac function and 
remodelling for these groups. Data was normally distributed and differences between 
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treatment groups were initially assessed using one-way ANOVA. Where this analysis 
suggested significant differences existed, the students unpaired t-test was used to 
calculate precise differences between pairs of groups. Data for all parameters are 
presented in table 6.2 along with relevant statistical information. 
 
Cine MR images reveal striking LV dilatation and wall thinning in the MI with PBS 
group 4 weeks following surgery (figure 6.8G-L) compared to sham-operated control 
hearts (figure 6.8A-F). Furthermore, comparison of LV functional parameters between 
these two groups revealed markedly increased end diastolic and end systolic LV 
volumes in the MI group as well as significantly reduced EF both at 1 week and at 4 
weeks following surgery (table 6.2). At 1 week, none of the parameters analysed were 
significantly different between PBS and WT-CDC recipient infarcted mice, however at 
4 weeks the reduction in LV volume indices in the WT-CDC recipient group reached 
statistical significance compared to PBS controls (EDVI, 8.4±1.1µl/g versus 5.2±0.6µl/g 
(p=0.032) and ESVI, 6.8±0.9µl/g versus 3.9±0.7µl/g (p=0.048)). Representative cine 
MRI images also demonstrate attenuated LV remodelling by showing reduced cavity 
dilatation of the LV in WT-CDC compared to PBS recipient mice. The primary 
endpoint in many cell transplantation studies is an increase in left ventricular EF, which 
is a common parameter used to indicate the level of effect a therapeutic intervention has 
on cardiac function. The EF in CDC recipient mice was found to be appreciably 
increased relative to PBS controls, but this difference failed to reach statistical 
significance (18.6±0.8% versus 32±6.3% at 1 week (p=0.19) and 18.4±1.7% versus 
30.8±6.1% at 4 weeks post MI (p=0.21)) which may have been due to small sample 
sizes.  Similarly a small reduction in infarct size in WT-CDC recipient mice compared 
to PBS controls did not reach statistical significance at 1 or 4 weeks following surgery 
(40.1±3.7% of LV versus 50.2±4.7% at 1 week and 42.1±4.7 versus 51.8±1.9 at 4 
weeks, figure 6.13). 
 
Changes in cardiac function over time (between week 1 and week 4 following surgery) 
were also analysed and WT-CDC infusion following MI resulted in significantly 
attenuated increases in myocardial mass index and ventricular volume indices compared 
to the PBS injected group (figure 6.10, table 6.3). These data suggest that CDC 
transplantation results in reduced adverse left ventricular remodelling following MI.  
   188 
Overall, the MRI-assessment employed in this study confirms that WT-CDC 
transplantation augments cardiac function in injured hearts.  
 
6.2.2.3. Wild-Type CDC Transplantation following MI results in 
Increased Neovessel Formation  
To establish the contribution of neovascularisation to CDC-mediated cardiac rescue 
following MI, I quantified blood vessel density in the infarct border zone at 4 weeks 
following surgery.  Multiple sagittal cryosections (n=8 to 10 sections per mouse) were 
taken from the mid-point of the infarcted heart (or equivalent region in sham-operated 
controls) and stained with anti-CD31 antibody. The percentage area stained positively 
with CD31 was calculated per section using ImageJ software (NIH) and normalised to 
total area to derive mean percentage CD31 expression per mm2 (26±6 images were 
analysed per heart). Data was normally distributed and differences in vascular density 
between groups were initially assessed using one-way ANOVA (p=0.001) and 
subsequently significant differences between pairs of groups were verified using the 
students unpaired t-test.  
 
Comparisons between groups revealed that vascularity at the infarct border zone was 
significantly reduced in MI mice with PBS injection compared to sham-operated 
controls (0.073±0.002 versus 0.135±0.007% CD31 expression/mm2 (p<0.001)) (figure 
6.11).   Whereas CDC transplantation following MI resulted in a significant increase in 
capillary density than was observed in PBS treated infarcted mice (0.088±0.003 versus 
0.073±0.002 CD31 expression/mm2 (p<0.001)) (figure 6.11).  
 
These results demonstrate that injection of WT-CDCs into the infarct border zone 
results in functional cardiac improvement by MRI analysis and immunofluorescent 
analysis of vascularity indicates that this is likely, in part, due to an enhanced 
angiogenic response. 
 
 
6.2.2.4. Endoglin Depleted CDCs Improve Cardiac Function 
without an Enhanced Angiogenic Response 
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To determine the effect of endoglin loss on CDC-mediated heart repair, CDCs were 
prepared from Engfl/fl;Rosa-CreERT2;CAG-farnesyl-eGFP mice and treated with 2µM 
4OH-tamoxifen for 96hours in vitro to achieve gene deletion via Cre/loxP 
recombination (as described in section 5.2.2.1).  The aim of this part of the study was to 
compare the effects of transplanting Eng-iKO CDCs into the infarct border zone with 
the effects of transplanting untreated control CDCs (WT-CDCs).   
 
Figure 6.12 shows images of a sample of donor Engfl/fl;Rosa-CreERT2;CAG-farnesyl-
eGFP CDCs cultured for in vivo cell transfer and demonstrate a clear knock-down of 
endoglin expression in 4OH-tamoxifen treated cultures. As previously discussed in 
chapter 5 (see tables 5.1 and 5.3), I have observed that 70-90% of CDCs express 
endoglin and I am able to achieve approximately 80% endoglin knock down following 
treatment with 4OH-tamoxifen. These findings have also been replicated by an 
independent researcher using my protocols (personal communication, Muhammad 
Amirrasouli). Although it would have been desirable to verify the precise endoglin 
levels in all WT and Eng-iKO cells used for in vivo transfer,  due to time constraints this 
was not possible. However it is likely that expression levels fall within the boundaries 
quoted above. 
 
The 4 week survival data for the MI with Eng-iKO CDC transfer mice (80% 
discounting perioperative mortality, final group size n=4) was similar to survival rates 
described for the other experimental groups (see section 6.2.2.2). MRI analysis 4 weeks 
after surgery revealed there was a significant increase in EF (35.1±10. 6% versus 
18.4±1.7% (p=0.024)) in mice that received Eng-iKO CDCs compared to PBS recipient 
controls. In parallel there was a non significant trend of reduced myocardial mass index 
(5.7±0.8mg/g versus 6.6±0.9mg/g (p>0.05)) and decreased left ventricular volume 
indices (EDVI; 5.7±1.6µl/g versus 8.4±1.1µl/g (p=0.271) and ESVI; 4.3±1.8µl/g versus 
6.8±0.9µl/g, (p=0.313)) (see figure 6.9. figure 6.8. for representative cine MR images 
and table 6.2. for full data set). Although these differences did not reach statistical 
significance they do indicate that Eng-iKO CDCs retain a capacity to contribute to 
repair following heart injury. Furthermore, comparisons between WT-CDC and Eng-
iKO CDC infused hearts revealed no significant difference in cardiac function by MRI 
assessment (see figure 6.9). In fact myocardial mass and LV volume indices were 
similar between these two groups at 4 weeks post surgery (myocardial mass index, 
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4.9±0.2mg/g versus 5.7±0.8mg/g (p>0.05); EDVI, 5.2±0.6µl/g versus 5.7±1.6µl/g 
(p=767); ESVI, 3.9±0.7µl/g versus 4.3±1.8µl/g (p=0.804)) as well as CI, SVI, EF and 
infarct size (CI, 0.65±0.06ml/min/g versus 0.62±0.07ml/min/g (p>0.05); SVI, 
1.4±0.1µl/g versus 1.4±0.2µl/g (p>0.05); EF, 30.8±6.1% versus 35.1±10.6% (p=0.711); 
infarct size, 42.1±4.7% of LV versus 38.3±6.8%).   
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Figure 6.8. Representative cine MR images of post infarct murine hearts following intramyocardial CDC transplantation.  Images of a sham-
operated heart show normal wall thickness and motion (diastole A-C, systole D-F), whereas images of an infarcted heart (diastole G-I, systole J-L) show 
increased LV dilatation as well as wall thinning and akinesis in the anterolateral and apical regions (see white arrows).  Transplantation of WT-CDCs 
(diastole M-O, systole P-R) and Eng-iKO cells (diastole S-U, systole V-X) immediately following LAD coronary artery occlusion leads to attenuated 
adverse remodelling, note the reduced LV wall thinning and cavity dilatation (see red arrows) compared with MI controls at 4 weeks following surgery.  
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Figure 6.9.  MRI-assessed 
analysis of cardiac function  
reveals a cardioprotective 
effect for CDCs. Left 
ventricular functional analysis at 
1 and 4 weeks post infarct shows 
that both WT and Eng-iKO CDC 
transfer protects against adverse 
remodelling and dilatation of the 
heart. Reduced myocardial mass 
index and ventricular volume 
indices are observed at 4 weeks 
in both cell recipient groups 
compared to the MI with PBS 
injection control group.  One-
way ANOVA was used to assess 
if statistically significant 
differences were present for 
each parameter, then the 
students unpaired t-test was used 
to calculate p-values between 
specific pairs of groups, p<0.05 
considered statistically 
significant (please see table 6.2 
for detailed statistical analyses). 
Error bars represent SEM and * 
denotes p<0.05.  
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Figure 6.10. Changes in cardiac function between 1 and 4 weeks following MI and cell transplantation. The data demonstrates attenuated 
increases in myocardial mass index and ventricular volume indices in both WT and Eng-iKO CDC injected groups compared to PBS-only recipient 
mice. There was no significant difference in the change in EF between 1 and 4 weeks following surgery. These results suggest reduced adverse LV 
remodelling in CDC recipients. One-way ANOVA was used to assess if statistically different changes were present between groups for each parameter, 
then the students unpaired t-test was used to calculate p-values between specific pairs of groups, (please see table 6.3 for detailed statistical analyses). 
Error bars represent SEM and * denotes p<0.05.  
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SHAM 
 
n=4 
MI + PBS 
 
n=3 
MI +     
CDCWT 
n=6 
MI + 
CDCEngKO 
n=4 
p Values 
ANOVA Sham vs MI+PBS 
MI+PBS vs 
MI+CDCWT 
MI+PBS vs 
MI+CDCEngKO 
 MI+CDCWT vs 
MI+CDCEngKO 
Age at Infarct (weeks) 
Pre-operative Weight (g) 
12.9±0.1 
25.7±1.6 
12.7±0.3 
25.3±1.04 
12.8±0.2 
29.6±1.2 
12.7±0.2 
29.2±3.2 
0.921 
0.303 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
Day 7 SCAN          
Mean HR (bpm) 423.5±15 429±27.9 447.7±24 432.3±9.1 0.842 n/a n/a n/a n/a 
CO(ml/min) 19.4±1.3 11.7±2.2 16.1±1.4 16.1±2.6 0.114 n/a n/a n/a n/a 
CI (ml/min/g) 0.76±0.03 0.46±0.08 0.54±0.09 0.54±0.04 0.003 0.01 0.305 0.346 0.976 
Mean myocardial mass (mg) 113±6.1 146±18 136±4.3 146.6±7.5 0.049 0.105 0.477 0.976 0.218 
Mean mass index (mg/g) 4.4±0.2 5.8±0.6 4.6±0.2 5.2±0.6 0.147 n/a n/a n/a n/a 
EDV (µl) 66.26±3.6 146.3±24.6 125.8±14.8 124.9±20.8 0.038 0.013 0.473 0.534 0.972 
EDVI (µl/g) 2.6±0.2 5.8±0.9 4.2±0.5 4.6±1.2 0.081 n/a n/a n/a n/a 
ESV (µl) 20.5±1.5 119.4±20.7 87.7±15.4 87.4±25.6 0.019 0.002 0.267 0.400 0.992 
ESVI (µl/g) 0.8±0.08 4.7±0.7 3±0.5 3.3±1.3 0.032 0.001 0.099 0.419 0.804 
SV (µl) 45.72±2.31 26.9±4 36.7±4.2 37.5±6.6 0.137 n/a n/a n/a n/a 
SVI (µl/g) 1.79±0.1 1.06±0.1 1.2±0.1 1.3±0.1 0.011 0.01 0.394 0.282 0.898 
EF (%) 69.1±1 18.6±0.8 32±6.3 33.4±7.9 0.001 <0.001 0.190 0.176 0.899 
Infarct size (% of LV) n/a 50.2±4.7 40.1±3.7 38.2±6.5 0.304 n/a n/a n/a n/a 
Weight (g) 23.78±2.27 23.2±1.5 25.5±0.9 25.5±2.3 0.750 n/a n/a n/a n/a 
Day 28 SCAN          
Mean HR(bpm) 425±11.2 420.7±7.9 456.2±15.2 440±15.1 0.305 n/a n/a n/a n/a 
CO(ml/min) 21.2±2.2 16.5±3.3 19.2±1.9 18.3±3.2 0.693 n/a n/a n/a n/a 
CI (ml/min/g) 0.84±0.1 0.65±0.1 0.65±0.06 0.62±0.07 0.320 n/a n/a n/a n/a 
Mean myocardial mass (mg) 120.9±8.7 167.7±21.9 144.5±4.7 159.5±9.3 0.040 0.076 0.187 0.715 0.151 
Mean mass index (mg/g) 4.7±0.3 6.6±0.9 4.9±0.2 5.7±0.8 0.097 n/a n/a n/a n/a 
EDV (µl) 72.9±4.1 210.5±27.3 153.1±17.2 153.9±30.1 0.008 0.002 0.106 0.238 0.982 
EDVI (µl/g) 2.9±0.2 8.4±1.1 5.2±0.6 5.7±1.6 0.025 0.003 0.032 0.271 0.767 
ESV (µl) 23.3±2.2 171.3±20.4 110.6±20.7 111.7±37.7 0.013 <0.001 0.109 0.267 0.980 
ESVI (µl/g) 0.9±0.04 6.8±0.9 3.9±0.7 4.3±1.8 0.023 0.001 0.048 0.313 0.804 
SV (µl) 44.7±6.1 39.2±7.6 41.2±4.9 42.2±8 0.956 n/a n/a n/a n/a 
SVI (µl/g) 2±0.2 1.6±0.3 1.4±0.1 1.4±0.2 0.187 n/a n/a n/a n/a 
EF (%) 67.9±3 18.4±1.7 30.8±6.1 35.1±10.6 0.002 <0.001 0.212 0.240 0.711 
Infarct size (% of LV) n/a 51.8±1.9 42.1±4.7 38.3±6.8 0.310 n/a n/a n/a n/a 
Weight (g) 26.3±2.4 25.5±2 28.3±1 28.9±2.8 0.630 n/a n/a n/a n/a 
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Table 6.2. Summary of MRI assessed LV functional analyses at 1 and 4 weeks following sham-operation (thoracotomy) and MI with or without CDC 
transfer (with or without endoglin depletion).  All parameters are expressed as mean ± SEM. Table illustrates the results of one-way ANOVA and the 
significant results of unpaired t-tests between specific pairs of groups. Significant values (p<0.05) are highlighted in red. Abbreviations: HR, heart rate; CO, 
cardiac output; CI, cardiac index; EDV, end diastolic volume; EDVI, end diastolic volume index; ESV, end systolic volume; ESVI, end systolic volume index; 
SV, stroke volume; SVI, stroke volume index; EF, ejection fraction; LV, left ventricle. n/a = not applicable. MRI data analysis performed by Dr Ben Davison. 
 SHAM  MI + PBS MI +  CDCWT  
MI + 
CDCEngKO 
p Values 
ANOVA Sham vs MI+PBS 
MI+PBS vs 
MI+CDCWT 
MI+PBS vs 
MI+CDCEngKO 
 MI+CDCWT vs 
MI+ CDCEngKO 
∆Mean HR (bpm) 1.5±24.6 -8.3±31.8 8.5±19.7 7.8±13.7 0.956 
 
n/a n/a n/a n/a 
∆CO (ml/min) 1.8±2.2 4.9±1.1 3.1±2.4 2.3±1.1 0.284 n/a n/a n/a n/a 
∆CI (ml/min/g) 0.004±0.07 0.2±0.04 0.11±0.08 0.08±0.04 0.309 n/a n/a n/a n/a 
∆Mean myocardial mass (mg) 7.9±2.7 21.7±7 8.5±1.7 12.8±4.5 0.096 n/a n/a n/a n/a 
∆Mean mass index (mg/g) 0.3±0.1 0.9±0.3 0.3±0.1 0.5±0.2 0.092 n/a n/a n/a n/a 
∆EDV (µl) 6.7±1.1 64.2±12.8 27.3±5.4 29±11.2 0.004 0.003 0.015 0.094 0.885 
∆EDVI (µl/g) 0.3±0.1 2.6±0.6 1±0.2 1.1±0.5 0.007 0.007 0.015 0.127 0.781 
∆ESV (µl) 2.7±2.7 51.9±12 23±7.6 24.3±12.8 0.035 0.006 0.071 0.189 0.926 
∆ESVI (µl/g) 0.1±0.1 2.1±0.6 0.9±0.3 1±0.6 0.038 0.009 0.057 0.228 0.821 
∆SV (µl) -1±6.8 12.4±3.9 4.5±4.8 4.7±2.1 0.442 n/a n/a n/a n/a 
∆SVI (µl/g) 0.2±0.1 0.5±0.16 0.19±0.16 0.15±0.08 0.440 n/a n/a n/a n/a 
∆EF (%) -1.2±3.9 -0.2±2.1 -1.3±3.4 1.78±3.8 0.926 n/a n/a n/a n/a 
∆Infarct size (%) n/a 1.6±3.5 2.1±1.7 0.1±0.9 0.755 n/a n/a n/a n/a 
 
Table 6.3. Summary of changes in cardiac function between 1 and 4 weeks following MI and cell transplantation. All parameters are expressed as mean 
± SEM. Table illustrates the results of one-way ANOVA and unpaired t-tests between specific pairs of groups, Significant values (p<0.05) are highlighted in 
red.  Abbreviations: ∆, difference between week 1 and 4 measurement; HR, heart rate; CO, cardiac output; CI, cardiac index; EDV, end diastolic volume; EDVI, 
end diastolic volume index; ESV, end systolic volume; ESVI, end systolic volume index; SV, stroke volume; SVI, stroke volume index; EF, ejection fraction; 
LV, left ventricle; n/a = not applicable. MRI data analysis performed by Dr Ben Davison. 
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Figure 6.11. WT-CDC transplantation, but not Eng-iKO CDC infusion, results in an increased angiogenic response in the infarct border zone. 
Angiogenesis in the border zone of the infarcted heart was quantified using multiple CD31 immunostained sections (examples are shown in (B-E)) of hearts 
harvested 4 weeks post injury. Images were analysed using image J software and vessel density is represented as percentage CD31 expression per mm2. WT-
CDC injection into the border zone at the time of infarct led to an increased angiogenic response, which was significantly reduced when endoglin was 
genetically removed from the CDCs (A). Data was analysed using one-way ANOVA (p=0.001) and individual students t-test were performed to identify 
significant differences between pairs of groups. Representative images of the infarct border zone (or equivalent) in hearts of sham-operated mice (B, n=2), 
infarct with PBS injection (C, n=4), infarct with WT-CDC injection (D, n=4) and infarct with Eng-iKO CDC injection (E, n=4). Inset image (A) representative of 
no primary antibody control. ** denotes p < 0.01.  
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 Figure 6.12. Endoglin depletion in 4OH-tamoxifen treated Engfl/fl;Rosa-
CreERT2;CAG-farnesyl-eGFP CDC cultures.  CDCs were immunostained with anti-
endoglin (primary) and alexa-594 conjugated (secondary) antibodies (red). High 
endoglin expression is observed in WT-CDC cultures (A), whereas there is a marked 
reduction in expression in CDC cultures treated with 2µM 4OH-tamoxifen (B).  Scale 
bar, 20µm. N.B. these cells were treated in the same way as those used for recipient 
expeimental mice and serve as an indicator of gene deletion efficiency.  
 
Additionally, changes in cardiac function between 1 and 4 weeks following MI 
demonstrated significantly attenuated increases in myocardial mass index and LV 
volume indices in the Eng-iKO CDC injected group in comparison to PBS injected 
controls (figure 6.10). These differences are similar to those observed in the WT-CDC 
infused group (table 6.3) and suggest that both WT and Eng-iKO CDCs are able to 
reduce adverse LV remodelling following infarction. This data suggests that endoglin 
expression in CDCs is not necessary to improve cardiac function following LAD 
coronary occlusion and direct intramyocardial cell transplantation. Larger sample sizes 
would be required to verify this conclusion. 
 
Interestingly analysis of vascularity (using anti-CD31 staining) revealed that 
intramyocardial injection of Eng-iKO CDCs led to significantly reduced angiogenesis in 
the border zone at 4 weeks following MI compared with WT CDCs (0.075±0.001 
versus 0.088±0.003% CD31 expression/mm2 (p<0.001) (figure 6.11). In fact levels of 
CD31 in Eng-iKO CDC treated mice were comparable to infarcted controls receiving 
only PBS (0.073±0.002% CD31 expression/mm2 (p=0.545)) suggesting that endoglin 
expression is necessary to stimulate an enhanced angiogenic response in CDC mediated 
heart repair.  
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To follow up these results, I analysed the relationship between infarct border zone 
vessel density (measured as % CD31 expression/mm2) and infarct size as well as EF (as 
a readout of cardiac function) for each individual mouse using the pearson correlation 
method (figure 6.13).   Interestingly no correlation was detected between CD31 
expression and infarct size (r= 0.036, p= 0.915) or between CD31 expression and EF 
(r= -0.006 , p= 0.987), suggesting that in this study vessel density does not significantly 
correlate with either infarct size or global LV function (Figure 6.13).  As expected 
infarct size displayed inverse correlation with EF (r= -0.977, p= 0.00; Figure 6.13E).  
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Figure 6.13. Relationship 
between ischaemic border zone 
vessel density and infarct size or 
EF. Charts displaying the vessel 
density of the infarct border zone 
per mm2 (red) and either infarct 
size (% of LV; A, blue) or EF (%; 
C, blue) for each individual 
infarcted mouse included in this 
study. N.B. There is no 
correlation between blood vessel 
density in the infarct border zone 
and infarct size (r = 0.036, p = 
0.915; B) or cardiac function as 
measured by EF (r = -0.006, p = 
0.987; D). As expected infarct 
size displayed inverse correlation 
with EF (r = -0.977, p = 0.00; E). 
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6.2.2.5. Tracking GFP Positive CDCs 4 Weeks following 
Intramyocardial Transplantation into Infarcted Hearts 
Transplanted CDCs were genetically tagged with eGFP (see section 6.2.2.1.) to allow in 
vivo tracking following intramyocardial cell injection 4 weeks following surgery. 
Multiple cryosections (approximately 6 to 8 per heart) from both WT-CDC (n=4) and 
Eng-iKO CDC (n=4) recipient hearts were stained with an anti-GFP antibody (directly 
conjugated to alexa 488). No eGFP expression was detected in sham-operated mice 
(n=2) or infarcted animals that received PBS only (n=4) (figure 6.14B). Of the cell 
injected groups, in 2 of 4 WT-CDC and 1 of 4 Eng-iKO-CDC recipient hearts analysed, 
I observed small clusters eGFP positive cells within the infarcted scar region, proximal 
to the border zone (figure 6.14A). This initially suggested survival of eGFP positive 
CDCs 4 weeks following intramyocardial injection.  
 
 
Figure 6.14. Identification of GFP positive cells within infarcted hearts 4 weeks 
following intramyocardial injection of eGFP tagged CDCs. Cryosections from CDC 
(A) and PBS (B) recipient hearts were stained with anti-GFP antibody (directly 
conjugated to alexa 488) and imaged using fluorescent microscopy. No GFP positive 
cells were identified in PBS treated heart tissue, whereas in 2/4 WT-CDC and 1/4 Eng-
iKO-CDC recipient hearts included in this study I observed small clusters of small, 
round GFP positive cells in the scar tissue. Inset image (A) is a digital zoom 
magnification of representative GFP positive cells. Scale bars = 20µm. 
 
Morphologically the vast majority of these GFP positive cells were small and round, 
resembling a primitive, stem-like cell rather than a terminally differentiated cell type. 
To assess whether transplanted CDCs differentiated into cardiomyocyte or vascular 
cells I co-stained heart cryosections with specific lineage markers (CD31, endoglin, α-
actinin or α-SMA) and anti-GFP.  Careful analysis revealed that none of the small GFP 
positive cells colocalised with any of these cell type specific markers (for representative 
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images see figure 6.15).  This indicates that the pro-angiogenic effect generated by CDC 
infusion is most likely attributable to a paracrine mechanism. However, due to selective 
non-expression of eGFP in CAG-farnesyl-eGFP endothelial and aSMA cells (see 
section 6.2.2.1.) it is not possible to definitely determine lineage expression in this 
study. Additionally, within one WT-CDC recipient heart I was able to identify a very 
small number of eGFP positive cells (approximately 8-10, representing less than 2% of 
total visible eGFP positive cell population) that were larger and morphologically 
distinct to those previously described (figure 6.16.). Imaging of these cells required 
lower exposure times suggesting enhanced eGFP expression and approximately 3-4 
cells co-stained with eGFP and either α-actinin, CD31 or endoglin. I used only double 
immunofluorescent staining (GFP and α-actinin, endoglin or CD31) so was unable to 
determine whether these GFP positive cells displayed antigenic plasticity and expressed 
multiple lineage markers (figure 6.16.). 
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Figure 6.15. The majority of GFP positive cells do not express cardiac or vascular 
markers.  Cryosections prepared from heart tissues 4 weeks after MI and cell 
transplantation were co-stained with anti-GFP antibody (conjugated to alexa 488, green) 
and either (A) anti-α-actinin, (B) anti-CD31 (C) anti-endoglin, (visualised using alexa 
594 conjugated secondary antibodies, red) or (D) anti-SMA (conjugated to Cy5, 
orange). The images clearly show that GFP expression does not co-localise with any of 
the terminally differentiated cell type specific markers included in this analysis. This 
suggests that the cardioprotective effects associated with CDC transplantation are 
achieved by paracrine mechanisms. Inset images representative of no antibody (A) and 
no primary antibody (B) controls. Scale bars = 20µm. 
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Figure 6.16. Co-expression of eGFP with cardiac and vascular markers in a WT-
CDC recipient heart. Heart cryosections were co-stained with eGFP antibody 
conjugated to alexa 488 and either (A) α-actinin, (B) CD31 or (C) endoglin specific 
antibodies (visualised using alexa 594 conjugated secondary antibodies). A small 
number of eGFP positive cells co-expressed cell type specific markers in putative WT-
CDCs (dual positive cells highlighted with white arrows). 
 
Further analysis of stained heart sections revealed evidence of small, round eGFP 
positive cells (similar to those shown in figure 6.15) within the lumen of a blood vessel 
(figure 6.17) suggesting that these cells may represent an endogenous inflammatory 
infiltrate with the capacity to ingest transplanted eGFP positive CDCs or GFP-positive 
cell debris. To further characterise and identity these cells as either a donor cell 
population or resident inflammatory cells I co-stained heart sections with antibodies to 
GFP and either cKit  or CD11b (a marker expressed predominantly by macrophages and 
monocytes but also by other immune response cell types including natural killer and  
granulocytes). I was unable to detect cKit expression although it is possible that the 
immunostaining method may require further optimisation. However, the majority of 
eGFP-positive cells were positive for CD11b (figure 6.18). The scale of CD11b positive 
cells strongly suggests that the eGFP expression observed in CDC recipient hearts 
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represents endogenous macrophages that have ingested donor GFP positive cells or 
cellular debris.  
 
 
 
 
 
Figure 6.18. GFP positive cells within CDC recipient infarcted hearts express the 
macrophage marker CD11b but not cKit. Serial heart cryosections from a CDC 
recipient mouse were co-stained for GFP (green) and either cKit (A, red) or CD11b (B, 
red). These representative images clearly show that whilst eGFP positive cells do not 
express cKit, they do express the macrophage marker CD11b. These results suggest that 
the majority of observed GFP expression in CDC recipient hearts does not represent 
true transplanted donor cells but rather the remnants of these cells following 
inflammatory cell ingestion. Inset images representative of a no primary antibody 
control (A) and a digital zoom magnification of GFP/CD11b dual positive cells (B). 
Scale bars = 20µm. 
 
Figure 6.17. GFP positive 
cells within a blood vessel 
lumen. Serial heart 
cryosections from a WT-CDC 
recipient mouse were co-
stained for GFP (green) and 
either CD31 (A, red) or SMA 
(B, orange) markers. Both 
images show GFP positive 
cells that appear to reside 
within the blood vessel lumen 
(see white arrows) consistent 
with a circulating cell 
population with the capacity 
to ingest GFP positive cells.  
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6.3.  Discussion 
The aims of this study were to (i) confirm that mouse CDC transplantation rescues heart 
function following acute MI and (ii) to investigate if endoglin is essential in this 
process. Specifically, I tested whether or not increased endoglin expression results in an 
enhanced pro-angiogenic response in the infarct border zone. 
 
Using a surgical MI mouse model I have successfully shown that intramyocardial 
injection of WT-CDCs into the infarct border zone leads to significantly attenuated 
adverse LV remodelling. At 4 weeks post MI, I observed an approximate 12% increase 
in EF as well as significantly reduced left ventricular volumes in those mice receiving 
WT-CDCs compared to PBS recipient controls. This improvement in cardiac function is 
comparable to other published studies159, 161, 163, 169, 187 (see table 1.1 for study details) 
therefore I have independently confirmed the beneficial effect of CDC delivery 
following acute MI. Furthermore, this functional improvement was associated with 
increased neovessel formation in the ischaemic border zone. Deriving CDCs from 
Engfl/fl;Rosa-CreERT2 mice enabled me to test the effect of endoglin depletion in vivo 
following in vitro gene deletion. Surprisingly, I observed no significant difference 
between WT- and Eng-iKO-CDCs in their ability to rescue global LV function post 
infarct with both groups showing a similar increase in EF and decreased LV volumes 
compared to PBS recipient controls. However, in agreement with my original 
hypothesis intramyocardial injection of Eng-iKO CDCs did lead to significantly reduced 
angiogenesis in the infarct border zone 4 weeks following MI compared to WT-CDCs. 
In the following section I will discuss this discrepancy and suggest some alternative 
hypotheses to help explain these results. 
 
The reduced secretion of VEGF343, decreased NO synthase expression353-354 as well as 
defective proliferation and migration237, 264 observed in Eng+/- endothelium helped lead 
to the hypothesis that endoglin depletion in cardiac repair cells would significantly 
impair post infarct neovascularisation resulting in deterioration of cardiac function. 
However the attenuation of adverse LV remodelling observed in Eng-iKO cell recipient 
mice has led me to revise this hypothesis. An alternative scenario that explains the 
improved cardiac function without concurrent increased neovascularisation, is that both 
WT and Eng-iKO CDCs are able to stimulate an enhanced angiogenic response in the 
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acute phase of infarct healing (within 7 days) via pleiotropic means. However, due to 
the important role of endoglin in vascular stabilisation and homeostasis, the neovessels 
formed following Eng-iKO CDC transplantation do not persist at later stages of 
remodelling (i.e. 4 weeks) when the analysis of angiogenesis was performed (Figure 
6.11). As discussed in section 1.2 following MI a complex healing response consisting 
of cytokine release, inflammatory cell infiltration, EC proliferation and myofibroblast 
activity is necessary to create a mature scar9. At an early stage of the initial 
inflammatory response, neovessels form to support this healing process and during the 
maturation phase (approximately 7 days post-MI in mice) the neovessels regress from 
the infarct to prevent excessive fibrosis9. In this process exposed, uncoated neovessels 
regress, whilst other vessels acquire a mural coat, mature and stabilise. It has previously 
been shown that during mouse development, ECs lacking endoglin entirely are defective 
in their ability to process and secrete active TGFβ protein, which in turn affects their 
ability to differentiate and attract mural cells to the vessel wall341. Therefore defective 
processing of TGFβ or other cytokines associated with mural cell recruitment (e.g. 
PDGF-BB) by CDCs could play a role in the stability of neovessels. In this scenario 
endoglin loss may not affect CDC-mediated neovessel formation during the acute phase 
of infarct remodelling resulting in improved cardiac function, however due to an 
impaired ability to process and secrete important paracrine factors there is a failure to 
stabilise neovessels in the border zone through pericyte maturation and recruitment 
leading to their regression at a later stage. This would result in a lower vessel density at 
the border zone with decreased perfusion of viable myocardium which could increase 
the risk of heart failure at a later stage. To test this hypothesis it would be useful to 
compare CD31 and vascular smooth muscle staining of vessels at the infarct border 
zone at 1 week (which marks the peak phase of angiogenic activity275) and at 4 weeks 
post MI to compare vessel number as well as vessel maturation. It would also be 
interesting to perform a protein array analysis of CDC conditioned media with or 
without endoglin expression and assess the relative amounts of relevant cytokines and 
growth factors important in this process (e.g. TGFβ or PDGF-BB etc).  
 
Infarct healing and repair actually encompasses a highly coordinated, complex process 
involving multiple networks of molecular mediators with pleiotropic effects, dictated by 
multiple cell types as well as spatial and temporal variables. As demonstrated by studies 
addressing the post infarct inflammatory response, pathways within this system often 
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display redundancy as well as pleiotropic, synergistic and antagonistic effects on each 
other9.  In this respect it is plausible that therapeutic interventions aimed at enhancing 
cardiac repair may have both cardioprotective and injurious effects or indeed that an 
approach may have a beneficial effect on the mechanical and functional properties of 
the infarcted heart irrespective of deleterious changes elsewhere. With respect to the 
present study it is therefore possible that endoglin expression does mediate neovessel 
formation in the border zone but additional endoglin-independent CDC mediated effects 
attenuate adverse LV remodelling by other unknown mechanisms.  For example, in 
addition to promoting angiogenesis the paracrine effects of CDCs may also attenuate 
mass cardiomyocyte loss which is the basic cause of heart failure following MI. 
Although this theory would have to be investigated (for example by looking at Akt and 
caspase protein levels or TUNEL staining), such an effect could be endoglin 
independent and hence help to explain the lack of significant differences in LV function 
between recipient groups following transplantation of WT and Eng-iKO CDCs.  Further 
studies are required to investigate these mechanisms. 
 
Regardless of the above suppositions regarding the role of endoglin in CDC-mediated 
repair, it is imperative that longer term studies are performed. Critically, it has been 
shown that although transplantation of human ESC derived cardiomyocytes into an 
experimental model of MI improves cardiac function at 4 weeks, this cardio-protective 
effect disappeared at 3 months355. This not only exemplifies the need for longer term 
studies to determine the efficacy of novel treatments but more specifically related to the 
current study, analysis of cardiac function and angiogenesis in CDC recipient mice at 3 
months would also allow me to investigate whether or not the increased number of 
vessels observed in WT-CDC recipient hearts persist and similarly whether the 
decreased vessel density associated with Eng-iKO CDCs leads to deteriorated cardiac 
function or heart failure. Additional modifications to a second larger study would also 
include perfusion studies (e.g. with FITC lectin) to gauge whether neovessels associated 
with cell treatment are functional and ideally the inclusion of a cardiac fibroblast control 
group to exclude non-specific effects of CDC transplantation. 
 
An important limitation of this study is the small group sizes, which occurred as a result 
of peri-operative mortality which was high in all groups: sham operated mice, 43% 
(n=7); MI mice with PBS 60% (n=10); and MI with CDC transfer 50% (n=36). This 
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was due to problems with anaesthesia and ventilation that induced a condition 
diagnosed as ‘exaggerated breathing reflex’ (Paul Flecknell personal communication). 
The original power calculations used to determine group numbers assumed a 17% 
difference in LVEF159 and indicated that groups of 8 animals would provide 80% power 
at alpha 0.05. I therefore intended to begin with groups of 10 animals to allow for 20% 
mortality however the final sample sizes were between 3 and 6 mice per group. This 
gave insufficient power to provide reliable answers to the questions under investigation. 
Therefore although this study provides important preliminary data, larger animal 
numbers are required to reliably interpret results.  
 
Follow up investigation of this problem revealed that peri-operative mortality was also 
observed in intubated/ventilated mice that did not undergo thoracotomy. Mice were 
adequately anaesthetised with depth assessed by testing the loss of primitive reflexes 
(e.g. pedal reflex) as more sophisticated measures of depth were not available (e.g. 
MAC – minimum alveolar concentration). Inspiratory and expiratory ventilatory 
pressures were determined using pre-set parameters provided by the ventilator 
manufacturer (standardised to mouse weight). I routinely used a mouse pulse oximeter 
to measure oxygen saturation and found it to be consistently >90% and body 
temperature was maintained at 37oC. Additionally it would have been informative to 
measure CO2 levels, but unfortunately our rodent capnograph did not provide reliable 
results. Several precautions were taken to minimise the impact of this 
anaesthesia/mechanical ventilation related problem, including optimisation of ventilator 
parameters (stroke volume and rate) to oppose any possible retention of CO2 and also 
the administration of a pre-anaesthetic sedative (0.2ml/kg hypnorm administered via I.P 
injection prior to inducing surgical depth of anaesthesia with isoflurane). Following the 
completion of this study we discovered that our Harvard minivent was delivering a 
stroke volume that was approximately 20% lower than that which was set.  We have 
since invested in a Harvard 687 volume controlled rodent ventilator which allows 
increased control over stroke volume and rate but also offers the ability to introduce 
positive end expiratory pressure and change the inspiration: expiration ratio. This new 
ventilator will allow a larger more refined study to be performed to give adequate group 
sizes. 
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The reduced power of the study is further confounded by an increase in infarct 
variability which occurred as a result of the problems associated with sub-optimal 
anaesthesia and mechanical ventilation protocols. The extent of adverse LV remodelling 
following MI is directly proportional to infarct size9 and similarly decreasing capillary 
density in the infarct border zone is observed with increasing infarct size350. Therefore, 
the generation of infarcts of comparable size between experimental groups is critically 
important when testing interventions aimed at influencing LV remodelling and 
angiogenesis. The murine LAD coronary artery occlusion model is known to produce a 
wide range of infarct sizes (10-70% of the LV)356, most likely due to differences in 
rodent coronary artery branching patterns which are apparent even between 
littermates357. However with careful attention to surgical technique it is possible to 
reduce variability in infarct size by placing ligations proximal to the site where the 
artery emerges from under the left atria, immediately before the bifurcation of the major 
left coronary artery and also by eliminating mice that clearly show evidence of 
exceptionally small or large infarcts as indicated by the degree of myocardial blanching 
seen directly following coronary artery occlusion (see figure 6.1). Serial contrast-
enhanced studies have indicated that infarct size in mice reaches 95% of its final size 
within 1 hour in a reperfusion model of experimental MI12. This indicates that it would 
be advantageous to measure infarct size using a non-invasive technique such as MRI358 
at an early time point i.e. within 24-48 hours following infarct (allowing some time for 
the animal to recuperate) to give baseline data. However for my infarcted mice this was 
not possible due to cardiac surgery and MR imaging being performed at different sites 
(approximately one mile apart) and strict regulations regarding animal transportation. 
Therefore the earliest time point that infarct size could be measured was 1 week 
following MI. To give an indication of the variation in infarct size that I initially 
observed after establishing the MI model, MRI was used in a pilot group of mice (n=10) 
4 weeks following coronary artery occlusion (table 6.1.). Infarcted tissue was 
characterized as the area of akinesis and the infarct size measurement is calculated as a 
percentage of the LV wall using mid-ventricular end-diastolic cine MRI slices and the 
following dimensions; length of infarcted epicardial and endocardial circumference and 
length of total epicardial and endocardial circumference. Infarct size ranged from 27.6-
45% of the LV wall with a mean size of 36.2±1.8% indicating good reproducibility 
which is essential to detect changes in cardiac structural and functional parameters 
(table 6.1.). However, in the current study (with its increased mortality) although infarct 
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size measurements recorded at both 1 week and 4 weeks following coronary artery 
occlusion showed no significant differences between groups, marked variation within 
groups was noted (table 6.2). This could be directly due to cell treatment or, if 
associated with variation in surgical technique, an important confounding factor in 
conjunction with small sample sizes. Interestingly, no correlation between border zone 
vascularity and either infarct size or EF was observed as would have been expected. 
This is potentially due to compensatory endogenous repair mechanisms as discussed 
above but may also reflect the reduced power of the study (i.e. small sample sizes and 
increased variation in surgical technique) and further illustrates the need for larger 
group sizes. 
 
At week 4, I analysed eGFP expression in heart cryosections and observed what I 
believed to be putative donor CDCs. However further analysis revealed that these cells 
were negative for both endoglin and cKit (both markers of CDC subsets), but were 
CD11b positive. Therefore they most likely represent host response inflammatory cells. 
The implications of this are unknown but it is worthy of note that such a strong immune 
response is still present at 4 weeks following infarct and it would be interesting to study 
this in greater detail to ascertain whether the endogenous immune response plays an 
important role in CDC mediated repair. Although an excessive or extended 
inflammatory response can be deleterious and extend cardiac injury9, substantial 
evidence has shown that the immune response in the post-infarct heart can promote 
repair by enhancing phagocytosis and paracrine secretion of growth factors and 
cytokines related to scar formation and angiogenesis9. Additionally it would be 
desirable to investigate whether endoglin loss differentially affects this process (e.g. by 
attracting different subsets of circulating immune cells to the healing infarct). A very 
small number of GFP cells co-stained with terminally differentiated cell markers 
however they appeared primitive in morphology rather than mature, functioning 
vascular or cardiac cells. Therefore this data suggests that the cardioprotective effects of 
CDC transplantation result from paracrine mechanisms rather than direct cellular 
differentiation. Secreted angiogenic factors (such as VEGF, bFGF or EGF) could be 
analysed using a protein array to help us to begin to define the precise mechanisms that 
have led to this CDC-dependent repair. It would also be useful to track GFP expression 
at earlier time points to assess how long these cells remain within the myocardium and 
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possibly to introduce strategies aimed at propagating their effect in vivo (such as sealing 
the injection site with fibrin glue194 or employing magnetic targeting161. 
 
Van Laake et al275 have also tested the ability of endoglin deficient cells to rescue heart 
function following experimental MI in mice. Importantly whereas both of our studies 
show reduced neoangiogenesis in the infarct border zone following injection of 
endoglin deficient cells versus WT controls, van Laake and colleagues further 
demonstrate that Eng+/- cells are impaired in their ability to rescue heart function.  
However there are several important differences between this study and my own. 
Primarily, in the van Laake study human circulating MNCs (derived from healthy 
volunteers or HHT1 patients) were systemically delivered to the mouse via tail vein 
injection 1 to 3 hours following surgery whereas I delivered murine CDCs (with or 
without genetic deletion of endoglin) via intramyocardial injection. This is an important 
distinction because by delivering the cells into the peripheral circulation the authors 
were in effect also measuring the ability of these cells to home to the ischaemic heart 
rather than directly assessing their contribution to heart repair and angiogenesis. Indeed 
Eng+/- MNCs were found to reach the heart at a significantly lower rate than WT cells275 
and a subsequent study has gone on to show that these cells have a defective 
SDF1/CXCR4 homing axis276. Thus it is not known whether the delivery of a similar 
number of WT and Eng+/- MNCs directly into the heart would have rescued cardiac 
function to a similar degree. Furthermore van Laake et al275 only delivered cells to 
infarcted Eng+/- mice which show a defective angiogenic response and a greater 
deterioration in cardiac function relative to WT animals following MI. Therefore this 
study informs on the ability of transplanted cells to restore cardiac function in patients 
with defective TGFβ signalling (e.g. HHT patients) and suggests that BM cell-mediated 
endogenous repair is impaired in these individuals and that they would benefit less from 
autologous BM infusion into the heart. It would be of interest to know whether the same 
outcomes would occur following MI and cell transplantation in WT mice.  A further 
obvious difference between the two studies is cell type. It is possible that CDCs have a 
greater ability to attenuate adverse LV remodelling than MNCs independent of 
angiogenic response. In addition the mice used in the van Laake study were 
immunosuppressed and it is possible that this may have affected WT and Eng+/- cells 
differently. 
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The work described in this chapter confirms that CDC transfer can produce benefit over 
4 weeks post MI with an associated increase in neoangiogenesis. The mechanism 
underlying this repair is likely a paracrine one however the exact role of endoglin in this 
process remains uncertain and will require further study. 
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CHAPTER 7. 
 
Final Discussion               
and Future Directions 
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TGFβ signalling mediates a range of cellular responses in a variety of cell types and the 
canonical TGFβ/Smad signalling pathway is known to regulate endothelial activation 
and is essential for angiogenesis. Many studies support the TGFβ/Alk1 versus 
TGFβ/Alk5 angiogenic switch hypothesis in which the former pathway is pro-
angiogenic while the latter is important for the resolution phase of angiogenesis204. In 
this model endoglin is able to mediate the angiogenic response and is thought to be a 
positive regulator of TGFβ/Alk1 and angiogenic activation while antagonistically 
regulating the TGFβ/Alk5 pathway237. However conflicting reports have arisen and it is 
now accepted that endoglin’s role is likely to be context dependent306. 
I hypothesised that the endothelial TGFβ signalling axis plays an important role in 
cardiac repair cell biology; specifically by mediating cellular proliferation, 
differentiation and pro-angiogenic properties. 
In chapter 3 I have shown that the inhibition of Alk5 kinase activity leads to an 
increased yield of WT BM-derived STC-EPCs. This suggests that manipulating the 
TGFβ/Alk5 pathway in EPCs could have clinical applications and may be used to 
expand endothelial progenitors ex vivo. However the effect of Alk5 inhibition on the 
ability of cells to contribute to angiogenesis in vivo would also have to be investigated. 
While my data indicated that Alk5 inhibition resulted in increased cellular proliferation 
it is also possible that inhibiting TGFβ/Alk5 signalling facilitates endothelial 
differentiation by blocking the acquisition of a mesenchymal phenotype. This 
hypothesis is in agreement with the findings of Diez et al299 as they have reported that 
the process of EndMT is abrogated in EPCs treated with an Alk5 inhibitor. I also found 
that endoglin deficient BM-MNC cultures (derived from Eng+/- mice) yielded a reduced 
number of STC-EPCs in comparison to WT cultures indicating that endoglin expression 
is important in EPC proliferation and/or endothelial differentiation. Interestingly, I did 
not detect a difference in proliferation/viability between WT and Eng+/- cells as may 
have been expected. Therefore my data suggests that endoglin may play a more 
prominent role in the differentiation, rather than the proliferation, of endothelial 
progenitors. This is in contrast to studies suggesting that endothelial differentiation is 
unaffected by endoglin loss during development232-234. However, I did find that 
treatment of Eng+/- BM-MNC cultures with the Alk5 inhibitor rescued the associated 
reduction in STC-EPC number with levels increasing to those observed with WT cells. 
   215 
This shows that endoglin is important in modulating vascular progenitor cell fate and it 
is possible that endoglin may also have an important role in EndMT. This would help to 
explain how Alk5 inhibition is able to counteract the effects of endoglin deficiency. 
Indeed endoglin has an identified role in the mediation of the related process of 
epithelial-to-mesenchymal transition (EMT) during development359 and there is growing 
interest to elucidate whether endoglin is also involved in EMT or EndMT leading to 
cardiac fibrosis. Additional work is required to elucidate the exact mechanisms of action 
underlying the observations made in this study. Nethertheless my findings do suggest 
that TGFβ and endoglin play regulatory roles in endothelial progenitors and 
manipulation of these signalling pathways may prove to be of therapeutic benefit.        
In chapter 4 I tested whether endothelial-specific endoglin depletion would result in EC 
replacement by BM-derived progenitor cells.  My subsequent analysis of cardiac and 
pulmonary vasculature did not support this hypothesis. However I did observe an 
increase in endoglin expression within the BM of Eng-iKO mutant animals suggesting 
that endoglin positive cells expand in response to vascular assault. However, Eng-iKO 
adult mice appear phenotypically normal and no evidence of vascular malformations 
have been detected in the lung vasculature following endoglin depletion (personal 
communication, Dr Marwa Mahmoud). This is likely due to the fact that the role of 
endoglin in mediating TGFβ signalling in the endothelium is largely restricted to areas 
of active angiogenesis whereas the adult pulmonary vasculature is likely to remain 
relatively quiescent.   Therefore it may be that a second pathological and/or angiogenic 
stimulus, such as inflammation or ischaemia, is required for EPC mobilisation from the 
BM and subsequent repair/replacement of the endoglin deficient endothelium. Indeed in 
HHT1 patients vascular lesions appear at distinct sites in certain organs and Bernabeu et 
al306 hypothesise that this is because an external trigger (e.g. infection) is required that 
synergises with endoglin deficiency to generate a lesion localised to the area of the 
trigger. Mahmoud et al270 support this model of ‘second hit’ by showing that in a 
conditional Eng-iKO model AVMs form only when endoglin loss is combined with an 
angiogenic stimulus. Therefore, in a similar way an additional angiogenic stimulus may 
be required to mobilise the expanded BM-resident endothelial progenitors.  
 
In chapters 5 and 6 I analysed the effect of endoglin loss on CDCs both in vitro and in 
vivo. In vitro data revealed that endoglin depletion results in a small but significant 
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reduction in cellular proliferation and migration which concurs with a positive role for 
endoglin in endothelial cell proliferation and angiogenesis as reported by several 
published in vitro studies (refer to section 1.9.3). Unexpectedly, endoglin loss in CDCs 
did not affect TGFβ/Alk1 responses (as indicated by western blotting for phospho-
Smad1). This was in contrast to reported effects of endoglin depletion on pSmad1 
signalling in ECs237 and any effects may have been masked by the high basal levels of 
signalling caused by the serum rich media used for this work.  The increased levels of 
phospho-Smad2 that I detected in Eng-iKO CDCs, indicating that the TGFβ/Alk5 
pathway is upregulated in the absence of endoglin, was in agreement with the 
previously reported role of endoglin in the canonical TGFβ signalling pathway in ECs. I 
then proceeded to test whether endoglin loss affected CDC-mediated angiogenic 
responses and functional rescue in vivo using a murine MI model.  Following LAD 
coronary artery ligation the transplantation of WT cells resulted in a significant 
improvement in cardiac function as evidenced by an increase in EF and an attenuation 
of adverse LV remodelling. This was associated with a significant increase in ischaemic 
border zone vessel density at 4 weeks as compared with PBS injected controls. 
Intramyocardial injection of Eng-iKO cells led to significantly reduced angiogenesis 
relative to WT-CDC recipient mice though intriguingly cardiac function in these two 
groups was comparable.  This suggests that while endoglin is likely to be important in 
mediating the pro-angiogenic effects of CDCs in vivo, endoglin-independent 
mechanisms may be responsible for improving cardiac function by other means, for 
example by preserving cardiomyocyte viability. I also observed that very few donor 
cells differentiated to vascular or cardiac cell phenotypes indicating that CDCs 
generated a pro-angiogenic effect and improved cardiac function via a paracrine 
mechanism. In addition only a small number of CDCs were detected in recipient hearts 
at 4 weeks suggesting that the pro-repair effects of transplanted cells occur at an early 
stage following infarct. Given the length of time taken to culture CDCs (approximately 
4-6 weeks from human tissue159) this will be an important consideration in the clinical 
transition of CDC therapy. This is further made evident by meta-analysis data indicating 
that cardiac function is improved to a significantly greater degree when BM cells are 
transplanted within 7 days of MI135 and the knowledge that early cell-based intervention 
following MI is likely to promote vascular regeneration to a greater extent than 
treatment at later stages. Therefore alternative options such as a readily available tissue 
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typed cell bank or the use of universal donor cells that possess immune privilege may be 
required for the optimisation of future cell-based therapies.  
The general aims of future studies will be to investigate the mechanisms underlying the 
role of endoglin in CDC-mediated repair as well as optimising efficient neovessel 
formation following ischaemic heart injury. 
 
I have shown that endoglin depletion impairs the ability of CDCs to stimulate an 
increased angiogenic response in the ischaemic border zone of mice following MI. The 
mechanisms underlying this defect remain unclear therefore it will be important to 
further investigate the precise role that endoglin plays in CDC-mediated pro-angiogenic 
repair. Given that my findings suggest that transplanted cells act via paracrine means it 
would be advantageous to assess which proteins are synthesised by CDCs (with and 
without endoglin depletion) using a protein array focusing on angiogenesis and mural 
cell recruitment. To help inform on prospective targets I could take advantage of a 
custom Q-PCR array developed in my host laboratory for analysis of gene expression 
downstream of endoglin in primary ECs to reveal pathways and specific components 
required to promote CDC-mediated angiogenesis. In addition given that very few donor 
cells were detected in recipient hearts at 4 weeks post MI my data also indicates that 
CDCs may exert their effects at an earlier stage of remodelling therefore it may prove 
more informative to analyse tissue at 1 week  as this represents the stage of maximal 
angiogenic response. At this earlier time point an in depth assessment of vessel size and 
density would be performed as well as tracking genetically tagged donor cells. In 
addition it will be essential to assess the effect of endoglin loss in CDCs on heart repair 
and angiogenesis over a longer time course (minimum of 12 weeks) to assess whether 
the effects observed at 4 weeks persist. Vascular perfusion studies could also be 
performed by injecting FITC-lectin into tail veins prior to harvest to inform on whether 
the neovessels are functional. 
 
It will also be important to progress to utilising more clinically relevant models such as 
a MI reperfusion mouse model (see section 6.1). Furthermore, in this thesis the CDCs 
used in all experiments described in chapters 5 and 6 were derived from neonatal tissue 
primarily due to the reduced time required for culture compared with adult hearts 
(approximately 5 weeks versus over 8 weeks using adult mouse heart tissue). The use of 
adult–derived cells in future studies would provide a more clinically relevant scenario.   
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However, the use of human CDCs derived from atrial tissue obtained from surgical 
waste is achievable and represents the gold standard of cell-type for pre-clinical studies. 
In addition to investigating the role of endoglin in CDC-mediated heart repair another 
major focus of future studies will be to develop strategies to optimise efficient neovessel 
formation in vivo. On going work in my host laboratory is the investigation into whether 
pre-acclimatising CDCs to sub-physiological oxygen levels (3%) prior to injecting into 
a heart repair model will improve donor cell survival and promote a greater angiogenic 
response. Furthermore, the Bischoff laboratory have shown that a combination of 
endothelial progenitor and mesenchymal cells are able to generate neovessels with a 
higher efficiency than either cell type alone using an in vivo subdermal Matrigel mouse 
model107. Therefore we would like to investigate if supplementing CDCs (which express 
mesenchymal markers such as CD90 and endoglin) with an endothelial cell source (for 
example human circulating EPCs or human cells derived from induced pluripotent 
fibroblast cells that are differentiated to an endothelial lineage) would enhance CDC-
mediated angiogenesis and improve cardiac function to a greater extent than CDCs 
alone. 
 
The results of recent clinic trials assessing the safety and efficacy of BM and cardiac 
stem cell therapy for MI patients have revealed this to be a promising avenue to pursue 
however cell types tend to be poorly defined and only modest positive effects have been 
observed. Therefore to improve patient outcomes functionally active cells need to be 
better characterised and it would be advantageous to actively prime these cells for 
repair, for example by exposing cells to sub-physiological oxygen levels as described 
above. Future work on endoglin and TGFβ could potentially influence further 
improvements for example the enrichment of endoglin expressing cells may lead to 
enhanced pro-angiogenic repair. Additionally, it is known that there are dynamic 
changes in TGFβ ligand expression following MI such that levels of TGFβ1 are 
elevated from 3 days post infarction for up to 8 weeks in rodents. While it is believed 
that TGFβ1 plays a beneficial role in infarct healing at a very early stage (24-72 hours 
following infarct) by suppressing a deleterious immune response and promoting 
fibrosis, thereafter this ligand is thought to cause harm by inhibiting efficient scar tissue 
formation360. However little is known about the effect of TGFβ1 on vessel formation in 
the infarcted heart therefore it would be interesting to investigate the effect of inhibiting 
this ligand in both early and late preclinical models of MI and focussing both on 
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vascular regeneration as well as inflammatory cell recruitment. Indeed an improved 
understanding of the panel of TGFβ family cytokine (including BMP9, a circulating 
angiogenic quiescence factor) expression following infarct may facilitate in optimising 
pro-angiogenic therapy. Expanding this point in more general terms evidence suggests 
that indirect (paracrine) effects may be more relevant to cell-mediated repair than direct 
cellular differentiation and regeneration. Although further research is required to 
validate this theory and evaluate the relative contribution of paracrine factors, it may 
transpire that delivery of an optimised array of paracrine factors via slow release 
nanobeads may be a more useful treatment than cell transplantation.  Further work is 
awaited. 
  
The results reported in this thesis serve to highlight the important regulatory and pro-
angiogenic roles that TGFβ signalling and endoglin are likely to play in cell-mediated 
cardiac repair. Additional pre-clinical studies such as those outlined above will be 
required to verify these conclusions and may provide direction to enable the translation 
of this knowledge to the development of more effective future therapies. 
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